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Summary 
Chronic hepatitis B virus (HBV) infection is a major risk factor for the development of 
hepatocellular carcinoma (HCC) and more than 350 million people are chronically 
infected with HBV worldwide. The non-cytopathic hepatitis B virus is acting as a 
stealth virus and is, therefore, hardly detected by the innate immune system, thus 
contributing to chronicity. So far, it is known that infiltrating cytotoxic T cells are the 
main effector cells involved in the elimination of HBV-infected hepatocytes. However, 
the direct molecular mechanisms through which HBV-infected cells are eliminated by 
the immune system, as well as the signalling pathways up-regulated in infected host 
cells to combat the virus remain unclear. The present study was designed to 
investigate both the influence of the hepatocytes’ p53 status on the outcome of HBV 
infection and vice versa the influence of HBV infection on p53 and p53 target gene 
activation in hepatocytes. In summary, hepatitis B virus infection triggers the 
activation of the DNA damage response leading to the stabilization and activation of 
the tumour suppressor p53 in an ATM/ATR-dependent manner. Activation of p53 
upon HBV infection induces the up-regulation of different p53 target genes playing 
important roles in the extrinsic and the intrinsic apoptosis signalling pathway. In the 
present study the functionality of the CD95 pathway has been identified to be 
essential for the elimination of HBV-infected hepatocytes. The expression of proteins 
involved in apoptosis signalling leads to the alteration of the mitochondrial membrane 
potential, the subsequent release of cytochrome c and finally to apoptosis induction 
of HBV-infected hepatocytes. Furthermore, HBV infection triggers the induction of 
CD95L gene transactivation in an AP-1-dependent manner which leads to the so far 
unrecognized capability of virus-infected hepatocytes to secret CD95L by 
themselves.  
Our results propose a new p53-dependent model for virus elimination in HBV-
infected hepatocytes and show that p53 beyond its role as a tumour suppressor also 
plays an important role in viral clearance. The identification of prominent members of 
the apoptosis signalling pathways as crucial proteins activated upon HBV infection 
demonstrate an underlying mechanism for the diverse outcomes (clearance vs. 
chronicity) of an HBV infection. The significant contribution of p53 in cellular antiviral 
defence suggests a potential implication in the pathogenesis of HBV infection and 
opens new therapeutic options via stabilization of p53. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zusammenfassung 
Eine chronische Infektion mit Hepatitis B Virus (HBV) ist ein Hauptrisikofaktor für die 
Entstehung des Hepatozellulären Karzinoms. Als ein nicht-zytotoxisches Virus wird 
HBV kaum vom Immunsystem erkannt, agiert als ein sogenanntes „verstecktes“ 
Virus und fördert dadurch die Entstehung einer chronischen Infektion. Kürzlich wurde 
beschrieben, dass in die Leber infiltrierende, zytotoxische T Zellen eine bedeutende 
Rolle in der Elimination von HBV-infizierten Hepatozyten spielen. Wie genau 
zytotoxische T Zellen Virus-infizierte Hepatozyten eliminieren und welche 
Mechanismen in infizierten Wirtszellen selbst aktiviert werden, um sich gegen die 
Virusinfektion zu verteidigen, ist jedoch noch nicht bekannt. In der vorliegenden 
Arbeit wurde deshalb die Rolle des Tumorsuppressors p53 auf den Verlauf einer 
HBV Infektion sowie der Einfluss von HBV auf p53 und p53-Zielgene untersucht. Die 
vorliegenden Ergebnisse beschreiben die essentielle Rolle eines intakten p53-Status 
sowie eines funktionellen CD95 Signalweges für die effektive Elimination HBV-
infizierter Hepatoyzten durch das Immunsystem. Eine HBV-Infektion induziert die 
Aktivierung von DNA Reparatur Mechanismen, die zur ATM/ATR-abhängigen 
Stabilisierung von p53 führen. Die Stabilisierung von p53 resultiert in der Aktivierung 
verschiedener p53-Zielgene des extrinsischen und intrinsischen Apoptose 
Signalweges. Die Aktivierung von Apoptose Signalwegen führt zur Veränderung des 
mitochondrialen Membranpotentials, der Sekretion von Cytochrom c und endet in der 
Apoptose von HBV-infizierten Hepatozyten. Zudem konnte in der vorliegenden Arbeit 
gezeigt werden, dass HBV-infizierte Hepatozyten nicht nur sensitiv gegenüber 
CD95L-CD95-vermittelter Apoptose sind, sondern ihrerseits in der Lage sind CD95L 
zu sezernieren. Störungen innerhalb dieser Signalwege fördern die Entwicklung 
chronischer Infektionen und die Entstehung des Hepatozellulären Karzinoms. 
Unsere Ergebnisse beschreiben ein neues p53-abhängiges Model der 
Viruselimination und zeigen, dass p53 über seine Rolle in der Tumorsuppression 
hinaus auch eine wichtige Rolle in der viralen Bekämpfung spielt. Zusammenfassend 
lässt sich sagen, dass die Identifizierung der für eine effektive Elimination HBV-
infizierter Hepatozyten verantwortlichen Proteine einen grundlegenden 
Mechanismus, entscheidend für die unterschiedlichen Verläufe (Elimination vs. 
Chronizität) einer HBV Infektion, darstellt. 
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 1 Introduction 
1. Introduction 
 
1.1 The tumour suppressor p53 
 
p53, a short-lived transcription factor, belongs to the p53 family of proteins and is 
stabilized and activated in response to cellular stress, e.g. genomic instability, 
cytokine signalling, oncogene activation and virus infection. The activation and 
accumulation of p53 upon cellular stress is usually mediated by post-translational 
modifications (e.g. phosphorylation). p53 activation facilitates the transcription of p53 
target genes and the activation of different cellular responses, among others cell 
cycle arrest, DNA repair, and apoptosis (c.f. figure 1.2). Therefore, the tumour 
suppressor p53 plays an important role in the inhibition of cancer development and 
beyond its role as a tumour suppressor also in viral defence.  
p53 target genes possess one or more p53 specific response elements (REs), 
however p53-dependent transactivation is also dependent on the p53 protein level 
itself and on co-factors, such as apoptosis-stimulating of p53 protein 1 (ASPP1) with 
whom p53 interacts after severe DNA damage (Vousden and Lane 2007; Riley, 
Sontag et al. 2008; Menendez, Inga et al. 2009; Aylon and Oren 2011). Prominent 
target genes of p53 encode for proteins involved in the apoptosis signalling 
pathways, e.g. CD95, Puma and Bax as well as its negative regulator Mmd2 (Müller, 
Wilder et al. 1998; Vogelstein, Lane et al. 2000; Wang 2011). Beside its function as a 
transcription factor, p53 is also able to interact directly with members of the Bcl-2 
family by acting as a Bcl-2-homology domain-3 (BH3)-only protein (Vousden and 
Lane 2007; Maclaine and Hupp 2009; Aylon and Oren 2011). Recently, it has been 
shown that p53 is also able to regulate miRNAs which are short non-coding RNAs 
binding to specific mRNAs and regulating protein levels by translation inhibition or 
mRNA degradation (Brosh, Shalgi et al. 2008; Menendez, Inga et al. 2009; Aylon and 
Oren 2011). Another mechanism of p53 as the guardian of the genome to prevent 
cancer development is the regulation of metabolic pathways. Metabolic alterations 
are common features of cancer cells caused through poor O2 supply and increased 
oxidative stress. Basal or low levels of oxidative stress result in the expression of 
anti-oxidant genes promoting the repair of moderate damage, while higher or 
persistent stress levels lead to the induction of pro-oxidant genes, facilitating 
apoptosis induction (Vousden and Ryan 2009; Aylon and Oren 2011).  
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The crucial role of p53 as the guardian of the genome has been demonstrated in p53 
knock-out mice. Even though p53-/- mice develop normally, they are predisposed to a 
wide variety of tumours (primarily lymphomas and sarcomas) by 6 months of age 
(Donehower, Harvey et al. 1992). Loss or mutation of p53 in general is associated 
with an increased susceptibility to cancer. In fact, up to 50% of human tumours carry 
a p53 mutation, demonstrating the outstanding role of p53 in tumour prevention 
(Polager and Ginsberg 2009; Whibley, Pharoah et al. 2009; Aylon and Oren 2011).  
 
1.1.1 The p53 family gene structure 
The other p53 family members, p63 and p73, are also clearly involved in human 
tumourigenesis and tumour response to therapy. They are sharing several p53 
functions such as induction of cell cycle arrest and apoptosis (Maisse, Guerrieri et al. 
2003; Müller, Schleithoff et al. 2006).  
Due to the use of multiple promoters and alternative splicing, the p53 gene family is 
able to produce an array of different protein isoforms, including transactivation-
competent full-length isoforms (TA-isoforms) and amino-terminally truncated (∆N-) 
isoforms, acting as dominant inhibitors of the TA-isoforms (Melino, Lu et al. 2003; 
Müller, Schilling et al. 2005; Murray-Zmijewski, Lane et al. 2006). In addition to the 
transactivation domain, the p53 family proteins also contain (i) a DNA binding domain 
which enables these proteins to bind to their target sequences and (ii) an 
oligomerization domain which serves as an interaction surface upon homotetramer 
formation (figure 1.1). While p53-/- mice develop normally and show enhanced tumour 
susceptibility, p63-/- and p73-/- mice have severe defects in development but show 
less tumour susceptibility compared to p53-/- mice (Melino, Lu et al. 2003).  
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Figure 1.1 Gene structure of the p53 family (a) p53: the alternative promoters and the splicing 
variants are shown. The ∆40p53 protein isoforms have lost the conserved N-terminal transactivation 
domain. The ∆133p53 protein isoforms lack the entire transactivation domain. (b) p63: the alternative 
promoters and the splicing variants are shown. The TA-isoforms contain the transactivation domain, 
while ∆N-isoforms are amino-truncated proteins. (c) p73: the alternative promoters and the splicing 
variants are shown. TAp73 proteins transcribed from P1 promoter contain the conserved N-terminal 
transactivation domain. Ex2p73 entirely lost the transactivation domain due to alternative splicing of 
exons 2 and 3. ∆N-isoforms are amino-truncated proteins containing different N-terminal domains. 
Numbers indicate the exons encoding p53-family proteins. Figure was adapted from Müller et al. 
(Müller, Schleithoff et al. 2006). 
 
1.1.2 p53 regulation and activation 
p53 stabilization and activation is achieved by numerous stress sensors through 
phosphorylation, acetylation, ubiquitylation and methylation of specific p53 amino 
acid residues. More than 50 different enzymes are known to be involved in p53 
modification (figure 1.2) (Maclaine and Hupp 2009; Whibley, Pharoah et al. 2009).  
(a) 
(b) 
(c) 
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To prevent strong inhibitory effects on cell growth and proliferation multiple 
mechanisms negatively control p53 (Harris and Levine 2005; Vousden and Lane 
2007). The p53 protein levels in normal cells are kept low by Mdm2, one of the most 
prominent p53 regulators. The E3 ubiquitin ligase Mdm2 targets p53 for ubiquitylation 
and subsequently proteosomal degradation. In turn, p53 positively regulates the 
Mdm2 gene, generating an autoregulatory negative feedback loop, which is essential 
for restraining p53 function (Michael and Oren 2002; Shmueli and Oren 2007; Ofir-
Rosenfeld, Boggs et al. 2008; Eischen and Lozano 2009). The ability of Mdm2 to 
inhibit the function of p53 is blocked by e.g. ARF (alternative reading frame), another 
tumour suppressor gene activated upon oncogene expression or cellular stress, 
leading to the ubiquitylation and degradation of Mdm2 (Junttila and Evan 2009; Meek 
2009; Rivas, Aaronson et al. 2010; Pang, Scott et al. 2011). Tumours not containing 
a p53 mutation often show an indirect p53 abrogation generated through 
overexpression of Mdm2 or inactivation of ARF (Polager and Ginsberg 2009; 
Whibley, Pharoah et al. 2009). Once activated, p53 acts as a transcription factor, 
activating genes involved in cell cycle arrest and apoptosis. Furthermore, p53 
translocates to the mitochondria, where it physically interacts with members of the 
Bcl-2 family thereby stimulating apoptosis (Whibley, Pharoah et al. 2009). 
 
1.1.3 p53 and the DNA damage response 
One cellular pathway involved in p53 stabilization through phosphorylation is the 
DNA damage response pathway (DDR), an important barrier against tumourigenesis 
(Meek 2009; Wilhelm, Rufini et al. 2010) (figure 1.3). The protein kinases ATM 
(ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia and Rad3 related), 
central components of the DDR, are recruited to single- and double-strand DNA 
breaks, thereby activated and leading to the amplification of the response by 
phosphorylation of several target substrates including p53 and CHK1/CHK2 
(checkpoint kinase 1 and 2). Furthermore, ATM/ATR mediate the rapid destruction of 
Mdm2 and Mdm4, which results in the inhibition of p53 ubiquitylation. ATM/ATR-
dependent phosphorylation of p53 on the key phosphorylation site serine 15 also 
results in the inhibition of p53 and Mdm2 interaction (Canman and Lim 1998; 
Canman, Lim et al. 1998; Takaoka, Hayakawa et al. 2003; Jackson and Bartek 2009; 
Polager and Ginsberg 2009; Bensimon, Aebersold et al. 2011; Nam and Cortez 
2011). 
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Figure 1.2 The p53 pathway The tumour suppressor p53 can be modified by more than 50 different 
enzymes, which alter p53 stability, cellular localization or activity. The p53 protein level in normal cells 
is kept low by Mdm2. Mdm2 targets p53 for ubiquitylation and proteosomal degradation. The activation 
of p53 by cellular and genomic stress disrupts the interaction between p53, Mdm2 and Mdm4 by 
posttranslational modifications. p53 can now act as a transcription factor, activating or repressing 
genes involved in apoptosis, cell cycle arrest and senescence. The localization of p53 at the 
mitochondria membrane enables a direct protein-protein interaction of p53 with members of the Bcl-2 
family. ATM: ataxia-teleangiectasia mutated; Bax: Bcl-2-associated X; JNK: Jun N-terminal kinase; 
Kat5: K (lysine) acetyltransferase 5; MLH1: MutL protein homologue 1; PRMT5: protein arginine 
methyltransferase 5; SMYD2: SET and MYND domain-containing 2; Mdm2: murine double minute 2; 
Erk: extracellular signal-regulated kinase; p38: p38MAP kinase; p300: p300 acetyl transferase; ARF: 
alternative reading frame. Figure was adapted from Whibley et al. (Whibley, Pharoah et al. 2009). 
Pathway was generated using the pathway builder from www.proteinlounge.com. 
 
The phosphorylation of histone H2A.X at the site of DNA damage is another very 
early step in the cellular response to DNA double-strand breaks. H2A.X is rapidly 
phosphorylated at serine 139 by ATM/ATR upon DNA damage, which causes 
chromatin condensation and plays an important role in efficient double-strand break 
repair. A further ATR/ATM down-stream target which rapidly relocates to the site of 
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DNA damage in a phospho-H2A.X (y-H2A.X)-dependent manner is 53BP1 (p53 
binding protein 1). 53BP1 interacts with the DNA-binding domain of p53, enhances 
its transcriptional activity and is involved in tumour suppression (Ryan and Vousden 
1998; Burma, Chen et al. 2001; Li-Weber and Krammer 2002; Wang, Matsuoka et al. 
2002; Wang, Gregori et al. 2004; Gulow, Kaminski et al. 2005; Aly and Ganesan 
2011).  
 
 
Figure 1.3 DNA damage response signalling pathway DNA double-strand breaks are recognized 
by the MRN (MRE11-Rad50-NBS1) complex. The MRN complex leads to the phosphorylation and 
activation of ATM (ataxia-teleangiectasia mutated) which in turn phosphorylates p53, CHK2 and 
Mdm2/Mdm4 (not shown here) as well as H2A.X. In the case of single-strand breaks the Rad3-related 
(ATR)-ATR-interacting protein (ATRIP) is attracted by RPA (replication protein A) (not shown here), 
which phosphorylates the 9-1-1 complex (Rad9, Rad1, HUS1). Ataxia-telangiectasia and Rad3 related 
(ATR) is activated by the 9-1-1 complex and phosphorylates p53, Mdm2 and CHK1. Another 
ATR/ATM down-stream target which rapidly relocates to the site of DNA damage in a phospho-H2A.X 
(y-H2A.X) dependent manner is 53BP1 (p53 binding protein 1). Additionally poly-(ADP-ribose) 
polymerase (PARP-1) swiftly binds to DNA breaks and catalyzes the addition of negatively charged 
PAR chains to itself and other proteins. Figure was partly adapted from Meek (Meek 2009). Pathway 
was generated using the pathway builder from www.proteinlounge.com. 
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Additionally, poly-(ADP-ribose) polymerase (PARP-1) promptly binds to DNA breaks 
and catalyzes the addition of negatively charged PAR chains (poly (ADP-ribose) 
polymers) to itself and other proteins. The binding of PARP-1 to single-strand breaks 
protects DNA lesions from further processing. PARP-1 plays an important role in the 
DNA base excision repair and is essential for the maintenance of genomic integrity. 
Accumulation of negatively charged PAR polymers leads to the dissociation of 
PARP-1 from the DNA (Schultz, Lopez et al. 2003; Jackson and Bartek 2009; Aly 
and Ganesan 2011). Furthermore, inactivation of PARP-1 through caspase 3-
mediated cleavage is an intermediate step in programmed cell death (D'Amours, 
Sallmann et al. 2001). A further way of p53 phosphorylation is the Jun NH2-kinase 
(JNK) pathway which is activated upon cellular stress and is able to control 
apoptosis, both positively and negatively. Phosphorylation of JNK on amino acid (aa) 
183 and 185 by MKK4, which is itself phosphorylated by its upstream kinase MEKK1, 
leads to the increased activity of JNK. Tightly bound to its substrates e.g. p53, JNK is 
able to control their ubiquitinylation and phosphorylation. Under normal conditions 
JNK leads to the ubiquitinylation of p53, which switches to phosphorylation and 
stabilization of p53 under cellular stress. Moreover, the transcription factor AP-1 
component c-Jun and Bcl-2 related proteins are pro-apoptotic substrates of JNK 
(Fuchs, Adler et al. 1998; Fuchs, Adler et al. 1998; Hamdi, Kool et al. 2005). 
 
 
1.2 p53 and apoptosis 
 
Apoptosis or programmed cell death is a highly conserved intrinsic program involved 
in the regulation of several physiological and pathological processes. Triggered in 
response to a variety of signals, two distinct but interlinked pathways, the extrinsic 
and intrinsic apoptosis signalling pathway, lead to the induction of apoptosis (Fulda 
2009; Zuckerman, Wolyniec et al. 2009). Stimuli leading to the activation of the cell 
suicide machinery are among others genotoxic or cellular stress, heat shock, toxins, 
oncogenic transformation and bacterial or viral infection (Ashkenazi 2008). The role 
of p53 in apoptosis induction is well-defined. p53 is able to transactivate or repress a 
panel of p53 target genes playing important roles in the extrinsic and intrinsic 
apoptosis signalling pathway. The targets transactivated by p53 represent a large 
range of molecules with different functions. While p53 transactivates pro-apoptotic 
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members of the Bcl-2 family, the apoptosis machinery as well as several cell death 
receptors, it represses the transcription of anti-apoptotic genes e.g. Bcl-2 and Mcl-1. 
By inducing the oligomerization of the mitochondrial proteins Bax and Bak as well as 
by associating with anti-apoptotic proteins, p53 is able to control and influence the 
apoptosis machinery also in a transcription-independent manner (Chipuk and Green 
2004; Chipuk, Kuwana et al. 2004; Aylon and Oren 2007; Pietsch, Sykes et al. 2008; 
Zuckerman, Wolyniec et al. 2009).  
 
Figure 1.4 Mechanisms involved in p53-mediated apoptosis p53 induces apoptosis in a 
transcription-dependent and transcription-independent manner. It transactivates multiple genes 
encoding for proteins involved in the apoptosis machinery, such as the Bcl-2 family, cell death 
receptors and cell death ligands (TNFSF10 and TNFSF6). Furthermore, p53 represses the 
transcription of genes encoding for anti-apoptotic proteins. Direct interaction of p53 with Bax and Bak 
has effects on the intrinsic apoptosis pathway. Figure was modified from Zuckerman et al. 
(Zuckerman, Wolyniec et al. 2009). 
 
1.2.1 Extrinsic apoptosis signalling pathway 
The extrinsic or death receptor apoptosis signalling pathway is normally activated by 
specialized immune cells, natural killer cells (NK cells) or cytotoxic T cells, producing 
specific pro-apoptotic ligands. The ligands belong to the cytokine tumour-necrosis 
factor (TNF) superfamily and bind specifically to their corresponding pro-apoptotic 
death receptor expressed on the surface of target cells (Ashkenazi 2008). The death 
receptors, such as CD95 (Fas), TRAILR1, TRAILR2 and TNFR, belong to the 
tumour-necrosis factor receptor (TNF-R) superfamily (Rufini and Melino 2011). 
Ligation of the death receptors with their corresponding ligands is followed by the 
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formation of the death-inducing signalling complex (DISC) through homologous 
domain interactions, the recruitment of the adaptor protein Fas-associated death 
domain (FADD) and the activation of caspase 8. Activated caspase 8 then cleaves 
and activates caspase 3, 6 and 7 which induce the release of death substrates and 
finally cell death (Bouillet and O'Reilly 2009). Alternatively, caspase 8 can also trigger 
the cleavage of Bid, which translocates to the mitochondria upon cleavage and 
triggers cytochrome c release through the activation of Bax and Bak (Ashkenazi 
2008; Fulda 2009). 
One member of the TNF-R superfamily, CD95, is constitutively expressed in a wide 
range of tissues including the liver, which is highly sensitive to CD95-mediated 
apoptosis (Galle, Hofmann et al. 1995; Krammer 2000; Schilling, Schleithoff et al. 
2009). Müller et al. have previously shown that the CD95 gene can be transactivated 
directly by binding of wild-type p53 (wt p53) to a strong p53-responsive element 
located within the first intron of the gene cooperating with sequences in the CD95 
promoter to achieve maximal transactivation by wt p53 (Müller, Wilder et al. 1998; 
Schilling, Schleithoff et al. 2009).  
 
1.2.2 Intrinsic apoptosis signalling pathway 
The activation of the intrinsic apoptosis signalling pathway is regulated by members 
of the Bcl-2 family which can have either pro- or anti-apoptotic functions. Proteins 
with only a single Bcl-2 homology 3 (BH) domain are called BH3-only proteins and 
have pro-apoptotic features. While Bid, Bim, Puma and Noxa belong to the BH3-only 
protein group, the pro-apoptotic Bcl-2 family proteins Bax, Bak, and Bok possess 
multiple BH domains. The anti-apoptotic members of the Bcl-2 family, Bcl-2, Bcl-w, 
Bcl-XL and Mcl-1 inhibit the function of the pro-apoptotic family members and are 
required for cell survival. Similar to CD95, the Bax gene can be transactivated 
directly by binding of wt p53 to one of the four p53-responsive elements located 
within the promoter (Miyashita and Reed 1995; Coultas and Strasser 2003; 
Ashkenazi 2008; Rufini and Melino 2011).  
Bcl-2 family proteins regulate caspase activation through regulation of the 
mitochondrial outer membrane permeabilization (MOMP). Upon cell death stimuli 
Bax and/or Bak, present in a normal cell as inactive monomers, are activated by 
BH3-only proteins, e.g. Puma and Noxa, and oligomerize within the mitochondrial 
outer membrane. The activation of Bax and Bak results in the formation of a channel 
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in the mitochondrial outer membrane, permitting the release of cytochrome c (Autret 
and Martin 2009).  
Figure 1.5 Key steps in apoptosis signalling pathways Upon cellular stress the tumour-suppressor 
p53 is activated. p53 in turn induces the initiation of the intrinsic apoptosis signalling pathway by up-
regulating the BH3-only proteins Puma and Noxa, which subsequently activate Bax and Bak. Due to 
the permeabilization of the outer mitochondrial membrane, cytochrome c is released, binds to the 
adaptor Apaf-1 and recruits procaspase 9 into a signalling complex, the apoptosome. The extrinsic 
pathway is usually activated by cytotoxic immune cells, producing pro-apoptotic ligands, such as 
CD95L or TRAIL. Binding of the ligand to its corresponding receptor is resulting in receptor clustering 
and the recruitment of FADD as well as the initiator caspases 8 and 10, which form the DISC. The 
DISC initiates the activation of the apical caspases, driving their autocatalytic processing and their 
release into the cytoplasm, where they activate the effector caspases 3, 6 and 7. Both pathways can 
function separately, however they often interact. Initiation of the intrinsic pathway is mainly induced by 
p53, which also up-regulates some of the pro-apoptotic receptors. The activation of caspase 8 leads to 
the processing of Bid, a protein connecting the extrinsic and the intrinsic pathway. Truncated Bid 
stimulates Bax and Bak to activate the intrinsic pathway. Signalling pathway was partly adapted from 
Ashkenazi (Ashkenazi 2008). Pathway was generated using the pathway builder from 
www.proteinlounge.com. 
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Cytochrome c release is resulting in the formation of the cytochrome c/Apaf-
1/caspase-9-containing apoptosome, the subsequent activation of caspase-3 and the 
release of death substrates (Chinnaiyan 1999; Kroemer, Galluzzi et al. 2007). As 
mentioned above the intrinsic apoptosis signalling pathway can also be activated by 
caspase 8-induced cleavage of Bid and the translocation of truncated Bid to the 
mitochondria (Adams and Cory 2007). 
 
 
1.3  Hepatocellular carcinoma 
 
Hepatocellular carcinoma (HCC) is one of the most frequent solid tumours worldwide 
(Di Bisceglie 2009). It is the fifth most common cancer in men and the seventh in 
women, the most common primary malignant liver cancer and the third leading cause 
of cancer-related death in the world. With over 85% developing countries show the 
highest disease incidence. The incidence rate of HCC is almost equivalent to the 
mortality rate due to its poor prognosis (Parkin 2001; Seitz, Schleithoff et al. 2010; El-
Serag 2011). 
 
 
Figure 1.6 Development of hepatocellular carcinoma Chronic HBV, chronic HCV, alcohol, 
metabolic liver diseases, aflatoxins and associated liver cirrhosis represent major risk factors for the 
development of HCC. The development of HCC is a multistep process going on for several years. It 
includes the progressive accumulation of different genetic alterations leading to malignant 
transformation, occurring due to increased liver cell turnover induced by chronic inflammation, 
followed by subsequent injury and regeneration. At least four different signalling pathways regulating 
either cell proliferation or cell death are affected in HCC, i.e. pRb1 pathway, TGF-ß1 pathway, p53 
family and Wnt signalling pathway. Figure was adapted from Levrero et al. (Levrero 2006) . 
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The p53 pathway is affected at multiple levels in hepatocellular carcinoma leading to 
apoptosis resistance (Wang, Hussain et al. 2002; Hussain, Schwank et al. 2007). 
Resistance of apoptosis is a key biological feature that contributes to the malignant 
phenotype of HCC (Buendia 2000; Hanahan and Weinberg 2011). More than 50% of 
HCCs induced by the human liver carcinogen aflatoxin (Liu and Wu 2010) and       
20-40% of aflatoxin-independent HCCs in humans show mutations in p53. Micro-
deletions of p14ARF occur in up to 20% of HCCs, while increased Mdm2 and 
gankyrin expression has been observed in the majority of HCCs. Gankyrin inhibits 
both the pRb- (retinoblastoma protein) and the p53-checkpoint function (Volkmann, 
Hofmann et al. 1994; Laurent-Puig, Legoix et al. 2001). The role of p53 and the p53 
family members, p63 and p73, in hepatocarcinogenesis, therapeutic response and 
prognosis of HCC has been described previously (Müller, Wilder et al. 1998; 
Eichhorst, Müller et al. 2000; Gressner, Schilling et al. 2005; Müller, Schleithoff et al. 
2006). 
 
 
1.4. Hepatitis B virus 
 
One major risk factor for the development of HCC is chronic infection with hepatitis B 
virus (HBV) (Kremsdorf, Soussan et al. 2006; Oyagbemi, Azeez et al. 2010). More 
than 350 million people worldwide are chronically infected with HBV, known to induce 
acute and chronic necroinflammatory liver injury and to promote 
hepatocarcinogenesis (Liang, Liu et al. 2007; Di Bisceglie 2009; Seitz, Schleithoff et 
al. 2010; El-Serag 2011). In fact, chronic HBV infection causes liver cirrhosis leading 
to over 50% of all HCC cases worldwide (Nguyen, Garcia et al. 2009; Grimm, 
Thimme et al. 2011). Every year about one million people die of HBV-related 
cirrhosis or HCC (Elgouhari, Abu-Rajab Tamimi et al. 2008). Integration of HBV-DNA 
sequences into the host genome and subsequent chromosomal rearrangements are 
found in approximately 90% of the patients (Ozturk 1999; Brechot, Gozuacik et al. 
2000).  
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1.4.1 Structure and molecular virology  
The hepatitis B Virus is a small non-cytopathic, parenterally transmitted, enveloped 
hepadnaviridae virus with circular, partially double-stranded DNA and represents the 
medically important prototype of enveloped DNA viruses (Schulze, Gripon et al. 
2007).  
The longer, negative DNA strand is the coding strand for viral mRNA and viral 
pregenomic RNA transcription. The shorter, plus strand is variable in length and 
includes two direct repeats (DR1 and DR2) at its 5’ end, required for strand-specific 
DNA synthesis during replication. At the 5’ end of both strands a short cohesive 
overlap region stabilizes the circular structure of the genome. Liver-specific 
expression of viral gene products is conferred by two enhancer elements, En1 and 
En2 (Chisari, Ferrari et al. 1989; Rehermann 2007; Liang 2009). The HBV genome is 
approximately 3200 bp in length and contains four overlapping open reading frames 
(ORFs). Each ORF encodes for specific structural proteins: The S gene, which can 
be structurally and functionally divided into the pre-S1/L-, pre-S2/M- and Surface/S-
region, encodes for the viral surface envelope proteins, HBsAg. Three in-frame start 
codons within the ORF are responsible for production of the different surface 
proteins. The L- and the M-protein share the aminoacids (aa) of the S-domain and 
are extended by 55 (M-protein) or 108/119 (L-protein) aminoacids, called pre-S2 or 
pre-S1 (Schulze, Gripon et al. 2007). The precore/core gene encodes for the 
nucleocapsid protein HBcAg and the secreted, non-structural precore protein, 
HBeAg. Multiple in-frame translation initiation sites in both the S and the C gene can 
give rise to related but functionally distinct proteins. The polymerase ORF encodes 
for the viral polymerase, which is functionally divided into three domains: the terminal 
protein domain involved in encapsidation and initiation of minus-strand synthesis, the 
reverse transcriptase domain responsible for genome synthesis and the ribonuclease 
H (RNase H) domain which degrades pregenomic RNA and initiates replication. The 
fourth ORF encodes for HBxAg, a protein with multiple functions. HBx is known to be 
involved in signal transduction, transcriptional activation, DNA repair and protein 
degradation inhibition. Furthermore, it is known that HBx is required for viral 
replication as well as productive HBV propagation (Elgouhari, Abu-Rajab Tamimi et 
al. 2008; Liang 2009; Grimm, Thimme et al. 2011; Kew 2011) (figure 1.7).  
Today eight HBV genotypes (A-H) – going along with differences in clinical    
outcome – are known. The genotypes have different geographic distributions. While 
 14 Introduction 
the genotypes A (serotype adw) and D (serotype ayw) are most common in the US 
and Europe, genotype B (serotype adw) and C (serotype adr) are more prevalent in 
Southeast Asia and China (Chu and Lok 2002; Dienstag 2008; Grimm, Thimme et al. 
2011).  
Figure 1.7 The HBV genome Genomic organization, RNA transcripts and gene products are shown 
on the left. HBV is a partially double-stranded enveloped DNA virus with four open reading frames, 
encoding for polypeptides of the surface antigen (S), the core protein (C), the polymerase (P) and the 
HBx protein (X). The transcription start sites of various HBV transcripts and their proteins are shown 
on the right. Figure was adapted from Liang et al. (Liang 2009). 
 
1.4.2 Life cycle 
The HBV life cycle has been studied in great detail; however, the hepatocyte-specific 
preS1 receptor, responsible for specific and probably irreversible binding of the virus 
to a hepatocyte remains unknown. Due to the strong liver tropism of HBV, replication 
exclusively takes place in hepatocytes. 
The initial phase of HBV infection is the reversible and non-cell-type specific 
attachment to cell-associated heparan sulfate proteoglycans, followed by the 
irreversible binding of the pre-S1 domain in the L-protein to an so far unknown 
preS1-receptor (Schulze, Gripon et al. 2007; Urban, Schulze et al. 2010). 
Two different virus entry pathways have been proposed: (i) endocytosis followed by 
the release of nucleocapsids from endocytic vesicles; (ii) fusion of the viral envelope 
with the plasma membrane. The direct mechanism has not been elucidated so far. 
The released nucleocapsid is transported to the nucleus, more precisely to the 
nuclear core complex along microtubules (Ganem and Prince 2004; Urban, Schulze 
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et al. 2010; Grimm, Thimme et al. 2011). After the release of the partially double-
stranded, relaxed circular viral DNA (rcDNA) into the nucleoplasm, the plus strand of 
the rcDNA is completed by the viral polymerase. Viral polymerase and RNA primers 
used for plus-strand synthesis are finally removed by cellular enzymes. The 
formation of the cccDNA (covalently closed circular DNA) is achieved by covalent 
ligation of both strands. The cccDNA molecule is organized as a chromatin-like 
structure (minichromosome) and seems to be regulated by host specific factors, 
however, it is not amplified during mitosis but has the potential to persist in host cells 
for several years (Levrero, Pollicino et al. 2009; Urban, Schulze et al. 2010). The host 
cellular transcription machinery is used by the cccDNA to produce viral RNAs 
necessary for viral protein production and viral replication. This process is regulated 
by both cellular and viral proteins, which may modulate viral gene expression by 
interacting with the promoters of the four viral ORFs. All four major mRNAs use a 
single common polyadenylation signal, however, processing of viral RNAs, nuclear 
export as well as stabilization seem to be exclusively mediated by host factors 
(Werle-Lapostolle, Bowden et al. 2004; Urban, Schulze et al. 2010; Grimm, Thimme 
et al. 2011). cccDNA transcripts, transcribed by cellular RNA polymerase II, are 
intronless, 5’-end capped and polyadenylated. They are divided into two different 
species: subgenomic RNA (sgRNA) and pregenomic RNA (pgRNA), relevant for viral 
replication. While the pgRNA serves as a template for reverse transcription and 
mRNA of the viral core protein and the viral polymerase, the sgRNA directs the 
translation of the regulatory x protein and the three envelope proteins by free 
ribosomes. The three envelope proteins are directly synthesised into the membrane 
of the endoplasmatic reticulum (ER). The pgRNA, in contrast, forms an encapsidised 
complex in the cytoplasm with the core protein and the polymerase, where it is 
transcribed into negative-strand DNA. rcDNA is then generated by plus-strand 
synthesis from the negative DNA strand. The viral nucleocapsids self-assemble via 
complex formation of the pgRNA with the core protein and the polymerase. 
Nucleocapsids are either re-imported to the nucleus to generate new cccDNA or 
enveloped by the envelope proteins and exported via the ER and the Golgi complex. 
Two different groups of secreted particles are distinguished: (i) Subviral envelope 
particles (SVPs; 22nm) without DNA-containing nucleocapsids or (ii) Dane particles 
(infectious virions; 42nm) which are enveloped DNA-containing nucleocapsids. 
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Naturally infected hepatocytes contain up to 50 or more copies of cccDNA (Beck and 
Nassal 2007; Liang 2009; Urban, Schulze et al. 2010; Grimm, Thimme et al. 2011).  
Figure 1.8 HBV life cycle Figure was adapted and modified from Urban et al. (Urban, Schulze et al. 
2010) and Grimm et al. (Grimm, Thimme et al. 2011). 
 
1.4.3 Epidemiology 
HBV prevalence as well as transmission patterns vary greatly throughout the world. 
Being highly prevalent in Asia and sub-Saharan Africa as well as other parts of the 
developing countries (high-prevalence countries), western countries e.g. Western 
Europe and United States are so called low-prevalence countries (Elgouhari, Abu-
Rajab Tamimi et al. 2008). While in high-prevalence countries HBV transmission 
usually occurs perinatal from chronically infected mothers, infection in low-prevalence 
countries predominately occurs horizontal during adolescence by sexual contacts or 
percutaneously by drug injection (Dienstag 2008; Grimm, Thimme et al. 2011). The 
risk of developing a chronic HBV infection is approximately 90% if HBV infection is 
acquired perinatal. Vertical perinatal HBV infection does not lead to the induction of a 
cellular immune response and a lifelong, persistent infection is established in most 
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cases (Dienstag 2008; El-Serag 2011). In contrast, up to 95% of immunocompetent 
adults spontaneously clear the infection (Chisari and Ferrari 1995; Lok and McMahon 
2007). Even though there is a safe and effective HBV vaccine available and national 
HBV vaccination programs have dramatically reduced the prevalence of HBV 
infection, chronic HBV infection is still a major health problem (El-Serag 2011). 
 
 
1.5 Hepatitis B virus infection 
 
1.5.1 Acute and chronic HBV infection 
Viral hepatitis is a necroinflammatory liver disease of variable severity. While 95% of 
immunocompetent adults usually suffer from a self-limiting, transient liver disease, 
5% of adults and up to 90% of newborns are persistently infected with HBV. 
Persistent HBV infection is associated with chronic liver diseases and a high risk for 
the development of cirrhosis or HCC (Protzer and Schaller 2000; Guidotti and Chisari 
2006; Chisari, Isogawa et al. 2010; Bauer, Sprinzl et al. 2011). 
Acute HBV infection can lead to anicteric, icteric or fulminant hepatitis, however 
about 60% of the patients show only a mild, asymptomatic and subclinical illness, 
which is not even detected. Acute fulminant hepatitis occurs only in 0.5% of patients 
and is characterized by signs of liver failure.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 Pathogenesis and outcomes of HBV infection Figure was adapted and modified from 
Feitelson et al. (Feitelson and Larkin 2001). 
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Acute hepatitis B Virus infection is characterized by increased ALT (Alanine 
aminotransferase) and AST (Aspartate transaminase) levels approximately 15 weeks 
after infection; icteric hepatitis also shows a rise in bilirubin levels. High HBV DNA 
levels are not detectable during the first weeks of infection; however, HBV DNA rises 
together with HBeAg and HBsAg to their peak titres after 6 weeks. HBcAg-specific 
IgM appears earlier and persists life-long. Life-long protection is also given by the 
production of anti-HBs- and anti-HBe-specific antibodies. Although all clinical 
symptoms are resolved, small amounts of HBV cccDNA persist in a few hepatocytes 
and are controlled by cellular and humoral immune responses (Rehermann and 
Nascimbeni 2005; Elgouhari, Abu-Rajab Tamimi et al. 2008; Liang 2009).  
While an acute HBV infection is characterized by a vigorous, polyclonal and multi-
specific T cell response, patients with persistent, chronic HBV infection show only a 
narrowly focused and weak HBV-specific T cell response (Rehermann 2007; Chisari, 
Isogawa et al. 2010). The failure of the immune system to clear and control the 
infection can lead to a subsequent liver inflammation, liver cirrhosis and finally HCC 
as long term complications of chronic infection. In contrast to acute hepatitis, liver 
enzyme levels in chronic hepatitis B can be normal and no significant liver disease 
can be seen, especially in those patients who acquired HBV infection vertically (Chen 
and Chen 1999; Elgouhari, Abu-Rajab Tamimi et al. 2008; Liang 2009; Thursz, Yee 
et al. 2011).  
 
1.5.2 Antiviral immune response  
The immune system is a network of cells, tissues and organs working together to 
defend the body against infections with e.g. viruses or pathogens. However, the 
immune system is not only able to control most of the viruses and pathogens 
infecting humans, it can also provide life-long immunity after successful clearance of 
an infection. The innate immune system thereby functions as the first line of defence. 
Possessing a number of fast reacting and unspecific components, it is able to 
recognize and eliminate invading pathogens and viruses. The components of the 
innate immune system include epithelial barriers, cytokines and several cellular 
elements: (i) the complement system, (ii) phagocytes: granulocytes and monocytes, 
(iii) natural killer (NK) cells, (iv) antigen-presenting cells (APC). Pathogens are 
recognized by a subset of immune receptors e.g. toll-like receptors (TLRs). 
Phagocytosis of invading pathogens leads to the activation of the respiratory burst 
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and the complement system, the induction of the inflammatory response as well as 
cytokine/chemokine release to attract more immune cells. Antigen-presenting cells 
represent the antigens towards T cells and trigger the induction of the adaptive 
immune response.  
While the innate immune system combats the invading pathogens in an unspecific 
manner, the adaptive immune response produces specific antibodies against a 
particular pathogen and protects the body against re-infection. CD4+ T cells, CD8+ T 
cells and B cells are the main cellular components of the adaptive immune response. 
CD4+ T cells recognize peptides derived from intravesicular sources and activate 
macrophage- and B cell-mediated responses to the antigen. Upon activation by CD4+ 
T cells, B cells differentiate into antigen producing cells. CD8+ T cells, in contrast, 
recognize antigens synthesized in the cytoplasm of host cells e.g. viral proteins and 
peptides. They differentiate into cytotoxic T cells and are able to kill host cells 
infected with cytosolic pathogens. Combining the properties of the innate and the 
adaptive immune system, the immune system is able to control many viral infections 
with limited damage to host tissue (Rouse and Sehrawat 2010). 
 
1.5.2.1 Innate immune response to viral infection 
The innate immune response plays an important role in the early control of viral 
infections. Invading viruses are first recognized by natural neutralizing antibodies, 
binding to the surface of the virus and preventing viral attachment and host cell entry 
(Barber 2001). Viruses are also recognized by TLRs, in general TLR3, TLR7, TLR8 
and TLR9 (Preiss, Thompson et al. 2008), leading to the production of pro-
inflammatory cytokines, the attraction of cells involved in inflammation and the 
induction of the adaptive immune response. Furthermore, the activation of the 
complement system promotes phagocytosis or lysis of the invading viruses (Barber 
2001; Pichlmair and Reis e Sousa 2007; Munz, Lunemann et al. 2009; Rouse and 
Sehrawat 2010). Virus-infected host cells are attacked by several humoral and 
cellular mechanisms to prevent virus spreading. Beside NK cells, large granular 
lymphocytes are potent effectors of the antibody-dependent cell-mediated cytotoxicity 
(ADCC) (Barber 2001; Pichlmair and Reis e Sousa 2007). The most prominent 
cytokines released upon viral infection are type I interferons. Type I interferons, 
multiple IFN-α isoforms, one IFN-β isoform and e.g. IFN-ε, can be produced by many 
different kind of host cells. Type II interferon, IFN-γ, in contrast is exclusively 
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produced by T cells and NK cells. IFN-induced antiviral function leads to the 
transactivation of different IFN-regulated genes (IRGs), the induction of apoptosis 
and cellular resistance to viral infection. Furthermore, NK cells as well as dendritic 
cells are activated, leading to the induction of the adaptive immune response (Barber 
2001; Munoz-Fontela, Garcia et al. 2007; Koyama, Ishii et al. 2008) 
 
1.5.2.2 Adaptive immune response to viral infection 
The release of cytokines/chemokines and inflammatory molecules leads to clonal 
expansion of pathogen-specific T and B cells (Munz, Lunemann et al. 2009). Once 
activated, adaptive immune receptor cells contribute to tissue damage. Cytotoxic T 
cells (CD8+ T cells) directly destroy virus-infected host cells through ligand-
dependent activation of cell death receptor-mediated apoptosis. Some CD4+ T cells 
boost a tissue-damaging inflammatory reaction, which can get chronic in the case of 
persistent virus infection. B cell-triggered antibody responses can also contribute to 
tissue damage by the activation of the complement system. To prevent itself against 
immune system-mediated tissue damage, the host produces a subset of anti-
inflammatory molecules, e.g. IL-10 and TGF-ß controlling the pro-inflammatory 
reactions (Barber 2001; Rouse and Sehrawat 2010).  
 
1.5.2.3 Liver immunity 
The unique anatomical structure of the liver favours its immunological function. A 
high amount (about 30%) of the total, antigen-rich, blood is passing through the liver 
every minute and the small diameter of the sinusoids (blood vessels), boost the 
contact between lymphocytes and APCs and promote lymphocytes extravasation. Up 
to 1010 lymphocytes, conventional T cells, B cells and NK cells are located in a 
human liver. In the liver cytotoxic CD8+ T cells usually outnumber CD4+ T cells. 
Kupffer cells, representing the largest group of fixed macrophages are localized 
within the sinusoidal vascular space together with dendritic cells. Beside Kupffer cells 
and dendritic cells, liver sinusoidal endothelial cells (LSECs) and hepatic stellate cells 
(HSCs) as well as hepatocytes function as APCs (Limmer, Ohl et al. 2000; Winau, 
Hegasy et al. 2007; Crispe 2009). The liver, therefore, is selectively enriched with key 
components of the innate and adaptive immune system (Wick, Leithauser et al. 2002; 
Tu, Bozorgzadeh et al. 2007). Considered to be an immune privileged organ, the liver 
 21 Introduction 
favours the induction of tolerance by the secretion of IL-10 (Knolle, Schlaak et al. 
1995), nitric oxide and reactive oxygen, resulting in the down-regulation of receptor-
mediated antigen uptake as well as T cell activation. The limited initiation of a proper 
T cell response results in a greater significance of the innate immune system. Strong 
pathogen-specific signals activate abundant NK cells as well as Kupffer cells, which 
in turn secret pro-inflammatory mediators e.g. TNF-alpha, IL-12 and, therefore, 
overcome the state of active tolerance (Racanelli and Rehermann 2006; Crispe 
2009; Yang, Chou et al. 2009). 
 
1.5.2.4 The role of p53 and HBx in antiviral immunity 
The tumour suppressor p53 is an important component of the antiviral defence 
mechanism (Takaoka, Hayakawa et al. 2003). Activated by type I IFNs p53 enforces 
the type I IFN response and induces apoptosis in virus-infected cells by the activation 
of classic p53 target genes (Munoz-Fontela, Macip et al. 2008; Rivas, Aaronson et al. 
2010). Furthermore, several DNA viruses trigger cellular signalling cascades 
characteristic for a DDR, which also lead to p53 activation (Lilley, Schwartz et al. 
2007).  
Many viruses, including HBV, have evolved mechanisms to abrogate the function of 
p53. Viral oncoproteins, such as HBx, are able to block p53-dependent responses in 
infected cells and, therefore, prevent the induction of apoptosis. By forming a 
complex with p53, HBx sequesters this pro-apoptotic protein, prevents its entry in the 
nucleus, blocks its transcriptional transactivation functions and disrupts protein-
protein interactions between p53 and other pro-apoptotic proteins of the apoptosis 
signalling pathways (Munoz-Fontela, Garcia et al. 2007; Kew 2011). On the other 
hand, it was reported that HBx displays also pro-apoptotic functions, even though no 
particular molecular mechanism has been indentified so far (Zhang, Chen et al. 
2005). Up till now it is proposed that HBx can promote p53-mediated apoptosis by 
stabilizing p53 through the induction of E2F1 and ATR-mediated p53 activation 
(Wang, Hullinger et al. 2008). HBx is able to inhibit early responses to DNA damage, 
therefore, sensitizing the infected cells towards p53-mediated apoptosis (Matsuda 
and Ichida 2009). HBx transfection also led to a decrease in the mRNA and protein 
levels of the anti-apoptotic Bcl-2-family member Bcl-xL, boosting the pro-apoptotic 
effect of HBx (Kew 2011). Similar observations have been made with the protease-
deficient caspase homology c-Flip, a key regulator of the DISC (Kim and Seong 
 22 Introduction 
2003). HBx-induced inhibition of c-Flip results in the promotion of death receptor-
mediated apoptosis, which has been described by Su et al. (Su and Schneider 1997). 
Furthermore, it has been shown recently that HBx sensitizes hepatoma cells to 
apoptotic stimuli by directly localizing to the mitochondria, altering the membrane 
potential and increasing cellular ROS (reactive oxygen species) production (Boya, 
Pauleau et al. 2004; Hu, Chen et al. 2011).  
 
1.5.2.5 Immune control of HBV 
Acute and chronic HBV infection is characterized by necroinflammatory 
lymphomononuclear cell infiltration and Kupffer cell hyperplasia, leading to a 
necroinflammatory liver disease (Chisari and Ferrari 1995; Rehermann and 
Nascimbeni 2005). Being a non-cytopathic virus, the immune response to viral 
antigens is said to be responsible for liver disease and viral clearance. In patients 
with an acute HBV infection a polyclonal, vigorous and multi-specific T cell response 
is detectable, whereas the T cell response in chronically infected patients is weak, 
narrowly focused and unable to control HBV replication (Chisari 1997; Guidotti and 
Chisari 2006; Phillips, Chokshi et al. 2010). The main cause of liver damage in HBV 
infection is the destruction of HBV-infected cells by CD8+ effector T cells (Thimme, 
Wieland et al. 2003; Rouse and Sehrawat 2010). CD8+ effector T cells are cross-
primed by cytokine producing CD4+ T cells, which are also responsible for the T cell 
dependent B cell response. While cytotoxic CD8+ T cells are responsible for the 
clearance of HBV-infected hepatocytes, the B cell-induced humoral immune 
response neutralizes free viruses and prevents virus spread (Chang and Lewin 2007; 
Bauer, Sprinzl et al. 2011). Cytotoxic T cell-dependent apoptosis induction results in 
the release of non-infectious viral particles from apoptotic cells, thus limiting the 
infection (Arzberger, Hosel et al. 2010).  
While the role of the adaptive immune response in HBV infection seems to be quite 
obvious, the role of the innate immune response in HBV infection is still poorly 
understood, since HBV infection is usually diagnosed long after the onset of the 
infection. The innate immune response is crucial for the early defence against viral 
infection and the induction of the adaptive immune response (c.f. 1.5.2.1). Most viral 
infections are recognized by pattern recognition receptors and are characterized by 
the release of antiviral cytokines, e.g. IFNs (Bauer, Sprinzl et al. 2011). HBV 
replication can be inhibited by type I INFs, but after HBV infection no IFN response 
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can be observed, leading to the hypothesis that HBV is acting as a “stealth” virus 
(Chisari, Isogawa et al. 2010).  
As a “stealth” virus, HBV does not modulate host cellular gene transcription and does 
not induce innate antiviral immune responses in the liver. However, low levels of 
antiviral cytokines could be detected in a subset of patients, leading to the conclusion 
that HBV can be detected in some way by the host during early infection and 
subsequently leads to the activation of the immune response (Ait-Goughoulte, 
Lucifora et al. 2010).  
 
Figure 1.10 Cellular Immune Response to HBV HBV replication results in the secretion of HBsAg 
and virions, which are recognized and taken up by APCs. After degradation of the viral proteins, the 
peptides are bound to and represented on the surface of APCs via major histocompatibility complex 
(MHC) class I or class II molecules. The peptides are recognized by CD4+ and CD8+ T cells. While 
CD4+ T cells activate antibody producing B cells and therefore the humoral immunity, CD8+ T cells, 
with the help of CD4+ T cells, are able to recognize viral peptides presented by MHC class I molecules 
on infected hepatocytes. Recognition of viral antigens can either lead to the inhibition of viral 
replication due to secretion of IFN-y and TNF-α, or more importantly to the direct induction of 
apoptosis of the infected hepatocytes. Figure was adapted and modified from Ganem et al. (Ganem 
and Prince 2004). 
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1.6 Aim 
 
Chronic hepatitis B virus infection is a major risk factor for the development of 
hepatocellular carcinoma (HCC). With over 350 million people chronically infected 
with HBV worldwide this is a major health burden even though there is an effective 
vaccine available. Although it is well known that cytotoxic T cells play a major role in 
the elimination of HBV-infected hepatocytes and that apoptosis of HBV-infected 
hepatocytes is mediated by several molecular pathways, the direct molecular 
mechanisms activated in HBV-infected cells to promote virus elimination are still 
poorly understood. So far, the virus regulatory protein HBx has been described to 
play an important role in apoptosis induction by interfering with cellular proteins, that 
are involved in p53-dependent and p53-independent apoptosis signalling (Chirillo, 
Pagano et al. 1997; Wang, Hullinger et al. 2008; Arzberger, Hosel et al. 2010). 
 
The major focus of the present study was to investigate both the influence of the p53 
status of hepatocytes on the outcome of HBV infection and vice versa, the influence 
of HBV infection and the different viral proteins on p53 activation in hepatocytes. The 
application of gene transactivation assays, real time PCR and protein analysis aimed 
at the identification of potential target genes and proteins involved in the elimination 
of HBV-infected hepatocytes. The objective was to elucidate factors leading to the 
persistence of HBV and, thus, to HBV-induced hepatocarcinogenesis with focus on 
proteins of the extrinsic and intrinsic apoptosis signalling pathway system as an 
underlying mechanism for the diverse outcomes of an HBV (viral clearance vs. 
chronicity). In a second step it was investigated whether HBV-infected hepatocytes 
are able to secret CD95L in a similar manner as it was previously described for 
hepatocytes treated with chemotherapeutics. Thus, different CD95L-luc reporter 
constructs were used to analyse CD95L transactivation in HBV-infected hepatocytes 
and to identify the molecular players responsible for the activation of CD95L gene 
transactivation. 
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2. Materials and Methods 
  
2.1 Cell culture  
2.1.1 Cell lines 
The following cell lines were used: 
HepG2 (human hepatoblastoma, wild-type (wt) p53) (Aden, Fogel et al. 1979), 
Hep3B cells (human liver carcinoma, deficient in p53 (Knowles, Howe et al. 1980), 
HEK293 cells (Graham, Smiley et al. 1977) and primary human hepatocytes (PHH) 
(Schulze-Bergkamen, Untergasser et al. 2003).  
All cell lines and PHHs were cultured at 37°C and 5% C O2 atmosphere. Cells (except 
PHHs) were splitted at a ratio of 1:5 when they were 90-100% confluent. 
 
2.1.2 Primary human hepatocytes (PHH) 
All experiments with human liver tissue have been approved by the local ethics 
commission (University of Heidelberg/ file number 110/2000). 
 
2.1.2.1 Isolation of PHH 
PHHs were isolated by a standard two-step collagenase perfusion protocol and 
cultured in Williams Medium E (Maintainace Medium, Invitrogen) in collagen-coated 
cell culture dishes (Schulze-Bergkamen, Untergasser et al. 2003). Healthy liver 
tissue used for perfusion was canulated at a large branch of a vene. The liver was 
perfused with 500 ml Perfusion Solution I (37°C) with  a flow rate of 15 ml/min to       
50 ml/min. In a second perfusion step the resectate was perfused with 250 ml of 
collagenase containing Perfusion Solution II (37°C). U pon successful perfusion, the 
colour of the resectate changed from red to brown and finally beige. The perfusion 
was stopped as soon as the resectate softened. The liver was cut into small pieces 
and the cells were scratched of with a scalpel. The cell suspension was filtered 
through a 70 µm cell strainer and centrifuged for 5 min at 400 rpm at 10°C without 
brake. The supernatant was discarded and the pellets re-suspended in 40 ml Wash 
Medium (4°C). This step was repeated twice, before the  cells were re-suspended in 
PHH Medium (37°C). After the determination of cell vi ability and cell number, the 
cells were seeded in 10% FCS containing PHH Medium and maintained at 37°C,   
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5% CO2. After 24 h the cells were kept in 5% FCS containing medium. From day 2 on 
the cells were cultured in PHH Medium without FCS.  
 
2.1.3 Culture media and buffers 
Table 2.1 Overview of cell culture media and supplements  
Medium Supplements Cell type 
Minimal Essential Medium (MEM)¬ 
500 ml 
50 ml FCS¬; 
5 ml Penicillin-Streptomycin (5000 U/ml) ¬ Hep3B 
Dulbecco`s MEM (DMEM) ¬ 
500 ml 
50 ml FCS; 
5 ml Penicillin-Streptomycin (5000 U/ml) HepG2 
Minimal Essential Medium (MEM) ¬ 
500 ml 
50 ml FCS; 
5 ml Hepes (1 M, pH=7,4)¬;  
5 ml Gentamycin (10 mg/ml) ¬ HEK293 
Dulbecco`s MEM (DMEM) ¬ 
500 ml 
50 ml FCS; 
5 ml Hepes (1 M, pH=7,4); 
5 ml Gentamycin (10 mg/ml) Jurkat 16 
Williams E Medium (Maintainace Medium) 
500 ml 
50 ml FCS;  
5 ml L-Glutamine (200 mM) ¬ 
5 ml Non essential amino acids (10 mM) ¬ 
 
PHH 
Perfusion solution I (HBSS, Ca2+/Mg2+
 
free) 
500 ml 
2.5 ml EGTA (100 nM) ± ; 
1 ml Heparin± PHH 
Perfusion solution II 
250 ml Williams E Medium 
0.9 ml CaCl2 (1 M) ±; 
2.5 ml Gentamycin (10 mg/ml); 
200 mg Collagenase type IV (450 U/ml) ± PHH 
Wash Medium 
500 ml Williams E Medium 
5.6 ml L-Glutamine (200 mM)*; 
6 ml Glucose (5%)*; 
11.5 ml Hepes (1 M, pH=7,4)*; 
5.6 ml Penicillin-Streptomycin (5000 
U/ml)* 
* Solutions were mixed and stored as premix at -
20°C  PHH 
PHH Medium 
500 ml Wash Medium 
5 ml Gentamycin (10 mg/ml); 
0.5 ml Hydrocortison (4,85 mg/ml) ±; 
1.4 ml Insulin (280 µg/ml)א; 
8.7 ml DMSO (78.13 g/mol)ґ PHH 
¬ Invitrogen, Karlsruhe, Germany 
ґ Roth, Karlsruhe, Germany 
±
 Sigma-Aldrich, Deisenhofen, Germany 
א Serva Feinbiochemica, Heidelberg, Germany 
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2.1.4 Calculation of cell numbers 
A Neubauer hemacytometer was used to determine the cell number of homogenous 
cell suspensions. Cells in 2 large squares of the hemacytometer were counted and 
cell number was calculated according to the following formula:  
(total cell number * dilution factor * 104)/ 2 = number of cells/ ml) 
Prior counting the cell suspension was diluted 1:1 with trypan blue. Since trypan blue 
exclusively stains dead cells, the number of viable cells could easily be determined 
by light microscopy. 
 
2.1.5 Seeding of hepatoma cell lines and PHH 
All cell lines and PHHs were cultured in culture flask and seeded in cell culture multi-
well plates obtained from Greiner Bio-One (CELLSTAR).  
 
Table 2.2 Number of cells seeded in the respective culture plate 
 
 
2.1.6 Spheroid culture 
Multicellular tumour spheroids (MCTS) are a well-established 3-D in vitro system 
simulating the pathophysiological in vivo situation in tumour micro-regions. In 
particular, spheroids can be used as an in vitro model to study tumour-immune cell 
interactions (Gottfried, Kunz-Schughart et al. 2006). Spheroids can be generated 
from an array of different cell types, furthermore, it is possible to generate mixed 
spheroids containing two or more different cell types (Santini and Rainaldi 1999). The 
spheroid culture was used to further investigate and characterize the CD95-mediated 
apoptosis of HBV-infected hepatocytes by CD95Ligand-secreting lymphocytes. 
Cell number HepG2 Hep3B PHH 
Culture time 48h-96h 12h-48h 48h-96h 12h-48h 48h-96h 12h-48h 
24 well plate 62,500 120,000 31,250 56,250 62,500 120,000 
12 well plate 112,500 170,000 56,250 85,000 112,500 170,000 
6 well plate 300,000 450,000 150,000 225,000 300,000 450,000 
175 cm2 cell 
culture flask 5,600,000 7,600,000 2,800,000 3,800,000 5,600,000 7,600,000 
75 cm2 cell   
culture flask 2,400,000 3,150,000 1,200,000 1,575,000 2,400,000 3,150,000 
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Spheroid culture was performed as previously described (Del Duca, Werbowetski et 
al. 2004).  
Briefly, hanging drops of Hep3B cells were generated by resuspending 1*106 cells in 
1 ml culture medium and suspending 25 µl drops of the cell suspension on the top 
cover of a 10 cm cell culture dish. After six days spheroids with optimal size and 
shape were selected and transferred to a collagen matrix. The spheroids were 
embedded in 400 µl collagen (PureColTM, Inamed, USA) in a 48-well plate and after 
solidification the collagen matrix was overlaid with growth medium. 24 h after 
embedding the spheroids were infected with the different AdHBV vectors and/or 
Adp53 and treated with the supernatant of PMA/Ionomycin (P/I)-stimulated           
(100 nM PMA, 2 µM Ionomycin) Jurkat 16 cells.  
Cell migration was monitored for 16 days by photographing the spheroids with an 
inverted Leica phase contrast microscope at time zero and in 72 h intervals. 
Calculation of invaded areas was done with Zeiss Axio Vision Release 4.6.3-SP1 
software. 
 
2.2 Adenoviral constructs and infection 
 
Replication defective adenoviral vectors generated according to the method of He et 
al (He, Zhou et al. 1998) were used for in vitro HBV infection. All adenoviral HBV 
vectors have been kindly provided by U. Protzer, Helmholtz Zentrum Munich, 
Germany. The vectors either contained the complete human wt p53 cDNA (Adp53), 
1.3-fold wt HBV cDNA (AdHBV wt), X- HBV cDNA (deficient in HBV HBx protein; 
AdHBV X-), L- HBV cDNA (deficient in the HBV large and middle surface protein; 
AdHBV L-) tagged with GFP, or GFP alone (AdGFP), each under the control of the 
cytomegalovirus immediate/early gene promoter (CMV).  
Cells were seeded in cell culture plates and infected with 10 MOI (multiplicity of 
infection) of recombinant adenovirus at 80% confluence at day 1 post-seeding. 
Infection with 10 MOI virus suspension resulted in an infection rate of 80-90%. In the 
case of combined AdHBV and Adp53 infection 10 MOI of each virus was used and 
infection with the control virus AdGFP was used to obtain an equal amount of 20 MOI 
in each sample.  
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Figure 2.1 Adenoviral HBV vectors generated according to He et. al. The vectors contained the 
1.3-fold HBV genome (AdHBV wt), HBx deficient 1.3-fold HBV genome (AdHBV X-) and 1.3-fold HBV 
genome deficient in the large and middle surface protein (AdHBV L-).  
 
2.2.1 Production of adenoviral vectors 
Pure and highly infectious AdHBV stocks were generated in HEK293 cells. The 
following protocol is designed for the production of 30 ml highly infectious AdHBV 
stocks (titre ≥ 4*105 infectious virus particles/ml). 20*106 HEK293 cells were seeded 
in 175 cm2 cell culture flasks to be 80-90% confluent at time of infection. For the 
production of 30 ml virus stock six culture flasks were used. Cells were infected with 
0.6 MOI of the respective adenoviral construct. 48 h - 96 h post infection (dependent 
on the time point the cell monolayer showed significant cytopathic features), the cells 
were harvested in their culture medium, transferred into 50 ml Falcon tubes, 
centrifuged at 1200 rpm (5 min, 4°C), resuspended in 5  ml hypotonous buffer (sterile 
H2O with 10% PBS) and disrupted by 1 freeze/thaw cycle (-80°C O/N and 37°C water 
bath). After sedimentation of the cell debris (5 min; 2000 rpm; 3x), the supernatant 
containing infectious adenoviral HBV vectors was mixed with glycerol obtaining a 
final concentration of 10%. 
 
2.2.2 Virus titration 
The infectivity of the produced adenoviral HBV vector stock was estimated by the 
number of GFP positive Hep3B or HepG2 cells 24h post infection.  
Therefore, Hep3B and HepG2 cells were seeded in a 24 well plate and infected with 
different MOIs of the respective virus.  
HBV wt
X-StopX-Stop
0 1000-841 2000 3000
HBV-X-
0-841 2000 3000L-Stop M-Stop
HBV-L-
0 1000-841 2000 3000
0 1000 2000 3000
preC Core
HBV Pol
preS1preS2 HBs HBxHBx
-841
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Table 2.3 Amounts of virus stock solution used for titration 
 
                                                                                                                          
 
 
 
 
 
 
 
 
The calculation of the virus titre (infectious units (IU)/ml) is based on the following 
assumptions: (i) 0.56*105 Hep3B cells were infected with the corresponding volumes 
of the virus suspension (based on the assumption that the cells proliferate over night 
the cell number was multiplied by 2); (ii) the minimal titre necessary to infect 100% of 
the seeded cells (assessed by the amount of GFP positive cells) correspond to a 
MOI of approximately 3 viral particles per cell. The amount of viral stock solution 
needed to infect about 50% of the cells, was used for the calculation of the virus titre.  
 
(cell number*2)*(% GFP positive cells*3)/ (µl adenoviral vector)/100 = IU/ml      
 
To estimate the functionality of the produced viral constructs, Hep3B and/or HepG2 
cells were infected with 10 MOI of the respective virus. 72 h p.i. (post infection) the 
cells were harvested and pooled with their corresponding supernatants. To assess 
the amount of apoptotic cells Nicoletti staining was performed (c.f. 2.6.2). 
The following apoptosis rates were expected 72 h p.i. with 10 MOI of the respective 
adenoviral constructs: 
 
Table 2.4 Apoptosis rates at 72 h p.i. 
 
 
 
 
 
 
well number adenoviral vector 
1-3 - 
4-6 2 µl 
7-9 1 µl 
10-12 0.5 µl 
13-15 0.2 µl 
16-18 0.1 µl 
19-21 0.05 µl 
22-24 0.02 µl 
adenoviral vector HepG2 Hep3B PHH 
AdGFP 3.00-6.00% 3.00-6.00% 3.00-6.00% 
Adp53 35-55% 35-55% 35-55% 
AdHBV X- 10-15% 
 
10% 10-15% 
AdHBV L- 15-25% 
 
15% 15-25% 
AdHBV wt 30-35% 
 
15% 30-35% 
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2.3 Plasmids 
 
Plasmid pCMVp53wt encoding human wild-type (wt) p53 has been described 
previously (Ryan and Vousden 1998). Plasmid expressing mutant p53-248W was a 
generous gift from H. Sirma (UKE, Department of Pathology, Hamburg, Germany). 
 
2.4 Immunoblot  
2.4.1 Preparation of cell extracts 
HBV-infected and untreated cells were washed with PBS and lysed in Ripa cell lysis 
buffer (120 mM NaCl, 1% Triton X-100, 0.5% Na. Deoxycholate, 0.1% SDS, 50 mM 
Tris pH=8, 1 mM DTT, 1 mM PMSF, Protease Inhibitor Mix (1 tablet/10 ml; Complete 
Mini, Roche, Mannheim, Germany)). Cell debris were removed by centrifugation at 
13000 rpm, 4°C for 45 min. The supernatants were col lected and protein 
concentration was determined (BCA assay). 
 
2.4.2 Immunoblot 
Protein extracts were boiled in reducing sample buffer and separated by SDS-PAGE. 
Proteins were transferred onto nitrocellulose membranes (Hybond C, Amersham 
Pharmacia Biotech, Freiburg, Germany) at 0.8 mA/cm² for 1.5 h using a wet blotting 
system with transfer buffer (25 mM Tris, 190 mM Glycin, 0.04% SDS, 20% 
Methanol). Protein molecular weight was controlled with the help of protein molecular 
weight standard (Rainbow marker, Amersham Pharmacia Biotech). Membranes were 
blocked with 5% non-fat dried milk powder (Roth) in PBS-T (PBS, 0.05% Tween-20) 
for 1 h, washed three times with PBS-T and incubated with the indicated antibodies 
overnight at 4°C. The membranes were further incubated  with horse-radish 
peroxidase coupled isotype-specific secondary antibody. The secondary antibody 
was diluted in a range from 1:1,000 to 1:20,000 in PBS-T with 0.125% milk powder. 
Blots were washed three times and developed with chemiluminescence reagent 
(Western Lightning® Plus-ECL, PerkinElmer, Waltham, MA, USA).  
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The following primary antibodies have been used: 
Table 2.5 Overview of primary and secondary antibodies used for immunoblotting (Secondary 
antibodies were purchased from Millipore (Billerica, MA, USA), Cell Signalling (Danvers, MA, USA) 
and Southern Biotechnology Associates (Birmingham, Alabama, USA)) 
1st Antibody supplier dilution 2nd Antibody dilution kDa 
p53 (SC-126)  
Santa Cruz Biotechnologies, 
CA, USA 1:500 mouse IgG2a 1:20,000 53 kDa 
Phospho-ATM 
(Ser1981) (#9947) Cell Signalling 1:500 mouse IgG 1:10,000 350 kDa 
Phospho-ATR  
(Ser 428) (#9947) Cell Signalling 1:500 rabbit IgG 1:10,000 300 kDa 
Phospho-CHK1 
(Ser296) (#9947) Cell Signalling 1:500 rabbit IgG 1:10,000 56 kDa 
Phospho-CHK2 
(Thr68) (#9947) Cell Signalling 1:500 rabbit IgG 1:10,000 62 kDa 
Phospho-p53 
(Ser15) (#9947) Cell Signalling 1:500 mouse IgG 1:10,000 53 kDa 
53BP1        
(NB100-305) 
Novus Biologicals, Cambridge, 
UK 1:1000 rabbit IgG 1:10,000 220 kDa 
Bax (sc-20067) Santa Cruz Biotechnologies 1:500 rabbit IgG 1:20,000 23 kDa 
Parp (#9542) Cell Signalling 1:1000 mouse IgG1 1:20,000 
116 kDa; 
89 kDa  
Cyt c (556433) 
Pharmingen, San Diego, CA, 
USA 1:500 mouse IgG2b 1:20,000 15 kDa 
Bid (#2002) Cell Signalling 1:1000 rabbit IgG 1:20,000 
22kDa; 
15kDa  
Caspase 3 
(#9661) 
Becton Dickinson, Heidelberg, 
Germany 1:1000 rabbit IgG 1:20,000 
28 kDa; 
19kDa  
Caspase 9 
(#9502) Becton Dickinson 1:1000 rabbit IgG 1:20,000 
45 kDa; 
25 kDa  
CD95L (sc-7237) Santa Cruz Biotechnologies 1:500 rabbit IgG 1:10,000 
40kDa; 
26kDa 
(cleaved) 
ß-Actin (A-5441) Sigma-Aldrich 1:1000 mouse IgG1 1:20,000 43kDa 
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2.5 Luminex® xMAP® technology 
Principle of Luminex® xMAP® technology: 
The Luminex® xMAP® technology combines the principles of flow cytometry, 
microspheres, lasers, digital signal processing and traditional chemistry and is used 
for multiplex analysis of cell lysates. Antibodies directed against target proteins of 
interest are coupled with internally dyed beads, called microspheres. The addition of 
a specific biotinylated detection antibody results in the formation of an antibody 
sandwich around the target protein. Streptavidin-PE conjugate is added to complete 
the reaction. A panel of 100 beads, each specific for a different target molecule, allow 
the simultaneous detection of different proteins within one sample at the same time. 
 
2.5.1 Quantification of protein phosphorylation 
Cells were treated as described in chapter 2.2. Protein phosphorylation was 
quantified using the Luminex® xMAP® technology (Bio-RAD Laboratories, Munich, 
Germany). Cleaved PARP(Asp214) and total human GAPDH were purchased from 
Millipore, Phospho-p53(Ser15), p-MEK1(Ser217/Ser221), p-ERK1/2(Thr202/Tyr204, Thr185/Tyr187) and 
p-JNK(Thr183/Tyr185) were purchased from Bio-RAD Laboratories. 
Cell lysis was performed 24 h, 48 h, 60 h and 72 h p.i. using the respective cell lysis 
buffer. Antibody capture beads, biotinylated detection antibody and Streptavidin-PE 
were prepared as stated in the manufacturer’s protocol. The protein concentration 
was adjusted to 1 µg/µl; detection antibody and Streptavidin-PE were used as 
recommended by the manufacturer. The lysates were incubated with the capture 
beads overnight (4°C Millipore beads and RT Bio-RAD be ads), followed by 
incubation with the detection antibody (1 h, RT Millipore; 30 min, RT Bio-RAD) and 
the addition of Streptavidin-PE (15 min, RT). The samples treated with the Milliplex 
Map Kit (Millipore) were additionally treated with Amplification Buffer. Analysis was 
conducted using a Luminex® instrument. 
 
 
 
 
 
 
 34 Materials and Methods 
2.6 Luciferase reporter assay 
2.6.1 Plasmids 
The CD95-luc construct containing 3.2 kb of the sequence of the CD95 gene was 
generated, that is, the 3’-part of the promoter, the complete exon 1 and the 5’-part of 
intron 1. This plasmid is denoted as p1142CD95-luc and has been engaged in all the 
transient transfection assays presented (Müller, Schilling et al. 2005). 
The Bax-luciferase reporter plasmid (Bax-Pr/luc) (Miyashita and Reed 1995) and the 
respective CD95L-luciferase reporter constructs (-36/+100 CD95L-luc, -220/+100 
CD95L-luc, -537/+100 CD95L-luc, -1204/+100 CD95L-luc) have been described 
previously (Takahashi, Tanaka et al. 1994; Li-Weber, Laur et al. 1998; Eichhorst, 
Müller et al. 2000; Li-Weber, Laur et al. 2000; Li-Weber and Krammer 2002; Li-
Weber and Krammer 2003). (CD95L-luc plasmid cards: see Appendix) 
 
2.6.2 Deletion of the AP-1 binding site (BS) in CD95L-luc reporter plasmids  
For further analysis of the transcription factors responsible for the transactivation of 
the CD95L-luc reporter construct upon HBV infection it was necessary to delete the 
the 5’ UTR AP-1 BS in the used CD95L-luc constructs. 
 
2.6.2.1 Preparation of linerazied vectors by restriction digestion 
Deletion of the AP-1 binding site in the following CD95L-luc constructs was 
performed using the In-Fusion®
 
HD Cloning System CE from Clontech (Mountain 
View, CA, USA): -36/+100 CD95L-luc, -220/+100 CD95L-luc, -537/+100 CD95L-luc, -
1204/+100 CD95L-luc. The luciferase constructs were digested with restriction 
enzymes (XhoI and HindIII) to generate linearized vectors and to isolate their 
corresponding inserts (c.f. 2.6.3.2). The vectors and their inserts were purified using 
QIAEX®II Gel Extraction Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol.  
 
2.6.2.2 PCR Amplification of target fragment and AP-1 BS deletion 
2.6.2.2.1 PCR primer design 
The following primers were designed according to the manufacturer’s protocol 
(http://bioinfo.clontech.com/infusion). The 5’ end of each primer contains 15 bases 
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homologous to 15 bases at the end of the vector. The designed primer induced an 
AP-1 BS deletion into the amplified inserts. 
 
Table 2.6 Primer sequences for insert amplification. Primers were purchased from Eurofins mwg I 
operon (Ebersberg, Germany). 
 
 
           
       
 
 
 
 
 
 
2.6.2.2.2 PCR amplification of the CD95L gene target fragments 
For amplification of the insert the Advantage® HD Polymerase Mix (Clontech) was 
used. Reagents were thawn on ice, the PCR reaction was assembled at RT.  
 
Table 2.7 PCR Amplification Mix 
 
 
 
 
 
 
 
 
 
For insert amplification the three step PCR method was used and adapted to every 
insert:  
 
 
 
 
Forward primer 
HindIII restriction site (fwd) -36: 
5’ CTGGATCTCGAAGCTTACTCTATAAGAGAGATCCAGCTTG 3’ 
HindIII restriction site (fwd) -220: 
5’ CTGGATCTCGAAGCTTCAGCAACTGAGGCCTTGAAGGC 3’ 
HindIII restriction site (fwd) -537: 
5’ CTGGATCTCGAAGCTTCATGGTCTCTCCCCTCAGAG 3’ 
HindIII restriction site (fwd) -1204: 
5’ CTGGATCTCGAAGCTTCGAGGGTGTCTGATATTCTGATAT 3’ 
Reverse Primer 
XhoI restriction site (rev): 
5’ CGGAATGGATCTCGAGGGCCAGCCCCAGCAAACG 3’ 
Reagents Volume/ final concentration 
Sterile deionized H2O ad 25 µl 
5x Advantage HD Buffer 5 µl 
dNTP Mixture 2 µl 
Primer 1 (fwd) 0.2 µM 
Primer 2 (rev) 0.2 µM 
Advantage HD Polymerase (2.5 units/µl) 0.25 µl 
Template 10 ng 
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Table 2.8 PCR conditions 
 
2.6.2.3 In-Fusion cloning procedure 
Unpurified PCR products (5 µl) were treated with 2 µl cloning enhancer and 
incubated at 37°C for 15 min followed by an incubation  at 80°C for 15 min. For the 
Infusion cloning reaction the reagents were thawn on ice and mixed: 
 
Table 2.9 In-Fusion Cloning Reaction 
 
 
 
 
 
 
 
 
The cloning reaction was incubated at 50°C for 15 min a nd then placed on ice. 
 
2.6.3 Plasmid propagation 
2.6.3.1 Transformation 
Routine cloning was performed using the One Shot Top10 competent cells from 
Invitrogen (In-Fusion cloning was performed using StellarTM Competent Cells from 
Clontech). 50 µl E. coli suspension was thawn on ice. To each aliquot 10 ng/µl 
ligation reaction (plasmid) (routine cloning) or 5 µl In-Fusion Cloning reaction (In-
Fusion cloning) was added and the tubes were further incubated on ice (30 min). 
Subsequently, heat shock was performed at 42°C for 30 sec. (routine) or at 42°C for 
60 sec. (In-Fusion cloning), followed by 2 min on ice. After the addition of 250 µl 
(routine) or 80 µl (In-Fusion cloning) S.O.C Medium (37°C) the vials were incubated 
for 1 h at 37°C with agitation at 225 rpm. 20 µl of  each transformation was spread on 
 -36/ +100 -220/ +100 -537/ +100 -1204/ +100 
98°C 00:00:10 00:00:10 00:00:10 00:00:10 
55°C 00:00:05 00:00:05 00:00:05 00:00:05 
72°C 00:00:07 00:00:12 00:00:30 00:01:30 
 Insert neg. control pos. control 
5x In-Fusion HD Enzyme Premix 2 µl 2 µl 2 µl 
Linearized Vector 200 ng 1 µl 
1 µl (pUC19 
control) 
Cloning Enhancer-Treated PCR Fragment 2 µl - 2 µl (control insert) 
dH2O X µl 7 µl 5 µl 
Total Volume: 10 µl 10 µl 10 µl 
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LB agar plates with Ampicillin (4 µg/ml). Inverted agar plates were incubated at 37°C 
O/N.  
 
2.6.3.2 Plasmid minipreparation and restriction endonuclease digestion 
A single plasmid containing bacterial colony was picked from a freshly streaked agar 
plate and was transferred into 6 ml LB-Medium (Ampicillin 4 µg/ml) and incubated at 
37°C O/N. Bacteria were pelleted by centrifugation (5 min, 5000 rpm) and 
resuspended in 200 µl Flex1 Buffer (10 mM EDTA, 200 µg/ml RNase A, 100 mM Tris, 
pH= 7.5). 200 µl Flex2 Buffer (0.2 mM NaOH, 1% SDS) was added and the contents 
were gently inverted several times and incubated for 5 min at RT. After the addition 
of 200 µl Flex3 Buffer (3 M Potassium, 5 M Acetat, pH= 5.75) the solution was 
incubated on ice for 5 min and pelleted by centrifugation (5 min, 13.000 rpm, RT). 
The clear supernatant was transferred into a new tube. Nucleic acids were 
precipitated by the addition of an equal volume of isopropanol and subsequently 
pelleted by centrifugation. The DNA was washed with 70% ethanol, air dried for      
10 min and resuspended in 15 µl H2O.  
 
For DNA digestion the following restriction endonuclease digestion was used: 
 
Table 2.10 Digestion setup for CD95L-luc plasmids 
10 µg DNA 
10 µl Fast Digest®HindIII 
10 µl Fast Digest®XhoI 
5 µl 10x Buffer (green) 
Ad 15 µl H2O 
                                 
Following digestion at 37°C for 30 min, the digestion  reaction was loaded on an 
agarose gel (1% agarose in TAE Buffer, 7 µl Ethidium-bromide). Gel running was 
performed for 1 h at 80 V. A 100 bp DNA marker (Fermentas, St. Leon-Rot, 
Germany) was used to control the size of DNA fragments.  
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2.6.3.3 Plasmid maxipreparation  
Plasmid containing bacterial hosts were transferred into 200 ml LB-Medium 
(Ampicillin 4 µg/ml) and incubated at 37°C O/N. Cells were pelleted by centrifugation 
at 4500 g for 15 min at 4°C. The pellet was resuspende d in Resuspension Buffer 
RES + RNase A before cell lysis buffer was added and incubated for 5 min at RT. 
Meanwhile the column together with the inserted column filter was equilibrated.  
After incubation the suspension was neutralized and immediately loaded on the 
column, emptied by gravity flow. After washing of the column with equilibration buffer 
and the removal of the filter, the column was washed with wash buffer and the 
plasmid DNA was eluted with elution buffer and collected. Plasmid DNA was 
precipitated with isopropanol, pelleted by centrifugation (5000 g, 15 min, 4°C), 
washed with 70% ethanol, pelleted and air dried for 15 min. The DNA was 
reconstituted in 200 µl sterile dH2O and stored at 4°C (Plasmid DNA purification Kit 
(Nucleo Bond® Xtra Maxi), Macherey Nagel, MA, USA). 
 
2.6.4 Transfection 
Transient transfections of luciferase reporter constructs were performed using 
FuGENE 6 (Wang, Gregori et al. 2004). 24 h after transfection, cells were infected 
with 10 MOI of the respective adenovirus or 30 µg/ml bleomycin (Cell Pharm GmbH, 
Hannover, Germany). 48 h after infection, cells were harvested and assayed for 
Luciferase activity as described by the manufacturer (Promega, Mannheim, 
Germany). 
To inhibit CD95L transactivation, HBV-infected cells were also pre-treated with a JNK 
II inhibitor (IC50= 40 nM), a reversible inhibitor of the c-Jun N-terminal kinase 
(InSolutionTM JNK Inhibitor II, Calbiochem, Darmstadt, Germany). To stimulate 
CD95L-luc transactivation 0.1 µg/ml recombinant human TNF-alpha (rh TNF-alpha, 
ImmunoTools, Friesoythe, Germany) was added. Furthermore, the TNF-receptor was 
blocked with 10 µg/ml Etanercept (Enbrel®) and CD95L-luc transactivation was 
assayed. In general, the cells were pre-treated with the inhibitors (JNK II inhibitor and 
Enbrel) 12 h prior infection and retreated after adenoviral infection, while TNF-alpha 
stimulation was only performed after infection. The generation of reactive oxygen 
species (ROS) was inhibited 30 min prior infection with 20 mM N-Acetyl-L-cysteine 
(NAC) from Sigma-Aldrich. 
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2.7 FACS  
2.7.1 Principle of FACS measurement 
Fluorescent-activated Cell Sorting (FACS) can be used to analyze and count single 
cells within a cell suspension. Equipped with up to four different lasers, it allows 
simultaneous multiparametic analysis. The forward scatter (FSC) and the sideward 
scatter (SSC) are used to differentiate the cells due to their size and granularity. 
Additional staining with antibodies coupled with a fluorescent dye to detect specific 
surface structures or intracellular proteins results in the emission of characteristic 
light signals while passing focused lasers. Emission is processed by the electronic 
detection apparatus. 
 
2.7.2 Sub-G1 (Nicoletti) staining for the detection of apoptosis 
Quantification of DNA fragmentation was performed by FACS analysis of propidium 
iodide-stained nuclei. Apoptotic cells with degraded DNA appear in the subG0/G1 
peak (Nicoletti, Migliorati et al. 1991) (FACSCalibur® flow cytometer (Becton 
Dickinson); CELLQuest® software).  
HBV-infected hepatocytes floating in the culture medium were collected by 
centrifugation at 200 g. Adherent hepatocytes were harvested by incubation with 1% 
trypsin for 2 min. The cells were washed with PBS, suspended in hypotonic lysis 
buffer (0.1% sodium citrate, 0.1% Triton X and 50 ng/ml propidium iodide) and 
incubated at 4°C for 2 h and analysed using FACSCalibur .  
 
2.7.3 Cell surface staining 
Cell surface expression of CD95, TRAILR1 and TRAILR2 after HBV infection was 
assessed by FACSCalibur®. A total amount of 2*105 HBV-infected hepatocytes were 
detached with EDTA (2 mM) treatment 72 h p.i. and stained with APO-1-1, TRAILR1 
and TRAILR2 or control mAb IgG1 for 30 min at 4°C. P rimary antibody staining was 
followed by biotinylated secondary goat anti-mouse antibody and Streptavidin-PE 
incubation (20 min, 4°C). To determine the amount of  apoptotic cells propidium 
iodide was added (1:2000). 
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Table 2.11 Overview of primary and secondary antibodies used for flow cytometry 
1st Antibody dilution 2nd Antibody dilution 3rd Antibody dilution 
APO-1-1 (Enzo 
Life Science) 
1:50 
Biotinylated secondary goat anti-
mouse antibody (Southern 
Biotechnology Associates, 
Birmingham, Alabama, USA) 1:200 
Streptavidin–
PE 
(Pharmingen) 1:200 
TRAILR1 (Alexis) 
1:100 
Biotinylated secondary goat anti-
mouse antibody (Southern 
Biotechnology Associates) 1:200 
Streptavidin–
PE 
(Pharmingen) 1:200 
TRAILR2 (Alexis) 
1:100 
Biotinylated secondary goat anti-
mouse antibody (Southern 
Biotechnology Associates) 1:200 
Streptavidin–
PE 
(Pharmingen) 1:200 
control mAb IgG1 
(Santa Cruz 
Biotechnology) 1:200 
Biotinylated secondary goat anti-
mouse antibody (Southern 
Biotechnology Associates) 1:200 
Streptavidin–
PE 
(Pharmingen) 1:200 
control mAb IgG1 
(Santa Cruz 
Biotechnology) 1:200 
APC-labelled affinity purified 
F(ab’)2-fragment goat anti-mouse 
(Dianova, Hamburg, Germany) 1:200 
 
 
control anti-rabbit 
IgG (Santa Cruz 
Biotechnology) 1:200 
APC-labelled affinity purified 
F(ab’)2-fragment goat anti-rabbit 
(Dianova) 1:200 
 
 
Bax (Santa Cruz 
Biotechnology) 
1:50 
APC-labelled affinity purified 
F(ab’)2-fragment goat anti-mouse 
(Dianova) 1:200 
 
 
Noxa (Santa Cruz 
Biotechnology) 
1:50 
APC-labelled affinity purified 
F(ab’)2-fragment goat anti-mouse 
(Dianova) 1:200 
 
 
Puma (Santa Cruz 
Biotechnology) 
1:50 
APC-labelled affinity purified 
F(ab’)2-fragment goat anti-rabbit 
(Dianova) 1:200 
 
 
Caspase 3 (Cell 
Signalling) 
1:50 
APC-labelled affinity purified 
F(ab’)2-fragment goat anti-rabbit 
(Dianova) 1:200 
 
 
Caspase 9 (Cell 
Signalling) 
1:50 
APC-labelled affinity purified 
F(ab’)2-fragment goat anti-rabbit 
(Dianova) 1:200 
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2.7.4 Detection of intracellular proteins 
Expression of intracellular proteins involved in apoptosis signalling was analyzed by 
intracellular fixation and staining for the respective proteins. A total amount of 2*105 
HBV-infected hepatocytes were detached with 1% trypsin 48 h post infection (p.i.). 
Cells were incubated with 100 µl Cytofix/ Cytoperm (Becton Dickinson) for 20 min 
(4°C, dark). Cells were stained with anti-Bax, or anti -Noxa mouse anti-human IgG1 or 
control IgG1 antibody, anti-Puma rabbit anti-human IgG or control anti-rabbit IgG, 
cleaved caspase-3 antibody or caspase-9 antibody anti-human IgG or control anti-
rabbit IgG. APC-labelled affinity purified F(ab’)2-fragment goat anti-mouse or anti-
rabbit IgG Fc antibody was used as secondary detecting reagent. Before analyzing 
the samples by flow cytometry, cells were washed twice with 200 µl Perm/Wash 
solution (Becton Dickinson) and resuspended in 50 µl Perm/Wash solution. 
 
2.7.5 Determination of mitochondrial membrane potential  
Cells were harvested, washed once with PBS and incubated with 20 nM 1,10 
dihexadecyl-3,3,30,30-tetramethylin-docarbocyanine perchlorate (DiIC1), (Invitrogen) 
for 20 min at 37°C (dark), washed once and analyzed at a n excitation of 633 nm by 
flow cytometry (Seitz, Schleithoff et al. 2010). 
 
2.8 Quantitative real time PCR  
2.8.1 Introduction 
Quantitative real time PCR (qPCR) reaction is the most sensitive technique for cDNA 
quantifications and detections. Quantity can be either given in an absolute number of 
copies (absolute quantification) or as a relative amount compared to reference genes 
(relative quantification). In contrast to a traditional PCR, a real time PCR reaction is 
combined with a fluorescent detection system. The two different fluorescent detection 
systems available today are (i) non-specific DNA intercalating fluorescent dyes, e.g. 
SYBR Green and (ii) sequence-specific oligonucleotide DNA probes, labelled with a 
fluorescent reporter, permitting detection after hybridization with its corresponding 
DNA target. The probe-based detection system was used for the following 
experiments. 
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2.8.2 qPCR conditions and protocols  
Total RNA was extracted from Hep3B-, HepG2-cells and PHHs cells infected with 10 
MOI AdGFP or Adp53, AdHBV wt, AdHBV-X-, AdHBV-L-, using the RNeasy Mini-Kit 
(Qiagen). The cDNAs were synthesised from total RNA (1 µg) using the QuantiTect 
Reverse Transcription Kit, Qiagen. 
 
Table 2.12a Genomic DNA elimination reaction components 
 
   
 
 
 
Table 2.12b ReverseTranscription Master-Mix 
 
 
 
 
 
 
 
 
Table 2.13 Primer sequences and probes used for qPCR analysis 
 
The entire genomic DNA elimination reaction was incubated for 2 min at 42°C and 
added to each tube containing Reverse Transcription Master-Mix. The RNA mix was 
incubated for 15 min at 42°C, inactivated for 3 min at  95°C and stored at -20°C. 
 1x 
gDNA Wipeout Buffer, 7x 2 µl 
Template RNA 1 µg 
RNase-free water x µl 
Volume 14 µl 
 1x 
Quantiscript® Reverse 
Transcriptase 1 µl 
Quantiscript RT Buffer 
(5x, includes Mg2+ and 
dNTPs) 4 µl 
RT Primer Mix (optimized 
blend of oligo-dT and 
random primers) 1 µl 
Volume 6 µl 
Target gene Primer sequence Probe number 
hCD95 fwd: atggccaattctgccataag      rev: tgactgtgcagtccctagctt #65 
hCD95L fwd: gctggcagaactccgaga       rev: ttttcagggggtggactg #20 
hBax fwd: atgttttctgacggcaacttc       rev: atcagttccggcaccttg #57 
hNoxa fwd: ggagatgcctgggaagaag    rev: cctgagttgagtagcacactcg #67 
hPuma fwd: gacctcaacgcacagtacga   rev: gagattgtacaggaccctcca #68 
hApaf-1 fwd: ggcattcctgttgtctcttctt        rev: aaacaactggcctctgtgg #39 
PBGD fwd: cctgtttaccaaggagcttga     rev: ggagtgaacaaccaggtcca #37 
HPRT fwd: tgaccttgatttattttgcatacc    rev: cgagcaagacgttcagtcct #26 
HMBS fwd: tgtggtgggaaccagctc         rev: tgttgaggtttccccgaat #73 
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Transcript analysis was done with primer pairs purchased from Sigma-Aldrich and 
UPL probes purchased from Roche, Mannheim, Germany.  
Endogenous reference genes were used to correct for variation in RNA content and 
variation in the efficiency of the reverse transcription reaction. All primers were 
designed using the Probe Finder qPCR assay design software 
(www.universalprobelibrary.com). 
PCR conditions have been used as described by the manufacturer (LightCycler 480 
Probes Master Kit; Roche).  
 
Table 2.14 Reaction mix for real time PCR. *cDNA was diluted 1:50 for real time PCR (CD95L 
analysis 1:5) 
 
 
 
                           
 
 
Table 2.15 Running conditions LightCycler 480 
 
Analysis was performed by the LightCycler 480 quantification software.  
 
2.9 Enzyme-linked immunosorbent assay (ELISA) 
For the quantitative analysis of CD95L (FasL) secretion after HBV infection enzyme-
linked immunosorbent assay (ELISA) was used. The Fas Ligand ELISA Kit detecting 
soluble and membrane bound CD95L was purchased from Calbiochem and was 
performed according to the manufacturer’s protocol. Briefly, the 96 well microtiter 
plate was captured with the biotinylated detection antibody and was incubated 
simultaneously at RT for 3 h with the standards and samples. After washing 
conjugate diluent was added and incubated for 30 min at RT. Conjugate diluent was 
 1x 
Buffer 
Primer 10 µM 
Probe10 µM 
7.5 µl 
0.3 µl 
0.15 µl 
H2O 3.3 µl 
 11.25 µl 
cDNA* 3.75 µl 
 Cycles Target (°C) Acquisition Mode Time Analysis Method 
Preincubation 1 95 None 00:10:00 None 
Amplification 55 
95 
60 
None 
single 
00:00:10 
00:00:30 Quantification 
Cool Down 1 40 None 00:00:10 None 
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removed with an additional washing step and the samples were incubated with TMB 
substrate for 30 min at RT in the dark. After the addition of stop solution the 
absorbance was measured at a wavelength of 450/595 nm.  
 
2.10 Induction of apoptosis 
To induce CD95 receptor-mediated apoptosis the CD95 receptor was stimulated with 
the agonistic monoclonal antibody anti-APO-1 IgG3κ (kindly provided by P. Krammer, 
DKFZ, Heidelberg, Germany) at a concentration of 1 mg/ml as described 
(Chinnaiyan, Tepper et al. 1996). Furthermore, HBV-infected hepatocytes were 
treated with 3x concentrated (Vivaspin) supernatant of Jurkat 16 cells at 24 h post-
infection. Prior to supernatant collection, Jurkat 16 cells were pretreated with PMA/ 
Ionomycin for 24 h at a concentration of 100 nM PMA and 2 µM Ionomycin to allow 
CD95L secretion. The amount of apoptotic hepatocytes was determined via Nicoletti 
staining 72 h after infection. APG101 (10 µg/ml), an antagonistic antibody against 
CD95L, was used to inhibit the CD95-CD95L dependent apoptosis. 
 
2.11 Kits 
2.10.1 RNA extraction 
RNeasy Mini-Kit, Qiagen, Hilden, Germany 
 
2.11.2 RT and qPCR 
QuantiTect Reverse Transcription Kit, Qiagen, Hilden, Germany 
LightCycler 480 Probes Master Kit; Roche, Mannheim, Germany 
 
2.11.3 Plasmid propagation 
One Shot Top10, Invitrogen, Karlsruhe, Germany 
Plasmid DNA purification Kit (Nucleo Bond® Xtra Maxi), Macherey Nagel, MA, USA 
 
2.11.4 Cloning 
In-Fusion HD Cloning Kit, Clontech, Mountain View, CA, USA 
Advantage HD Polymerase, Clontech, Mountain View, CA, USA 
QIAEXII Gel Extraction Kit, Qiagen, Hilden, Germany 
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2.11.5 Restriction enzymes  
FastDigest® XhoI 5’…C^TCGAG…3’ (#FD0694, Fermentas, St. Leon-Rot, Germany) 
FastDigest®HindIII 5’…A^AGCTT…3’ (#FD0504, Fermentas, St. Leon-Rot, Germany) 
 
2.11.6 Phosphoplex 
Milliplex® Map Kit, Millipore, Billerica, MA, USA 
Bio-Plex Cell Lysis Kit, Bio-Rad, Munich, Germany 
Bio-Plex Phosphoprotein and Total Target Assays, Bio-Rad, Munich, Germany 
Bio-Plex Phosphoprotein Detection Reagent Kit, Bio-Rad, Munich, Germany 
 
2.11.7 FACS analysis 
Cytofix/Cytoperm, Becton Dickinson, Heidelberg, Germany  
 
2.12 Signalling pathways 
The signalling pathways were generated with the help of the pathway builder from 
protein lounge (www.proteinlounge.com). 
 
2.13 Statistical analysis 
All data were analyzed by ANOVA (analysis of variance) or Student’s t-test to test for 
statistical significance. Statistical analysis was carried out using the SAS software 
system (SAS Institute Inc., Cary, NC, USA). p-Values ≤0.05 were considered 
statistically significant.  
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2.14 Chemicals 
Acrylamide (30%) Roth, Karlsruhe, Germany 
Agar-Agar  Roth, Karlsruhe, Germany 
Agarose Roth, Karlsruhe, Germany 
Ampicillin Sigma-Aldrich, Deisenhofen, Germany 
APS Roth, Karlsruhe, Germany 
BES Sigma-Aldrich, Deisenhofen, Germany 
ß-Mercapto-Ethanol Roth, Karlsruhe, Germany 
BSA Biomol, Hamburg, Germany 
Caffeine Sigma-Aldrich, Deisenhofen, Germany 
CaCl2 Sigma-Aldrich, Deisenhofen, Germany 
Cell Culture Lysis Reagent 5x Promega, Mannheim, Germany 
DMSO Roth, Karlsruhe, Germany 
EDTA Roth, Karlsruhe, Germany 
EGTA Sigma-Aldrich, Deisenhofen, Germany 
Acetic-acid Roth, Karlsruhe, Germany 
Ethanol Roth, Karlsruhe, Germany 
Ethidium-bromide Roth, Karlsruhe, Germany 
Glucose Roth, Karlsruhe, Germany 
Glycerol Roth, Karlsruhe, Germany 
Glycin Roth, Karlsruhe, Germany 
Insulin Serva Feinbiochemica, Heidelberg, Germany 
Kanamycin Merck, Darmstadt, Germany 
KCl Merck, Darmstadt, Germany 
Luciferin Promega, Mannheim, Germany 
Methanol Roth, Karlsruhe, Germany 
Na-Acetate Merck, Darmstadt, Germany 
Na-Citrate Roth, Karlsruhe, Germany 
NaCl Roth, Karlsruhe, Germany 
Na2HPO4 Serva Feinbiochemica, Heidelberg, Germany 
NaOH Roth, Karlsruhe, Germany 
N-Acetyl-L-cysteine 
Nitrocellulose-Membrane 
Sigma-Aldrich, Deisenhofen, Germany 
Amersham Pharmacia, Freiburg, Germany 
PBS (1x, sterile) Invitrogen, Karlsruhe, Germany 
Propanol Roth, Karlsruhe, Germany 
Propidium-Iodide Roth, Karlsruhe, Germany 
SDS Roth, Karlsruhe, Germany 
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TEMED Roth, Karlsruhe, Germany 
TRIS Roth, Karlsruhe, Germany 
Triton-X-100 Serva Feinbiochemica, Heidelberg, Germany 
Trypsin-EDTA (0.05% Trypsin, 0.2 g/l 
EDTA) 
Invitrogen, Karlsruhe, Germany 
Trypton Becton Dickinson, Heidelberg, Germany 
Tween Roth, Karlsruhe, Germany 
Water (sterile, distilled) Pharmacy University Hospital Heidelberg, 
Germany 
Whatman Paper Whatman, Maidstone, UK 
 
All current laboratory materials not listed here have been purchased from the major 
suppliers, e.g. Becton Dickinson, Roth, Bio-One, Merck, Greiner. 
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3. Results 
 
The direct molecular mechanisms through which HBV-infected cells are eliminated 
by the immune system as well as the signalling pathways up-regulated in infected 
host cells to combat the virus are still ill-characterized. The present study was 
designed to investigate both the influence of the hepatocytes’ p53 status on the 
outcome of HBV infection and vice versa, the influence of HBV infection on p53 and 
p53 target gene activation in hepatocytes. The aim was to elucidate factors leading to 
persistence of HBV and, thus, to HBV-induced hepatocarcinogenesis (viral clearance 
vs. chronicity). The use of different adenoviral HBV vectors (knock-out constructs and 
the HBV wt construct), two hepatoma cell lines and, of note, primary human 
hepatocytes allow us to work with an infection model closely related to the in vivo 
situation and to generate clinically relevant data. The following data provide evidence 
that a functional CD95 apoptosis pathway and an intact p53 status are essential for 
the elimination of HBV-infected cells by the immune system and that defects in these 
signalling pathways favours the development of chronic HBV infection and 
hepatocellular carcinoma. In addition, the role of the intrinsic apoptosis signalling 
pathway and the important function of the viral HBx protein for viral clearance are 
described. Finally, the following data indicate that HBV-infected hepatocytes are not 
only sensitive towards CD95-mediated apoptosis induced by CD95L-secreting 
lymphocytes, but that HBV-infected hepatocytes are also able to secret CD95L 
themselves.  
 
 
3.1 Hepatitis B virus infection, p53 and the extrinsic apoptosis 
signalling pathway 
 
The tumour suppressor p53 is stabilized and activated amongst others by DDR-
induced post-translational phosphorylation in response to cellular stress. In 
hepatocellular carcinoma (HCC) the p53 pathway is affected at multiple levels. Given 
that several DNA viruses, including HBV, more precisely the viral HBx protein, trigger 
or interfere with cellular signalling cascades characteristic of a DDR, the following 
experiments elucidated whether HBV wt infection leads to the activation of a DDR 
and therefore stabilization and activation of p53.  
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3.1.1 Hepatitis B virus infection induces p53 accumulation and activation via 
the DNA damage pathway 
Adenoviral transfer of the different recombinant HBV constructs (AdHBV X-, AdHBV 
L- and AdHBV wt) into the hepatoma cell lines HepG2 and Hep3B resulted in the 
accumulation of tumour suppressor p53 in p53+/+ HepG2 cells. As expected, no p53 
could be detected in the p53-/- Hep3B cells (figure 3.1). Adenoviral transfer of 
recombinant HBV constructs into primary human hepatocytes (PHHs), as a clinically 
relevant model, also resulted in the accumulation of p53. 
 
 
Figure 3.1 HBV infection induces up-regulation of endogenous p53 Western blot analysis of 
HepG2-, Hep3B-cells 48 h post HBV infection and PHHs 60h post HBV infection, showing an increase 
in p53 levels in HepG2 cells and PHHs. n.d. = not detected, ß-Actin was used as an internal control.  
 
Based on this observation, the mechanism leading to the stabilization and 
accumulation of p53 in HBV-infected hepatocytes was investigated. Specifically, p53 
was stabilized by Ser15 phosphorylation, one of the two serines typically becoming 
phosphorylated after DNA damage (figure 3.2) (Siliciano, Canman et al. 1997). As 
several DNA viruses trigger cellular signalling cascades characteristic of a DDR and 
the HBV protein HBx is known to interfere with the DNA damage pathway, we 
analyzed whether a cellular DDR is responsible for p53 accumulation observed upon 
HBV infection. Figure 3.2 shows the phosphorylation status of prominent members of 
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the DNA damage pathway upon infection with the indicated adenoviral HBV 
constructs. Adenoviral HBV infection resulted in Ser428 phosphorylation of the protein 
kinase ATR, Thr68 phosphorylation of CHK2 and 53BP1 accumulation. The analysis 
of the phosphorylation status of proteins involved in the DDR revealed cell type 
specific differences. While, as expected, there was no serine 15 phosphorylation of 
p53 in Hep3B cells, HepG2 cells and PHHs showed an increased p53 
phosphorylation on serine 15. Hep3B cells in contrast, showed the highest increase 
in threonine 68 phosphorylation of CHK2. In PHHs the phosphorylation of ATR on 
Ser428 was 22-fold higher in cells infected with AdHBV wt than in cells infected 
AdGFP, an effect which could not been observed in the hepatoma cell lines. The 
maximal fold increase in hepatoma cell lines was 1.5. The accumulation of 53BP1 
was similar in all three cell lines.  
 
Figure 3.2 HBV infection triggers the activation of the DNA damage response Western blot 
analysis of HepG2-, Hep3B-cells and PHHs after HBV infection, showing the phosphorylation of 
proteins involved in the DNA damage response. Protein extracts were prepared as indicated in 
chapter 2.4.2. For the detection of the phosphorylation status of DNA damage proteins the following 
time points were used: p-p53 (Ser15), p-ATR (Ser428), p-CHK2 (Thr68) and 53BP1 24 h p.i. (HepG2 and 
Hep3B); all proteins detected in HBV-infected PHHs were harvested 60 h p.i.; n.d. = not detected,     
ß-Actin was used as an internal control.  
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While the HBx-containing adenoviral constructs (AdHBV L- and AdHBV wt) led to an 
increased phosphorylation of all screened DNA damage proteins, infection with 
AdHBV X- as well as AdGFP resulted only in a minor or no increase in the 
phosphorylation status of the proteins.   
Furthermore, HBV infection did not only lead to the phosphorylation of p53 on serine 
15 but also to Jun-NH2 kinase (JNK) phosphorylation on Thr183/Tyr185.  
Phosphorylation of JNK is another event leading to the phosphorylation of p53 under 
cellular stress. The increased phosphorylation of JNK was statistically significant in 
HepG2 and Hep3B cells. In addition, HBV infection resulted in PARP-1 cleavage, an 
unalterable marker of apoptosis induction, in the presence and absence of p53 
(figure 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Infection of HepG2-, Hep3B-cells and PHHs with AdHBV wt results in the 
phosphorylation of p53 (p-p53 Ser15), JNK (Thr183/Tyr185) and PARP-1 cleavage Phosphorylation 
status was determined using Luminex® xMAP® technology (Phospho-Mek, Phospho-Erk and GAPDH 
were used as internal controls, not shown here). Except for the p-p53 signal in Hep3B cells, the 
differences between AdGFP and AdHBV wt are statistically significant (*p≤0.05 as determined by 
Student’s t-test). 
p-p5
3 (Se
r 15
)
p-JN
K 
clea
ved
 
PAR
P-1
0
2
4
6
8
100
200
fo
ld 
in
cr
e
as
e
 
(flo
u
re
sc
en
ce
 
in
te
n
si
ty
)
p-p5
3 (Se
r 15
)
p-JN
K 
clea
ved
 
PAR
P-1
0
2
10
15
20
fo
ld 
in
cr
ea
se
 
(flu
o
re
sc
e
n
ce
 
in
te
n
st
ity
)
p-p5
3 (Se
r 15
)
p-JN
K 
clea
ved
 
PAR
P-1
0
2
4
10
15
20
fo
ld 
in
cr
ea
se
 
(flu
o
re
sc
e
n
ce
 
in
te
n
si
ty)
*
AdGFP
AdHBV wt
*
*
*
*
*
HepG2 Hep3B
PHH
fo
ld 
in
cr
e
as
e
 
(flo
u
re
sc
en
ce
 
in
te
n
si
ty
)
fo
ld 
in
cr
ea
se
 
(flu
o
re
sc
e
n
ce
 
in
te
n
st
ity
)
fo
ld 
in
cr
ea
se
 
(flu
o
re
sc
e
n
ce
 
in
te
n
si
ty)
* 
* 
 52 Results 
In summary, these results reveal that HBV infection induces phosphorylation and 
activation of prominent proteins involved in the DDR, suggesting an integral role of 
ATM/ATR in the HBV-induced phosphorylation of p53. 
 
3.1.2 Apoptosis induction in HBV-infected hepatocytes is dependent on p53 
activation via the DNA damage pathway 
In order to investigate whether p53 phosphorylation and accumulation is also 
associated with its transcriptional activity and stability, the induction of apoptosis in 
HBV-infected hepatocytes was analysed next (figure 3.4).  
 
Figure 3.4 Apoptosis of HBV-infected hepatocytes Infection of HepG2-, Hep3B cells and PHHs 
with AdHBV led to an increased apoptosis induction within 72 h. FACSCalibur® analysis of propidium 
iodide stained nuclei in the subG0/G1 population. Error bars represent standard deviation             
(Mean ± SD, n=3); one representative experiment out of 3 independent experiments is shown, 
respectively. The differences between AdGFP and AdHBV wt are statistically significant in HepG2- 
and Hep3B cells. In Hep3B cells Adp53 addition led to a synergistic effect in apoptosis induction. 
(*p≤0.05 as determined by Anova, Bonferroni’s multiple range test). Western blot analysis of cleaved 
PARP-1 was used for apoptosis determination at 60 h p.i. in PHHs. ß-Actin served as an internal 
control.  
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Infection of HepG2-, Hep3B-cells and PHHs with adenoviral HBV constructs thereby 
led to an increased apoptosis induction within 72 h analysed by the amount of 
propidium iodide (PI) stained nuclei in the subG0/G1 population. The differences 
between AdGFP and AdHBV wt were statistically significant in HepG2- and Hep3B 
cells. Combined adenoviral transfer of Adp53 and the HBx-containing adenoviral 
constructs, AdHBV L- and AdHBV wt, resulted in a synergistic increase of apoptosis 
in Hep3B cells. In PHHs induction of apoptosis was shown by western blot analysis 
of cleaved PARP-1. Similar to the results obtained for the hepatoma cell lines the 
highest amount of apoptotic cells could be observed in PHHs infected with       
AdHBV wt. Adenoviral transfer of the different HBV constructs led to an accumulation 
of PARP-1, but in contrast to the other HBV constructs only AdHBV wt triggered the 
cleavage of PARP-1 and, therefore, apoptosis induction. The induction of apoptosis 
was markedly less in cells infected with the HBx knock-out construct (AdHBV X-) 
compared to cells infected with the HBx-containing constructs. Induction of apoptosis 
by HBV wt was also accompanied by cleavage of PARP-1 in the used hepatoma cell 
lines (figure 3.3).  
To investigate the role of the DDR in the apoptosis induction of HBV-infected 
hepatocytes, we used the specific ATM/ATR inhibitor caffeine to test whether 
apoptosis is dependent on the activation of ATM/ATR (figure 3.5). For this, HepG2 
and Hep3B cells were treated 24 h prior HBV infection with 5 mM caffeine. The 
amount of PI positive nuclei in the subG0/G1 population was analyzed at 96 h p.i. with 
HBV. The number of propidium iodide stained and, therefore, apoptotic cells was 
decreased in samples infected with HBV and additionally treated with caffeine. Pre-
treatment with caffeine inhibited the induction of apoptosis in HepG2 cells infected 
with each of the three adenoviral HBV constructs. The amount of apoptotic cells was 
similar to the amount of apoptotic cells obtained with AdGFP infection. In Hep3B 
cells, caffeine treatment of cells infected with the AdHBV X- and AdHBV L- 
constructs also inhibited the induction of apoptosis. In the case of AdHBV wt no 
effect could be detected, the amount of PI positive cells was almost the same as in 
cells without caffeine treatment. 
 
Thus, we hypothesise that HBV infection leads to the induction of apoptosis and that 
apoptosis induction is at least partly dependent on the activation of the DNA damage 
response, specifically on ATR/ATM.  
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Figure 3.5 Apoptosis induction in HBV-infected hepatocytes is dependent on p53 activation via 
the DNA damage pathway Treatment of HepG2 and Hep3B cells with caffeine (5 mM), an ATM/ATR 
inhibitor, prior infection with HBV results in a reduction of HBV-induced apoptosis. The apoptosis rate 
of hepatocytes infected with AdHBV wt was set to 100%, reduction of apoptosis was calculated 
accordingly for the other constructs. The amount of propidium iodide positive cells was calculated at 
96h p.i. Error bars represent standard deviation (Mean ± SD, n=3).  
 
 
3.1.3 HBV infection sensitizes hepatocytes towards p53-dependent and CD95-
mediated apoptosis 
In order to study the role of p53 target genes in the apoptosis of HBV-infected 
hepatocytes, infected hepatocytes were screened for the activation of prominent p53 
target genes involved in apoptosis signalling. One well-described target of p53 
playing a pivotal role in the activation of the extrinsic apoptosis signalling pathway is 
the cell surface death receptor CD95 (Fas). Müller et al. have previously shown that 
wt p53 transactivates the CD95 gene via binding to a regulatory region within the first 
intron (figure 3.6a) (Müller, Wilder et al. 1998). In both, Hep3B and HepG2 cell lines, 
infection with the different AdHBV constructs resulted in an increased CD95 gene 
activity 24h p.i. as determined by luciferase reporter assay (figure 3.6b). In contrast 
to HepG2 cells where HBV infection alone was already sufficient to induce CD95 
gene transactivation, p53-/- Hep3B cells only show a minor increase in CD95 
transactivation. However, in both cell lines infection with AdHBV wt led to a 
significant increase in gene transactivation. Co-infection of Adp53 with AdHBV in 
Hep3B cells elevated the CD95 transactivation levels.  
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Figure 3.6 HBV infection cooperates with p53 in the transactivation of the CD95 gene, leading 
to an up-regulation of CD95 mRNA in HBV-infected hepatocytes (a) Map of the human CD95 
gene. Exons 1-9 are numbered and represented by black boxes on the upper line. The wild-type 
sequence (top row) of the intronic p53 binding site (p53-IBS) is shown in comparison to the consensus 
p53 binding site (bottom row) (R=purine, Y= pyrimidin, W=A or T). (b) Analysis of HBV-dependent, 
CD95 promoter driven luciferase activity. HepG2- and Hep3B cells were transfected with 1 µg wt 
p1142CD95-luc and infected with 10 MOI of the respective adenoviral HBV constructs. Hep3B-cells 
were additionally infected with Adp53. Shown is the fold increase of each adenoviral HBV construct, 
calculated relative to the value obtained with AdGFP. (c) Quantification of CD95 mRNA in HBV-
infected hepatocytes by real time PCR after 24 h (72 h for PHHs).  
One representative experiment out of 3 independent experiments is shown, respectively (Mean ± SD, 
n=3). The differences between AdGFP and AdHBV wt are statistically significant (**p≤0.01, ***p≤0.001 
as determined by Anova, Bonferroni’s multiple range test). 
 
As a consequence of gene activation, HBV infection led to an up-regulation of CD95 
transcription in HepG2 cells (p53+/+) and PHH (figure 3.6c). In p53-/- Hep3B cells no 
CD95 transcription was observed. As CD95 is a typical p53 target gene this was 
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expected. However, after co-infection of AdHBV and exogenous Adp53, Hep3B cells 
showed similar CD95 transcription levels as observed in HepG2 cells. Similar to the 
results described above, CD95 transcription was weaker in hepatocytes infected with 
HBx negative adenoviral HBV constructs. 
 
Given that HBV infection resulted in the transactivation and transcription of CD95 we 
were interested to know whether there was also CD95 receptor expression on the 
surface of HBV-infected hepatocytes. Therefore, receptor expression was 
determined by FACSCalibur analysis (figure 3.7a). Adenoviral transfer of the different 
AdHBV constructs and AdGFP as control resulted in an increase in CD95 expression 
on the surface of HepG2 cells. The difference between AdGFP and AdHBV wt was 
statistically significant. Addition of exogenous Adp53 led to a synergistic effect in 
CD95 expression in Hep3B cells infected with the HBx-containing HBV constructs, 
AdHBV L- and AdHBV wt, which was also statistically significant in the case of 
AdHBV wt. 
Up-regulation of CD95 receptor resulted in an increased responsiveness towards 
CD95-mediated apoptosis. In fact, treatment with the agonistic, apoptosis-inducing 
antibody IgG3 anti-APO-1 (AA1) triggered cell death in HBV-infected hepatocytes 
(figure 3.7b). In HepG2 cells the amount of apoptotic cells increased from basically 
20% to almost 70% in the case of AdHBV wt. In contrast, AdHBV X- and AdHBV L- 
rarely showed a difference in the induction of apoptosis after AA1 treatment 
compared to AdGFP. However, AdHBV L- clearly induces apoptosis without 
additional treatment with AA1. In AdHBV- and Adp53-infected Hep3B cells additional 
treatment with AA1 also resulted in an increase of apoptosis, even if the observed 
effect was less than in HepG2 cells. 
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Figure 3.7 HBV infection 
together with p53 sensitizes 
hepatocytes towards CD95-
mediated apoptosis (a) 
Quantitative flow cytometry 
analysis (FACSCalibur®) of 
CD95 receptor expression in 
HBV-infected HepG2- and 
Hep3B cells. Only HepG2 
cells, possessing endogenous 
p53, display up-regulated 
CD95 receptor expression. 
Hep3B cells, lacking p53, were 
additionally treated with Adp53 
to obtain CD95 receptor up-regulation. Percent of CD95 expression was calculated as                        
% CD95+- % isotype control. (*p≤0.05, ***p≤0.001 as determined by Anova, Bonferroni’s multiple 
range test). One representative experiment out of 3 independent experiments is shown             
(Mean± SD, n=3).   
(b) Addition of the CD95 specific agonistic anti-APO-1 antibody (AA1) following HBV infection resulted 
in the induction of CD95-mediated apoptosis. AA1 was added at 72 h p.i. (post infection) for further   
24 h. This led to a significant increase of apoptosis mediated by CD95 in HepG2 cells. In He3B cells 
Adp53 was co-infected. The 
figure shows the apoptosis 
induction of cell treated with 
Adp53, AdHBV and AA1. 
Apoptosis was detected by PI 
staining followed by FACS 
analysis. The difference in 
CD95-mediated apoptosis 
between AdGFP and AdHBV wt 
infected hepatocytes are 
statistically significant (*p≤0.05, 
***p≤0.001 as determined by 
Anova, Bonferroni’s multiple 
range test). One representative 
experiment out of 5 independent experiments is shown (Mean ± SD, n=3).  
 
As a result of the experiments obtained with the agonistic antibody IgG3 anti-APO-1 
we wanted to look in more detail at the CD95-mediated apoptosis of HBV-infected 
hepatocytes. Therefore, HBV-infected hepatocytes were treated with the supernatant 
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of PMA/Ionomycin-treated (P/I) Jurkat 16 cells (SNJ16), which secret soluble CD95L 
in an increased amount after P/I stimulation, to induce CD95-mediated apoptosis and 
the induction of apoptosis was monitored. Treatment with SNJ16 resulted in a 
significant increase in the amount of propidium iodide positive nuclei in the subG0/G1 
population (figure 3.8). Up to 60% of the infected hepatocytes underwent CD95-
mediated apoptosis after HBV infection and additional treatment with SNJ16. 
Whereas the apoptosis rate of HepG2 cells did not exceed 40% in total, Hep3B cells 
benefited from the exogenous Adp53 addition, which led to apoptosis rates between 
40 and 60%.  
 
Figure 3.8 HBV-infected hepatocytes are sensitive towards CD95L-mediated apoptosis HepG2-, 
Hep3B-cells were infected with 10 MOI of the respective adenoviral HBV constructs. In the case of 
Hep3B-cells Adp53 was added. 72 h p.i. HBV-infected hepatocytes were additionally treated with the 
supernatant of CD95L-secrecting Jurkat 16 cells (SNJ16), for another 24 h. Apoptosis was detected 
by propidium iodide stained nuclei. APG101 (10 µg/ml) was used to inhibit CD95-dependent 
apoptosis. Error bars represent standard deviation of six independent experiments (Mean± SD, n=6). 
The difference in CD95-mediated apoptosis between AdGFP and AdHBV wt infected hepatocytes is 
statistically significant (*p≤0.05 compared to AdGFP, **p≤0.01 compared to the next left column, as 
determined by Anova, Bonferroni’s multiple range test). 
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To verify, that the increased induction of apoptosis was indeed CD95-mediated, we 
used APG101, a decoy receptor for CD95L (CD95Fc; 10 µg/ml) to specifically inhibit 
CD95-dependent apoptosis. Additional treatment of HBV-infected and SNJ16-treated 
hepatocytes with APG101 resulted in a decreased amount of propidium iodide 
positive cells and, therefore, in inhibition of CD95-mediated apoptosis of HBV-
infected hepatocytes. 
 
The effect of CD95L on the HBV-infected hepatocytes was, furthermore, visualized 
with the help of multicellular tumour spheroids (MCTS). Multicellular tumour 
spheroids are a well-established 3-D in vitro system simulating the 
pathophysiological in vivo situation in tumour microregions. In particular, spheroids 
can be used as an in vitro model to study tumour-immune cell interactions. Due to 
the results we obtained so far in this work, we show that an intact CD95 apoptosis 
system is essential for the elimination of HBV-infected hepatocytes. MCTS were 
used to further analyze and characterize the CD95-mediated apoptosis of HBV-
infected hepatocytes by CD95Ligand-secreting lymphocytes. 
Adenoviral transfer of the distinct recombinant HBV constructs into MCTS (generated 
from Hep3B cells) resulted in the inhibition of proliferation as well as the induction of 
apoptosis of hepatocytes (figure 3.10). To promote CD95-mediated apoptosis, HBV-
infected MCTS were treated with the supernatant (SNJ16) of CD95Ligand-secreting 
lymphocytes (Jurkat 16). While the treatment of MCTS with the supernatant of 
CD95Ligand-secreting lymphocytes merely led to a reduced hepatocyte-migration 
out of the spheroid, the treatment of HBV-infected MTCS with SNJ16 resulted in the 
induction of apoptosis and the disaggregation of the MCTS. This effect was boosted 
through additional adenoviral transfer of p53 (figure 3.9).  
Using MCTS, the interaction between HBV-infected hepatocytes and CD95Ligand 
secreting lymphocytes could be characterized. CD95Ligand secreting lymphocytes 
are able to induce CD95-mediated apoptosis in HBV-infected spheroids which 
confirmed the observations we obtained in experiments with monolayer cells         
(c.f. figure 3.6 -3.8).  
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(a)  
(b)        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Multicellular tumour spheroids visualize the pro-apoptotic effect of CD95L-
containing supernatant on HBV-infected hepatocytes Spheroids containing 25,000 Hep3B cells 
were embedded into a collagen matrix and infected with the different recombinant adenoviral HBV 
constructs and treated or not treated with the supernatant of PMA/Ionomycin stimulated Jurkat 16 
cells. (a) Spheroids infected with AdGFP, AdHBV X-, AdHBV L- and AdHBV wt in comparison at 24 h 
p.i. Fluorescence pictures on the right show the amount of infected cells. (b) In the picture the different 
treatments and the subsequent migration reduction can be seen. Cell migration was monitored for 16 
days by photographing the spheroids with an inverted Leica phase contrast microscope at 4x 
magnification at time zero and in 72 h intervals.  
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Figure 3.10 HBV infection reduces the migration radius of MCTS Spheroids containing 25,000 
Hep3B cells were embedded into a collagen matrix and infected with recombinant adenoviral HBV wt, 
Adp53 and treated or untreated with the supernatant of PMA/Ionomycin stimulated Jurkat 16 cells. 
Cell migration was monitored for 16 days by photographing the spheroids with an inverted Leica 
phase contrast microscope at time zero and in 72h intervals. Calculation of invaded areas was done 
with Zeiss Axio Vision Release 4.6.3-SP1 software. The size of the untreated spheroid at day 1 was 
set to 1; the fold increase of cell migration was calculated accordingly.  
 
In summary, these data provide evidence that the apoptosis of HBV-infected cells is 
mediated by the p53 target gene CD95. Combined adenoviral transfer of Adp53 and 
AdHBV led to a synergistic transactivation of the CD95 gene, consecutive up-
regulation of the CD95 receptor and an increased responsiveness of HBV-infected 
hepatocytes towards CD95-mediated apoptosis. 
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3.1.4 HBV infection leads to an increased expression of TRAILR2 in hepatoma 
cell lines 
Beside CD95 various other cell death receptors play an important role in the 
induction of apoptosis. The p53 target gene TNF related apoptosis inducing ligand 
receptor 2 (TRAILR2) is one of them. The expression of TRAILR2 was analyzed in 
HepG2- and Hep3B cells at 72 h post HBV infection (figure 3.11). In contrast to 
CD95, TRAILR2 was expressed in both hepatoma cell lines. Although, Adp53 was 
co-infected into Hep3B cells, AdHBV infection alone was sufficient enough to induce 
TRAILR2 expression. Nevertheless, Adp53 boosted the effect of AdHBV infection. 
Similar to CD95 expression, the TRAILR2 level was not significantly modulated in 
cells infected with AdHBV X-.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 In p53-/- Hep3B cells HBV infection results in the up-regulation of TRAILR2             
(a) Quantification of TRAILR2 mRNA in HBV-infected hepatocytes by real time PCR after 24 h. (b) 
Quantitative flow cytometry analysis (FACSCalibur®) of TRAILR2 receptor expression in HBV-infected 
hepatocytes. Percent of TRAILR2 expression was calculated as % TRAILR2+- % isotype control. 
White bars represent mRNA and accordingly protein expression in HeG2-, and Hep3B-cells infected 
with AdHBV. Black bars show the effect of Adp53 and AdHBV co-infection on TRAILR2 transcription 
and expression. Error bars represent standard deviation of 3 independent experiments (Mean± SD, 
n=3). The difference between AdGFP and Adp53 infected hepatocytes is statistically significant 
(**p≤0.01 compared to the next left column, as determined by Anova, Bonferroni’s multiple range test). 
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3.1.5 The p53 hot-spot mutant p53R248W inhibits apoptosis of HBV-infected 
hepatocytes 
Whereas the hallmark of wild-type (wt) p53 is its tumour suppressor activity, tumour-
associated mutant p53 proteins can exert not only dominant-negative activities but 
also novel anti-apoptotic “gain-of-function” (GOF) activities, which confer a selective 
advantage for tumour cells harbouring such mutations (Solomon, Madar et al. 2011). 
“GOF” mutants of p53 are oncogenic by repressing the activity of genes regulating 
both the extrinsic and the intrinsic apoptosis signalling pathway. Furthermore, mutant 
p53 bind and inactivate the TA-isoforms of the p53 family members’ p63 and p73, 
thus, contributing to apoptosis resistance (Schilling, Kairat et al. 2010). 
 
Combined adenoviral transfer of AdHBV and wt p53 into Hep3B cells led to an 
increased CD95 gene transactivation as well as CD95 protein expression, thus, 
sensitizing HBV-infected hepatocytes towards CD95-mediated apoptosis (figure 
3.12b-d). In contrast, transfection of a p53 hot-spot mutant, namely p53R248W (Ory, 
Legros et al. 1994), inhibited the viral clearance and apoptosis of HBV-infected 
hepatocytes. Whereas, wt p53 transactivated the CD95 gene, hence leading to an 
increased CD95 protein expression on the surface of HBV-infected hepatocytes, 
p53R248W inhibited CD95 gene transactivation and therefore CD95 protein 
expression and CD95-dependent apoptosis. In line with the results described so far 
in this thesis, the HBx-containing constructs show increased levels of CD95 
transactivation and expression and therefore a higher amount of apoptotic cells, 
while AdHBV X- did not differ from the AdGFP level. 
 
These data show that the p53 “gain-of-function” mutant, p53R248W, contributes to 
viral persistence by inhibiting CD95-mediated apoptosis of HBV-infected 
hepatocytes. This points to a possible synergy of alterations of the p53 pathway and 
HBV-induced hepatocarcinogenesis. 
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Figure 3.12 p53 hot-spot mutants inhibit apoptosis of HBV-infected hepatocytes 
Combined adenoviral transfer of AdHBV and wt p53 into Hep3B cells led to an increased CD95 gene 
transactivation as well as CD95 protein expression, thus, sensitizing HBV-infected hepatocytes 
towards CD95-mediated apoptosis. In contrast, transfection of a p53 “GOF” mutant, namely the hot-
spot mutant p53R248W, inhibited viral clearance and apoptosis of HBV-infected hepatocytes.           
(a) Distribution of reported missense mutations along the 393 amino-acid sequence of p53. Adapted 
from Brosh et al. (Brosh and Rotter 2009) (b) The hot-spot mutant p53R248W repressed the 
transcriptional activity of the CD95 gene as detected by luciferase reporter gene assay. Hep3B cells 
were transiently transfected with 1 µg of p1142CD95-luc together with 100 ng of either wt p53 or 
p53R248W. (c) FACSCalibur analysis of CD95 receptor expression in Hep3B cells following the 
transient transfection of either wt p53 or p53R248W. (d) Wild-type and mutant p53 differentially 
regulated apoptosis of HBV-infected hepatocytes. FACSCalibur analysis of propidium iodide stained 
nuclei of Hep3B cells transiently transfected with wt p53 or the hot-spot mutant p53R248W prior 
infection with HBV.  
Values are means ± SD, one representative experiment out of three independent experiments is 
shown. 
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3.2 HBV infection triggers AP-1-dependent CD95Ligand expression 
in HepG2 cells 
 
It has been shown that hepatocytes are not only sensitive towards CD95-mediated 
apoptosis but also able to express CD95Ligand (CD95L) by themselves and are, 
therefore, able to eliminate other cells via CD95L-CD95 mediated cytotoxicity (Guy, 
Wang et al. 2006). Moreover, Eichhorst, Müller et al. demonstrated that 
chemotherapeutics trigger the transactivation of CD95L in HepG2 cells via an AP-1 
element in the promoter of the CD95L gene (Eichhorst, Müller et al. 2000). Having 
shown that HBV-infected hepatocytes are sensitive towards CD95-mediated 
apoptosis and taking into account that cytotoxic T cells are, so far, the main effector 
cells involved in the elimination of HBV-infected hepatocytes, we further investigated 
the mechanisms of CD95L gene regulation in HBV-infected hepatocytes. In order to 
study the role of CD95L expression in HBV-infected hepatocytes, different CD95L-
luciferase constructs, lacking different regions of the putative binding sites were 
transfected into HepG2 cells to analyse CD95L transactivation. qPCR analysis and 
ELISA were performed to study the transcription and expression of CD95L. 
 
3.2.1 Treatment of hepatoma cells with bleomycin leads to the up-regulation of 
CD95L transactivation 
Given that the role of chemotherapeutics in the transactivation of CD95L gene was 
previously shown (Eichhorst, Müller et al. 2000), bleomycin (30 µg/ml) was used as a 
positive control for CD95L transactivation. To analyze the effect of bleomycin on the 
transactivation of the CD95L in hepatoma cells, HepG2 cells were transfected with   
1 µg of the following CD95L-luc (-36/+100 CD95L-luc, -220/+100 CD95L-luc,             
-537/+100 CD95L-luc, -1204/+100 CD95L-luc) constructs, respectively                  
(c.f. Appendix; page 124-125). The four promoter constructs differ in the base pair 
length 5’ of the transcription start site, therefore, containing or lacking specific binding 
sites (BS), enhancers or inhibitors and possess 100 bp 5’ UTR in front of firefly 
luciferase (figure 3.13).  
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Figure 3.13 Schematic overview of the CD95L promoter Figure was adapted and modified from Li-
Weber et al. and Eichhorst et al. (Eichhorst, Müller et al. 2000; Li-Weber and Krammer 2002). 
 
48 h after treatment with 30 µg/ml bleomycin CD95L gene transactivation was 
assessed by luciferase activity demonstrating a significant difference between treated 
and untreated hepatocytes. All four CD95L-luc promoter constructs showed an 
increase in CD95L transactivation after bleomycin treatment (figure 3.14). The 
highest fold increase in CD95L gene transactivation was observed with the                
-220/+100 CD95L-luc construct. However, no BS between -36 and -1204 could be 
identified as the major BS responsible for CD95L transactivation in bleomycin-treated 
HepG2 cells. To investigate if bleomycin triggers CD95L gene transactivation also via 
the AP-1 binding site at position + 84 - +91 (5’ UTR) as it was already described for 
other chemotherapeutics from Eichhorst et al. (Eichhorst, Müller et al. 2000), the 
hepatocytes were pre-treated with 40 nM JNK II inhibitor. The prevention of c-Jun 
activation and, therefore, the inhibition of AP-1 formation resulted in a decreased 
transactivation of CD95L gene after bleomycin treatment in all four constructs. To 
verify the suggestion that the AP-1 BS at position +84 - +91 (5’ UTR) in the CD95L 
gene is indeed responsible for transactivation of the CD95L gene after bleomycin 
treatment, AP-1 BS deletion constructs were generated and gene transactivation was 
assayed. The obtained results resembled the results achieved with the JNK II 
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inhibitor confirming the role of the 5’ UTR AP-1 BS in the transactivation of the 
CD95L gene. Except for the -36/+100 and accordingly the -36/ +81 CD95L-luc 
construct, the decrease in the fold increase of transactivation following bleomycin 
treatment was significant after JNK II inhibitor addition or the use of the deletion 
constructs (figure 3.14). 
  
Figure 3.14 Bleomycin treatment results in the transactivation of the CD95L promoter Deletion 
of the 5’ UTR AP-1 BS in the CD95L gene destroys the inducibilty of the four different promoter 
constructs and induction is inhibited by the JNK II inhibitor. To analyse the effect of the different 
promoter constructs and the inhibition of JNK on the transactivation of the CD95L promoter after 
bleomycin treatment (30 µg/ml), HepG2 cells were transfected with the different CD95L luciferase 
constructs and treated with JNK II inhibitor after transfection with the basal promoter constructs. 
Following transfection the cells were treated with 30 µg/ml bleomycin for 48 h. Luciferase activity was 
measured and fold increase was calculated. Luciferase activity measurement in cells transfected with 
the basal promoter constructs without any treatment was set to 1. One representative experiment out 
of 3 independent experiments is shown, respectively (Mean ± SD, n=3). (*p≤0.01 compared to 
untreated samples, **p≤0.01 compared to the AP-1 deletion constructs and JNK II inhibitor treated 
samples, as determined by Anova, Bonferroni’s multiple range test). 
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To summarize, treatment of the hepatoma cell line HepG2 with the chemotherapeutic 
drug bleomycin results in the AP-1 dependent transactivation of the CD95L promoter. 
With the use of the JNK II inhibitor and 5’ UTR AP-1 binding site deletion constructs, 
the AP-1 binding site located between position +84 and + 91 in the 5’ UTR of the 
CD95L gene could be identified as the major transcription factor binding site 
responsible for the transactivation of CD95L gene upon bleomycin treatment.    
 
3.2.2 HBV infection results in the transactivation, transcription and expression 
of CD95L in HepG2 cells 
Having established that bleomycin leads to the transactivation of CD95L in HepG2 
cells, we analyzed whether HBV infection has a similar effect on the transactivation 
of the CD95L gene. Thus, CD95L transactivation, transcription and expression in 
HBV-infected HepG2 cells were assessed. First of all, the amount of CD95L mRNA 
in HBV-infected HepG2 cells was measured and compared to samples treated with 
bleomycin. Cells were treated with the respective adenoviral HBV constructs or 
treated with 30 µg/ml bleomycin. Cells were lysed at 36 h p.i. and accordingly post 
treatment and the amount of CD95L mRNA was analyzed. Both, adenoviral transfer 
of recombinant AdHBV constructs and treatment with bleomycin led to an increased 
transcription of the CD95L gene compared to infection with AdGFP and accordingly 
untreated samples (figure 3.15a). Since there was almost no difference in the 
induction of CD95L between the untreated cells and the cells infected with AdGFP, 
CD95L gene transactivation due to adenoviral infection itself was obviated. In 
accordance with the results described so far in the present study, the highest 
transcription of the CD95L gene was obtained with the HBx-containing constructs, 
AdHBV L- and AdHBV wt. Both construct also outranged the fold increase achieved 
with bleomycin treatment. 
In order to study the expression of CD95L two different methods were used. The 
most sensitive method is the detection of CD95L with an ELISA assay. Therefore, 
cells were infected with the distinct adenoviral constructs or treated with bleomycin. 
To analyze the amount of soluble (sCD95L) and membrane-bound CD95L (mCD95L) 
supernatants were collected and cell lysates were prepared at 72 h p.i. (figure 3.15b). 
The supernatant of PMA/Ionomycin stimulated Jurkat 16 cells served as positive 
control for sCD95L expression. 
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Figure 3.15 HBV results in the transcription of the CD95L gene which leads to the up-regulation 
of CD95L on the cell surface of HepG2 cells (a) Quantification of CD95L expression after HBV 
infection by real time PCR in HepG2-cells (24 h p.i.). Total RNA was extracted and qPCR was 
performed as described in Materials and Methods. One representative experiment out of at least 3 
independent experiments is shown, respectively. (b) CD95L ELISA showing the fold increase of 
soluble and membrane-bound CD95L 72 h p.i.; shown is one representative experiment out of three 
independent experiments. (c) Quantitative flow cytometry analysis (FACSCalibur®) of CD95L 
expression in HBV-infected HepG2 cells 48 h and 72 h p.i. Percent of CD95L expression was 
calculated as % CD95L+- % isotype control. The fold increase of AdGFP was set to 1. Shown is mean 
± SD, n= 3.  
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Adenoviral transfer of recombinant HBV vectors led to increased levels of soluble 
CD95L (sCD95L) in HepG2 cells. In line with AdHBV infection, bleomycin treatment 
also resulted in augmentation of sCD95L. While the amount of soluble CD95L 
increased upon HBV infection or bleomycin treatment compared to infection with 
AdGFP or untreated samples respectively, the amount of mCD95L decreased. In the 
case of AdHBV wt and bleomycin no detectable amounts of mCD95L could be 
measured. The decrease in the amount of mCD95L was oppositional to the increase 
of sCD95L upon infection or respectively bleomycin treatment. Another method to 
analyze the amount of CD95L protein expression is FACS analysis. Thus, infected 
cells were stained with the corresponding antibody at 48 h and 72 h p.i. and analyzed 
by FACSCalibur. In contrast to the CD95L ELISA, FACS analysis only detects the 
amount of membrane-bound CD95L. FACS analysis showed an increase in mCD95L 
expression upon infection with AdHBV L- and AdHBV wt at 48 h p.i. After another   
24 h (72 h post infection) no mCD95L expression could be detected any more. These 
results, in combination with the results of the mCD95L ELISA, suggest that mCD95L 
expressed on the surface of hepatocytes is cleaved after 48 h. Figure 3.15c shows 
the elevated levels of mCD95L expression at 48 h upon HBV infection, as well as the 
decrease in mCD95L expression at 72 h post infection.  
To further analyse the upstream signalling cascade, leading to the transcription and 
expression of CD95L after HBV infection, CD95L-luc assays were performed.  
 
Figure 3.16 Time-course of CD95L gene 
transactivation after HBV infection HepG2 
cells were transiently transfected with 1 µg of 
the -220/+100CD95L-luc promoter construct. 
Cells were additionally infected with 10 MOI 
of the different AdHBV constructs, 
respectively. Cells were harvested and 
analyzed after 24 h, 36 h and 48 h to analyze 
time-dependent CD95L transactivation after 
HBV infection. (Mean ± SD, n=6). *p≤0.05, 
***p≤0.001 compared to AdGFP as 
determined by Anova. 
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Time kinetics of CD95L transactivation analyzing the transactivation of the -220/+100 
CD95L-luc reporter gene at 24 h, 48 h and 72 h post HBV infection were used to 
indicate the best time-point for analysis.  
In contrast to cells infected with HBV for 24 h, where there was no increase in CD95L 
gene transactivation detectable, lysates from cells infected for 36 h or 48 h showed 
an augmented fold increase. While the significance standard between the diverse 
HBV constructs 36 h p.i. was only p≤ 0.05 the fold increase of the diverse constructs 
48 h p.i. showed significance standards p≤ 0.001 compared to AdGFP (figure 3.16). 
Thus, the 48 h infection period was considered as an optimal time-point for the 
following transactivation studies. 
Figure 3.17 HBV infection leads to the transactivation of the CD95L gene HepG2 cells were 
transiently transfected with 1 µg of the following CD95L promoter constructs: -36/+100CD95L-luc, -
220/+100CD95L-luc, -537/+100CD95L-luc and -1204/+100CD95L-luc. Cells were additionally infected 
with 10 MOI of the different AdHBV constructs, respectively. One representative experiment out of at 
least 3 independent experiments is shown, respectively. The differences between AdGFP and AdHBV 
are statistically significant (Mean ± SD, n=3). Luciferase activity value obtained with AdGFP was set to 
1. (**p≤0.01, ***p≤0.001 as determined by Anova, Bonferroni’s multiple range test). 
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The distinct CD95L-luc promoter constructs (CD95L -36/+100, -220/+100, -536/+100, 
and -1204/+100) have been used to identify the binding site responsible for CD95L 
transactivation in HBV-infected hepatocytes (figure 3.17). AdHBV L- and AdHBV wt 
infection resulted in a significantly increased fold increase in all four different 
promoter constructs compared to infection with AdGFP.  
 
 
Figure 3.18 The transcription factor AP-1 is responsible for CD95L transactivation in HBV-
infected cells HepG2 cells were transiently transfected with 1 µg of the following CD95L promoter 
constructs: -36/+100CD95L-luc, -220/+100CD95L-luc, -537/+100CD95L-luc and -1204/+100CD95L-
luc as indicated. Cells were additionally infected with 10 MOI of the different AdHBV constructs, 
respectively. 40 nM JNK II Inhibitor was added as indicated. One representative experiment out of at 
least 3 independent experiments is shown, respectively. The differences between AdGFP and AdHBV 
are statistically significant (Mean ± SD, n=3). Luciferase activity value obtained with AdGFP was set to 
1. (*p≤0.01 compared to untreated, **p≤0.01 compared to JNK inhibitor, as determined by Anova, 
Bonferroni’s multiple range test). 
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In general, the fold increase was higher compared to the bleomycin-treated samples. 
However, there was no particular difference in the fold increase of the distinct 
CD95L-luc-reporter constructs. While the HBx-containing HBV constructs led to an 
increased CD95L gene transactivation, the HBx knock-out construct, AdHBV X-, did 
only marginally differ from AdGFP. The HBx-containing HBV constructs also led to an 
increase of endogenous CD95L transcription and translation (c.f. figure 3.15). 
Even though the CD95L-luc transactivation differed from 4-fold to up to 9-fold with 
AdHBV wt, no binding site between -36 and -1204 could be assigned as the major 
binding site responsible for CD95L transactivation in HBV-infected hepatocytes. 
Instead, inhibition of JNK (Jun NH2-terminal kinase) resulted in a significant decrease 
in CD95L transactivation (figure 3.18). Inhibition of JNK with a JNK II inhibitor was 
used to investigate the role of JNK, and in turn the function of the AP-1 BS at position    
+84 - +91 in the 5’ UTR of the CD95L gene. Pre-treatment of HepG2 cells with the 
JNK II inhibitor resulted in the reduction of CD95L gene transactivation in HBV-
infected cells. That CD95L transactivation was only significantly reduced in cells 
infected with AdHBV L- and AdHBV wt can be explained with the non-significant 
gene transactivation in AdHBV X- infected hepatoma cells. 
Taking the fact into account that the use of a JNK II inhibitor results in the inhibition of 
CD95L transactivation and that HBV infection led to the phosphorylation of JNK and 
accordingly to the subsequent activation of the transcription factor AP-1, we 
postulated that CD95L transactivation is triggered by Thr183/Tyr185 phosphorylation of 
JNK and the subsequent activation of AP-1. The phosphorylation status of JNK upon 
HBV infection in HepG2 cells is shown in figure 3.19 as well as in figure 3.3. 
 
Figure 3.19 HBV infection leads to the 
phosphorylation of the stress-activated Jun 
NH2-terminal kinase HepG2 cells were infected 
with 10 MOI of the different AdHBV constructs, 
respectively. (Phospho-Mek, Phospho-Erk and 
GAPDH are internal controls, not shown here). 
One representative experiment out of at least       
3 independent experiments is shown, 
respectively. The difference between AdGFP and 
AdHBV is statistically significant (**p≤0.01 as 
determined by the Student’s t-test).   
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To confirm the predominant role of the AP-1 binding site in the transactivation of the 
CD95L promoter we established 5’ UTR AP-1 binding site deletion constructs.  
While HBV-infected hepatocytes transfected with wt CD95L-luc reporter constructs 
showed an increased CD95L-luc gene transactivation hepatocytes transfected with 
CD95L-luc constructs lacking the 5’ UTR AP-1 binding site, namely -36/+81CD95L-
luc, -220/+81CD95L-luc, -536/+81CD95L-luc and -1204/+81CD95L-luc, displayed a 
lack in the induction of CD95L transactivation upon HBV infection. 
 
Figure 3.20 CD95L transactivation upon HBV infection is dependent on the AP-1 binding site in 
the promoter region HBV infection leads to the transactivation of the CD95L gene in HepG2 cells. 
Cells were transiently transfected with 1 µg of the following CD95L promoter constructs:                        
-36/+100CD95L-luc, -220/+100CD95L-luc, -537/+100CD95L-luc and -1204/+100CD95L-luc or              
-36/+81CD95L-luc, -220/+81CD95L-luc, -537/+81CD95L-luc and -1204/+81CD95L-luc as indicated. 
Cells were additionally infected with 10 MOI of the different AdHBV constructs, respectively. One 
representative experiment out of 3 independent experiments is shown, respectively. The differences 
between AdGFP and AdHBV are statistically significant (Mean ± SD, n=3). Luciferase activity value 
obtained with AdGFP was set to 1. (*p≤0.01 compared to untreated, **p≤0.01 compared to the next 
right column, as determined by Anova, Bonferroni’s multiple range test). 
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Whereas the CD95L-luc promoter gene was transactivated in the promoter 
constructs containing the 5’ UTR AP-1 BS, which suggests an increased CD95L 
protein expression driven from the endogenous promoter on the surface of HBV-
infected hepatocytes, 5’ UTR AP-1 binding site deletion constructs failed to induce a 
sufficient CD95L-luc promoter gene transactivation (figure 3.20). This suggests that 
the AP-1 BS at position 5’ UTR +84 - +91 is necessary for the expression of the 
endogenous CD95L gene upon infection with HBV. 
To investigate the upstream mechanisms leading to the activation of JNK and/or the 
later transactivation of CD95L gene, different cytokines and chemically reactive 
molecules were screened for their ability to induce CD95L. The tumour necrosis 
factor alpha (TNF-α) and reactive oxygen species (ROS) were identified as possible 
inducers of JNK and CD95L gene transactivation by literature research (Gulow, 
Kaminski et al. 2005; Guy, Wang et al. 2006; Kiessling, Linke et al. 2010) .  
 
 
 
 
 
 
 
 
 
 
Figure 3.21 CD95L transactivation is not dependent on TNF alpha in HBV-infected hepatocytes 
HBV infection leads to the transactivation of the CD95L gene in HepG2 cells. Cells were transiently 
transfected with 1 µg of the following CD95L promoter construct: -220/+100CD95L-luc. Cells were 
additionally infected with 10 MOI of AdHBV wt or AdGFP and treated with rTNF-α or the TNF-α 
inhibitor Enbrel as indicated. Luciferase activity value obtained with AdGFP was set to 1. One 
representative experiment out of 3 independent experiments is shown, respectively (Mean ± SD, n=3). 
(*p≤0.01 compared to untreated, **p≤0.01 compared to the next column, as determined by Anova, 
Bonferroni’s multiple range test).   
 
Treatment of AdHBV wt-infected hepatocytes with recombinant TNF-α led to an 
increased CD95L gene transactivation in HepG2 cells transfected with 1 µg                
-220/+100 CD95L-luc compared to infection with AdGFP. The treatment with the 
TNF-α inhibitor Enbrel, however, did not result in a decreased CD95L transactivation 
in HepG2 cells infected with AdGFP or AdHBV wt (figure 3.21).  
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To investigate the effect of ROS on the CD95L transactivation, HBV-infected 
hepatocytes were transfected with 1 µg -220/+100 CD95L-luc and additionally 
treated with the reactive oxygen species inhibitor N-acetyl L-cysteine (NAC). NAC 
treatment significantly decreased CD95L-luc transactivation in HBV-infected HepG2 
cells (c.f. figure 3.22). This inhibitory effect of NAC on the transactivation of CD95L-
luc could also be observed in HepG2 cells treated with bleomycin. This suggests that 
the CD95L gene is transactivated in HBV-infected hepatocytes through ROS-
mediated JNK phosphorylation and subsequent activation of the transcription factor 
AP-1. 
Figure 3.22 CD95L transactivation in HBV-infected HepG2 cells is regulated by reactive oxygen 
species HBV infection leads to the transactivation of the CD95L gene in HepG2 cells via ROS. Cells 
were transiently transfected with 1 µg of the following CD95L promoter construct: -220/+100CD95L-
luc. Cells were additionally treated with 30 µg/ml bleomycin or infected with 10 MOI of AdGFP or 
AdHBV wt and treated with the ROS inhibitor N-acetyl L-cysteine (NAC). One representative 
experiment out of 3 independent experiments is shown, respectively (Mean ± SD, n=3). Luciferase 
acitivity values obtained with AdGFP were set to 1. (*p≤0.01 compared to untreated, **p≤0.01 
compared to the next column, as determined by Anova, Bonferroni’s multiple range test).  
 
HBV infection triggers the induction of CD95L gene transactivation in a similar 
manner as it was previously described for chemotherapeutic-induced CD95L 
transactivation in HepG2 cells. The AP-1 binding site at position +84 - +91 in the      
5’ UTR of the CD95L gene was identified as the predominant binding site responsible 
for the transactivation of CD95L upon HBV infection. Furthermore, we could show 
that HBV infection does not only lead to the transactivation but also to the 
transcription and finally CD95L expression in the hepatoma cell line HepG2. 
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3.3 Hepatitis B virus infection and p53 target genes of the intrinsic 
apoptosis signalling pathway 
 
In this study it was demonstrated so far, that HBV infection triggers the induction of 
the DDR which in turn leads to the stabilization of p53. This subsequently results in 
the activation of p53 target genes which are playing a role in viral clearance by the 
immune system and are important elements of the extrinsic apoptosis signalling 
pathway. Knowing all this, the question emerges, to which extent the intrinsic 
apoptotic pathway is involved in the elimination of HBV-infected hepatocytes. In order 
to investigate the induction of the intrinsic apoptosis signalling pathway, the 
regulation of prominent members involved in the intrinsic apoptosis pathway upon 
HBV infection was analyzed. 
 
3.3.1 The p53 targets Bax, Puma and Noxa are activated upon HBV infection 
To analyze the expression of the p53 target genes Noxa and Puma in HBV-infected 
hepatocytes, hepatoma cells were permeabilized, fixed, stained with the 
corresponding antibody and protein expression was determined by FACSCalibur 
analysis.  
Adenoviral transfer of the different AdHBV constructs and AdGFP as control, resulted 
in an increased expression of Noxa and Puma in the cytoplasm of HepG2 cells 
(figure 3.23). Puma expression was slightly higher than the expression of Noxa, with 
a maximum of 50% Puma positive cells at 48 h post AdHBV wt infection. In contrast, 
AdHBV wt infection results only in approximately 22% of Noxa positive cells. In 
account with the data obtained for the extrinsic apoptosis signalling pathway there 
was almost no effect detectable between AdGFP and AdHBV X- infection. This again 
highlights the important role of HBx already observed in other experiments of this 
thesis. The density plots show the distribution of HBV wt infected cells. The X axis 
present the percentage of GFP positive and therefore AdHBV wt infected cells, while 
the Y axis indicates the amount of Noxa or Puma positive cells. The upper right (UR) 
quadrant shows the amount of GFP and Noxa or Puma positive cells. 
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Figure 3.23 HBV infection results in the expression of the p53 targets Noxa and Puma in HepG2 
cells  
Quantitative flow cytometry analysis (FACSCalibur®) of Noxa and Puma protein expression in HBV-
infected HepG2 cells. The upper charts display the fold increase of Noxa or Puma expression upon 
AdHBV infection. The density plots show the distribution of AdHBV wt infected cells. The X axis 
present the percentage of GFP positive and therefore AdHBV wt infected cells, while the Y axis 
indicates the amount of Noxa or Puma positive cells. The upper right (UR) quadrant shows the amount 
of GFP and Noxa or Puma positive cells. Percent of Noxa or Puma expression was calculated as      
% Noxa or Puma+- % isotype control (Mean ± SD, n=3). 
 
Analogous to the results showing CD95 expression (figure 3.7), adenoviral Adp53 
was added in Hep3B cells to increase Noxa and Puma expression (figure 3.24). In 
contrast to CD95 where Adp53 was needed to obtain an increase in CD95 
expression upon HBV infection, AdHBV infection alone was already sufficient to 
induce a slight increase in Noxa and Puma expression in Hep3B cells. Co-infection of 
adenoviral p53 and the different AdHBV constructs boosted the effect of AdHBV; 
however, there was no clear indication for a synergistic effect. Similar to the results 
obtained in HepG2 cells the constructs containing the viral transcription factor HBx 
induced Noxa and Puma expression in Hep3B cells, whereas AdGFP and the HBx-
lacking AdHBV X- construct did not lead to the expression of both proteins. 
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Figure 3.24 HBV infection results in the expression of the p53 targets Noxa and Puma in Hep3B 
cells  
Quantitative flow cytometry analysis (FACSCalibur®) of Noxa and Puma expression in HBV-infected 
Hep3B cells. The upper charts display the fold increase of Noxa or Puma expression upon HBV 
infection. To study a possible synergistic effect of Adp53 and AdHBV, Adp53 was co-infected with the 
adenoviral HBV constructs. The white bars represent the expression of Puma and Noxa induced by 
AdHBV alone, the black bars show the combined adenoviral infection of Adp53 and the distinct 
AdHBV constructs. The density plots show the distribution of AdHBV wt infected cells co-infected with 
Adp53. The X axis present the percentage of GFP positive and therefore AdHBV wt infected cells, 
while the Y axis indicates the amount of Noxa or Puma positive cells. The upper right (UR) quadrant 
shows the amount of GFP and Noxa or Puma positive cells. Percent of Noxa or Puma expression was 
calculated as % Noxa or Puma+- % isotype control (Mean ± SD, n=3). 
 
As a consequence of Noxa and Puma activation upon HBV infection their 
downstream target Bax was analyzed for transactivation, mRNA transcription and 
protein expression.  
In both, Hep3B and HepG2 hepatoma cell lines, infection with the different AdHBV 
constructs resulted in an increased Bax gene activity at 24h p.i. In contrast to HepG2 
cells (p53+/+) where AdHBV infection alone was already sufficient to induce Bax gene 
transactivation, p53-/- Hep3B cells did not show an increase in Bax gene 
transactivation at all. Co-infection of Adp53 in Hep3B cells boosted the Bax 
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transactivation levels. Figure 3.25b shows the statistically significant synergistic 
effect of Adp53 and the distinct AdHBV constructs. 
 
  
Figure 3.25 HBV infection leads to the transactivation and transcription of the pro-apoptotic 
Bcl-2 family member Bax HBV infection cooperates with p53 in the transactivation of the Bax gene, 
leading to an up-regulation of Bax mRNA in HBV-infected hepatocytes. (a) Map of the human Bax 
gene. The intronic p53 binding sites (p53-IBS) are shown. (b) Analysis of HBV-dependent Bax 
luciferase gene activity. HepG2- and Hep3B cells were transfected with 1 µg Bax-Pr/luc reporter 
plasmid and infected with 10 MOI of the respective adenoviral HBV constructs. Hep3B-cells were 
additionally infected with Adp53. Shown is the fold increase of each adenoviral HBV construct and 
AdGFP, calculated relative to the value obtained with AdGFP The differences between AdGFP and 
AdHBV wt are statistically significant in HepG2 cells (*p≤0.05 compared to AdGFP, **p≤0.001 
compared to the next left column as determined by Anova, Bonferroni’s multiple range test).              
(c) Quantification of Bax mRNA in HBV-infected hepatocytes by real time PCR 24 h p.i.  
One representative experiment out of 3 independent experiments is shown, respectively (Mean ± SD, 
n=3).  
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While Adp53 alone induced a 20-fold increase in Bax transactivation, co-infection of 
Adp53 and the different AdHBV constructs led to a fold increase of 40. In 
consequence of gene activation, AdHBV infection led to an up-regulation of Bax 
transcription in HepG2 cells. In contrast and accordingly to the transactivation 
experiments, no Bax transcription was observed in Hep3B cells. However, after co-
infection of AdHBV and exogenous Adp53, Hep3B cells showed similar Bax 
transcription as observed in HepG2 cells (figure 3.25c). In accordance with the 
results obtain so far, the induction of Bax transactivation and transcription was less in 
hepatocytes infected with the HBx negative adenoviral HBV X- construct. 
To analyze Bax protein expression in HBV-infected hepatocytes, we used 
FACSCalibur analysis. Adenoviral transfer of the different AdHBV constructs as well 
as AdGFP, resulted in an increase in Bax expression in the hepatoma cell line 
HepG2. The HBx-containing adenoviral HBV constructs, AdHBV L- and AdHBV wt, 
triggered an increase in the expression of Bax. This was in contrast to the HBx 
knock-out construct, AdHBV X-. Similar to the results showing CD95 expression 
(figure 3.7), adenoviral p53 had to be added in Hep3B cells to obtain Bax expression.  
Co-infection of Adp53 and the described AdHBV constructs resulted in a significant 
increase in Bax expression highlighting the role of Bax as a p53 target. However, the 
effect detected was not considered to be synergistic (figure 3.26a and b). The density 
dot plots demonstrate the distribution of AdHBV-infected hepatocytes with regard to 
infected, GFP positive, and Bax positive hepatocytes. Lysates of PHHs harvested at 
60 h p.i. also clearly indicate the expression of Bax upon HBV infection compared to 
infection with AdGFP (figure 3.26c). 
 
In summary, HBV infection triggers the activation and expression of p53 target genes 
of the extrinsic as well as the intrinsic apoptosis signalling pathway. The BH3-only 
proteins Puma and Noxa as well as the Bcl-2 family member protein Bax could be 
identified as crucial proteins activated upon HBV infection, thereby contributing to 
viral clearance. 
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Figure 3.26 Quantitative flow cytometry analysis 
(FACSCalibur®) of Bax protein expression in HBV-infected 
HepG2- and Hep3B-cells Only HepG2 cells (a), possessing 
endogenous p53, display up-regulated Bax protein expression. 
Hep3B (b), lacking p53, were additionally infected with Adp53 
to obtain up-regulation of the Bax protein. Percent of Bax 
expression was calculated as % Bax+- % isotype control. 
Shown is Mean ± SD, n=3. **p≤0.05 compared to the next left 
column as determined by Anova, Bonferroni’s multiple range test. (c) Western blot analysis of Bax 
expression in PHHs. HBV-infected PHHs were lysed 60h p.i. and expression of the Bax protein was 
investigated. ß- Actin was used as an internal loading control. 
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3.3.2 The p53-dependent expression of BH3-only and Bcl-2 family member 
proteins upon HBV infection results in the alteration of mitochondrial outer 
membrane potential and the subsequent release of cytochrome c 
The crucial point in the intrinsic apoptosis signalling pathway is the alteration of the 
mitochondrial outer membrane potential due to pore formation of the Bcl-2 family 
members Bax and Bak. Alteration of mitochondrial outer membrane potential results 
in the release of cytochrome c which forms the apoptosome together with the adapter 
protein Apaf-1 and pro-caspase 9. In contrast to all the results obtained so far in this 
thesis, AdHBV infection alone was not sufficient enough to induce a remarkable 
increase in the mitochondrial outer membrane potential in HepG2 cells. AdHBV wt 
only led to approximately 5% more cells with altered mitochondrial outer membrane 
potential than infection with AdGFP in HepG2 cells (figure 3.27). Additional 
exogenous Adp53 was needed to depict the differences within the adenoviral HBV 
constructs. According to the results obtained with the mitochondrial proteins Bax, 
Noxa and Puma infection with Adp53 and AdHBV wt resulted in a significant increase 
in cells with altered mitochondrial outer membrane potential.  
 
Figure 3.27 HBV infection leads to an alteration of the mitochondrial outer membrane potential 
FACSCalibur analysis of HepG2- and Hep3B cells following DiIC staining shows an alteration of the 
mitochondrial membrane potential. Error bars represent standard deviation of 3 independent 
experiments (Mean± SD, n=3). The difference between AdGFP and Adp53 infected hepatocytes is 
statistically significant (*p≤0.05 compared to the respective AdGFP, **p≤0.05 compared to the next left 
column as determined by Anova, Bonferroni’s multiple range test).  
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Quite the reverse was detected in Hep3B cells. In the p53-/- hepatoma cell line 
AdHBV wt infection alone was already sufficient to induce an alteration of the 
mitochondrial outer membrane potential. The increase in cells with altered 
mitochondrial outer membrane potential was significant compared the infection of 
AdGFP and AdHBV wt. Additional infection with Adp53 boosted the effect of AdHBV 
significantly compared to AdHBV infection alone. Combined infection of Adp53 and 
AdHBV wt into Hep3B cells resulted in almost 100% of hepatoma cells with altered 
membrane potential.  
The subsequent release of cytochrome c was also assessed by FACSCalibur 
analysis (figure 3.28). The cells were treated and stained as already described for the 
mitochondrial proteins Bax, Puma and Noxa. Again the effect of AdHBV alone and in 
combination with Adp53 was investigated. The HBx-containing adenoviral HBV 
constructs reflect the observations of the other functional experiments described in 
the present thesis. Infection of hepatoma cells with AdHBV L- and AdHBV wt resulted 
in the elevated release of cytochrome c in HepG2 cells. Additional infection with 
Adp53 amplified the increase of cytochrome c positive HepG2 and Hep3B cells. 
 
Figure 3.28 Alteration of the mitochondrial outer membrane potential upon HBV infection 
triggers the release of cytochrome c FACSCalibur analysis of HepG2- and Hep3B cells following 
intracellular cytochrome c staining. Cytochrome c release is displayed in the amount of cytochrome c 
positive hepatocytes. Error bars represent standard deviation of 3 independent experiments       
(Mean± SD, n=3). The difference in the case of AdHBV L- and AdHBV wt infected hepatocytes co-
infected with Adp53 and AdGFP are statistically significant (**p≤0.05 compared to the next left column 
as determined by Anova, Bonferroni’s multiple range test). 
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In summary, hepatitis B Virus infection triggers the activation of the DNA damage 
response leading to the stabilization and activation of the tumour suppressor p53. 
Activation of p53 upon HBV infection induces the activation of different p53 target 
genes playing important roles in the activation of the extrinsic as well as the intrinsic 
apoptosis signalling pathway. The expression of proteins involved in apoptosis 
signalling leads to the alteration of the mitochondrial membrane potential, the 
subsequent release of cytochrome c and finally to the induction of apoptosis in HBV-
infected hepatocytes and viral clearance. Our results propose a new p53-dependent 
model for virus elimination and show that p53 beyond its role as a tumour suppressor 
also plays an important role in viral clearance.  
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4. Discussion 
 
Chronic hepatitis B virus infection is a major risk factor for the development of 
hepatocellular carcinoma and more than 350 million patients are chronically infected 
with HBV worldwide. Therefore, HBV represents a foremost health burden especially 
in developing countries (El-Serag 2011). HBV infection is known to induce acute and 
chronic necroinflammatory liver injury, death of hepatocytes and to promote 
hepatocarcinogenesis resulting in the development of HCC, the most common 
primary malignant liver cancer and the third leading cause of cancer-related death in 
the world. It is still not clear whether the virus itself acts as a tumour initiator or if the 
subsequent inflammation, causing liver regeneration and cirrhosis, acts as a tumour 
promoter in hepatocarcinogenesis (Hussain, Schwank et al. 2007). 
The partially double-stranded hepatitis B virus is acting as a stealth virus and is, 
therefore, hardly detected by the innate immune system. Due to this reason, the 
immune system is unable to efficiently clear HBV from the liver leading to persistence 
of virus infection (Guidotti and Chisari 2006). Although, it is well known that mainly 
CD8+ T cells are involved in the immune response against HBV, the precise 
molecular interactions between the immune system and HBV-infected hepatocytes 
leading to virus elimination are not yet completely understood (Chisari and Ferrari 
1995; Protzer and Schaller 2000). The recent findings from Arzberger et al. 
(Arzberger, Hosel et al. 2010) demonstrating that apoptosis of HBV-infected 
hepatocytes results in the release of non-infectious viral particles, however, provide 
evidence for the important role of apoptosis in the elimination of HBV-infected 
hepatocytes. The precise steps in the process leading to the induction of apoptosis in 
virus-infected hepatocytes and the signalling pathways up-regulated in infected host 
cells to combat the virus are still awaiting elucidation. 
The data obtained in the present study allow us to propose a new p53-dependent 
model for the elimination of HBV-infected hepatocytes (c.f. figure 4.1). We could 
show that p53 beyond its role as a tumour suppressor plays an essential role in viral 
defence. HBV infection results in the activation of the DNA damage response (DDR) 
and the subsequent phosphorylation of p53 in an ATM/ATR-dependent manner. 
Stabilization of p53, due to serine 15 phosphorylation leads to the activation of 
prominent members of the extrinsic and intrinsic apoptosis signalling pathway. The 
activation of both, p53 target genes of the extrinsic and of the intrinsic apoptosis 
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signalling pathway, upon HBV infection suggests an interaction between HBV-
induced p53 stabilization and apoptosis induction. We identified a functional CD95 
pathway, a classical p53 downstream target, to be essential for the elimination of 
HBV-infected hepatocytes. However, not only CD95 is activated upon HBV infection 
in a p53-dependent manner, Bax, Puma and Noxa, whose genes are also up-
regulated by p53, were also identified as crucial proteins involved in the elimination of 
HBV-infected hepatocytes. The expression of proteins involved in apoptosis 
signalling leads to the alteration of the mitochondrial outer membrane potential, the 
subsequent release of cytochrome c and finally the induction of apoptosis in HBV-
infected hepatocytes, which is accompanied by the cleavage of PARP-1. Of note, 
experiments with primary human hepatocytes (PHH) confirmed the results we 
obtained in hepatoma cell lines and point towards the clinical relevance of our 
findings. In addition, our model provides evidence for the pro-apoptotic role of the 
viral HBx protein. Infection of the hepatoma cell lines and PHHs with the HBx knock-
out adenoviral HBV construct, demonstrate the important role of HBx in the induction 
of apoptosis. We could show that infection with the HBx knock-out construct resulted 
in a decreased phosphorylation of proteins involved in the DNA damage response 
and, therefore, also in a minor activation of the p53 targets, shown to be involved in 
the elimination of HBV-infected hepatocytes. We, thus, hypothesise that both, DDR-
induced stabilization of p53 and the activation of proteins involved in the apoptosis 
machinery, contribute to HBx-dependent apoptosis induction.  
Our data suggest a new p53-dependent model for virus elimination and show that 
p53 beyond its role as a tumour suppressor plays an important role in viral clearance. 
In summary, we postulate, that an intact p53 status and a functional CD95 apoptosis 
signalling pathway are essential for the elimination of HBV-infected hepatocytes by 
sensitizing them towards apoptosis, thus preventing chronic hepatitis B virus 
manifestation. The identification of prominent members of the apoptosis signalling 
pathways as crucial proteins activated upon HBV infection demonstrate an 
underlying mechanism for the diverse outcomes (clearance vs. chronicity) of an HBV 
infection. Furthermore, the significant contribution of p53 in cellular antiviral defence 
suggests a potential implication in the pathogenesis of HBV infection and, thus, 
opens new therapeutic options.  
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Figure 4.1 Key steps in the elimination of hepatitis B Virus infected hepatocytes HBV infection 
leads to the induction of a weak interferon response and, therefore, the activation of the innate 
immune response (1. displayed in grey on the left side). More importantly, the tumour-suppressor p53 
is activated by phosphorylation on serine 15. Upon phosphorylation, p53 induces the initiation of the 
intrinsic and extrinsic apoptosis signalling pathway by up-regulating the BH3-only proteins Puma and 
Noxa, which in turn activate Bax and Bak and induce mitochondrial membrane permeabilization        
(2. displayed in blue on the right side). Up-regulation of CD95 results in an increased responsiveness 
towards CD95-mediated apoptosis of HBV-infected hepatocytes. Binding of the CD95L (CD95L is not 
depicted in the figure) to its corresponding receptor results in receptor clustering and the recruitment 
of FADD (not depicted in the figure) as well as the initiator caspases 8 and 10. DISC (not labelled in 
the figure) formation initiates the activation of the apical caspases, driving their autocatalytic 
processing and the release into the cytoplasm, where they activate the effector caspases 3, 6 and 7. 
Finally, the activation of the death pathways leads to the induction of apoptosis and, therefore, 
elimination of HBV-infected hepatocytes. An additional mechanism of p53 stabilization is its 
phosphorylation by JNK, which also promotes apoptosis by inducing the translocation of Bax to the 
mitochondria.  
Pathway was generated using the pathway builder from www.proteinlounge.com. 
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Intriguingly, HBV infection also leads to the phosphorylation of the stress-activated  
c-Jun N-terminal kinase (JNK), known to trigger serine 15 phosphorylation of p53, 
thereby abolishing its association with Mdm2 (Fuchs, Adler et al. 1998). Furthermore, 
JNK is able to phosphorylate c-Jun which is a component of the transcription factor 
AP-1 (Fuchs, Adler et al. 1998). In the present study we show that HBV-induced 
phosphorylation of JNK triggers CD95L gene transactivation in an AP-1-dependent 
manner which leads to the, so far, unrecognized capability of HBV-infected 
hepatocytes to secrete CD95L by themselves (c.f. figure 4.2). Thus, our model 
provides evidence that HBV infection leads to the transactivation, transcription and 
expression of membrane-bound and soluble CD95L. The 5’ UTR AP-1 binding site 
within the CD95L gene was identified as the predominant transcription factor binding 
site responsible for CD95L transactivation upon HBV infection. Furthermore, we 
could show that reactive oxygen species (ROS) are necessary for the transactivation 
of the CD95L gene in HBV-infected hepatocytes. 
In summary, our model indicates that HBV infection leads to JNK-mediated AP-1-
dependent transactivation, transcription and expression of soluble CD95L, proposing 
a new mechanism for the elimination of HBV-infected hepatocytes independently of 
cytotoxic T cells.  
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Figure 4.2 The AP-1 element in the 5’ UTR of the CD95L gene is responsible for CD95L 
expression in HBV-infected hepatocytes HBV infection results in the phosphorylation of the tumour 
suppressor p53 and the stress activated c-Jun N-terminal kinase (JNK) (c.f. figure 4.1). The activation 
of p53 and JNK results on the one hand in the activation of the extrinsic and intrinsic apoptosis 
signalling pathway and on the other hand in the JNK-mediated activation of the transcription factor  
AP-1. Activated AP-1 binds to the 5’ UTR AP-1 binding site of the CD95L gene which results in the 
subsequent transcription and expression of sCD95L. The secretion of sCD95L upon HBV infection can 
trigger CD95-mediated apoptosis in other HBV-infected cells or on the ligand secreting hepatocytes 
themselves. Beside the activation of the caspase-dependent death pathway, the CD95L-CD95 
complex can also trigger caspase-independent cell death by ASK1 (Apoptosis signal-regulating kinase 
1)-dependent JNK phosphorylation and the subsequent accumulation of Bax at the mitochondria. 
Pathway was generated using the pathway builder from www.proteinlounge.com. 
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4.1 An intact p53 status is required for the elimination of HBV-infected 
hepatocytes  
Findings obtained in the present study allow us to propose that an intact p53 status 
plays a crucial role in the outcome of an acute HBV infection (viral clearance vs. 
chronicity). In line with Webster et al. (Webster and Bertoletti 2002) who argued that 
HBV might be able to induce apoptosis of its host cells even though it is classified as 
a non-cytopathic virus, we show that p53 stabilization sensitizes hepatitis B virus-
infected host cells towards CD95-mediated apoptosis. That apoptosis is a powerful 
antiviral defence mechanism to erase HBV infection as HBV particles which are 
released from apoptotic hepatocytes were immature, non-enveloped capsids and 
were proved not to be infectious has been shown recently (Arzberger, Hosel et al. 
2010). However, the direct molecular mechanisms leading to apoptosis and, 
therefore, elimination of HBV-infected cells have so far been controversially 
described.  
While Terradillos et al. showed in transgenic mice that functionally intact p53 was not 
required to transduce the death signal (Terradillos, Pollicino et al. 1998), instead they 
demonstrated HBx to be the essential protein, our data provide a new, p53-
dependent model for the elimination of HBV-infected hepatocytes and, therefore, 
prevention of chronicity. Here we show that p53 and its target CD95 are essential for 
the induction of apoptosis in HBV-infected hepatocytes and their elimination          
(c.f. figure 3.4, 3.8 and 3.12). Another protein found to play a controversial role in the 
induction of apoptosis is the viral HBx. Dependent on the differentiation status of 
hepatocytes HBx can promote or inhibit apoptosis (Pollicino, Terradillos et al. 1998; 
Pan, Duan et al. 2001; Kim and Seong 2003; Arzberger, Hosel et al. 2010; Hsieh, 
Hsu et al. 2011). Taking the controversial role of HBx in the induction of apoptosis of 
HBV-infected hepatocytes, our data provide evidence for the pro-apoptotic role of 
HBx. This is in accordance with the findings described by Pollicino, Kim and Hu 
(Pollicino, Terradillos et al. 1998; Kim and Seong 2003; Liu and Wu 2010; Hu, Chen 
et al. 2011). While Pan et al. described that HBx via NFκB protects against CD95-
mediated apoptosis in HepG2.2.15 cells (stably transfected with the complete HBV 
genome) and cells infected with HBxAg-containing recombinant retroviruses (Pan, 
Duan et al. 2001), we show that HBx is needed for the up-regulation of CD95 and, 
therefore, the responsiveness of HBV-infected hepatocytes towards CD95-mediated 
apoptosis. In contrast to the systems used by Pan et al. our model allows us to work 
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in an experimental setup simulating the in vivo conditions. By the use of different 
adenoviral vectors (containing either the whole HBV genome or specific knock-outs 
of designated viral proteins; AdHBV wt, AdHBV L- and AdHBV X-) and two different 
hepatoma cell lines and, of note, the use of primary human hepatocytes we could 
prove the important role of HBx in the up-regulation of CD95 in HBV-infected 
hepatocytes.  
Increased p53 activity during HBV infection in HepG2 cells and PHH leading to 
CD95-mediated and HBx-dependent apoptosis directs to the conclusion that p53 is a 
commonly activated protein in host cells during HBV infection. This is in accordance 
with Chirillo et al. who found a connection between HBx and p53-mediated apoptosis 
in mouse fibroblasts transfected with a human HBx-containing dexamethasone 
inducible mouse mammary tumor virus (MMTV)-X expression vector (Chirillo, 
Pagano et al. 1997).  
 
Previous studies showed an interaction between type 1 interferons (INF-α/β), as the 
first line of antiviral defence, and the transcriptional up-regulation of p53. The 
presence of an active ISRE (Interferon-stimulated response element) in the promoter 
of p53 leads to its INF-α/β-mediated transcription (Takaoka, Hayakawa et al. 2003; 
Vilcek 2003). p53, as a type 1 IFN signalling downstream target, also contributes to 
an IFN-inducing positive feedback loop, established through the p53-dependent 
transcriptional induction of IFN regulatory factor 9 (IRF9), which is a part of the IFN-
stimulated gene factor 3 (ISGF3) (Munoz-Fontela, Macip et al. 2008). However,   
type 1 interferons rather seem to be responsible for p53 accumulation than for 
activation, but increased p53 concentrations can enhance cellular responses to 
stress signals that activate p53 (Vilcek 2003). Munoz-Fontela et al. (Munoz-Fontela, 
Macip et al. 2008) propose a two phase model for the different roles of p53 in 
antiviral defence. First, p53 is enhancing IFN- production and signalling to counteract 
viral infection. In a second step, p53 inhibits viral propagation by the elimination of 
infected cells through the induction of apoptosis (Munoz-Fontela, Macip et al. 2008).  
Initial recognition of HBV infection and the induction of type 1 interferon response 
may be triggered by toll-like receptors (Boehme and Compton 2004; Chang and 
Lewin 2007). Furthermore, it has been reported that HBV replication elicits a type 1 
interferon response (Lucifora, Durantel et al. 2010). Although, type 1 interferons are 
able to inhibit transcriptional and posttranslational steps in HBV replication, HBV 
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infection, in contrast to most viral infections does not seem to induce a strong IFN 
type 1 response. Instead, it has been reported that HBx is able to inhibit type 1 
interferon induction (Jiang and Tang 2010). Therefore, HBV is considered as being a 
“partially stealth” virus (Wieland and Chisari 2005; Bauer, Sprinzl et al. 2011). Taking 
the controversial issues into consideration, type 1 interferon seems to be not the only 
player in viral defence against HBV.  
In the present study we could show that in contrast to other viruses, p53 
accumulation after HBV infection is not type 1 interferon-mediated. Our results 
indicate no induction of p53 gene transcription upon HBV infection (results not 
shown), instead our findings specify that p53 is stabilized and activated by Ser-15 
phosphorylation like in a classical DNA damage response (c.f. figure 3.2).  
In this study we demonstrate that HBV infection leads to the activation of proteins 
involved in the DDR, which directs to the conclusion that HBV infection leads to 
cellular and replication stress, due to the persistent presence of exogenous material 
and, therefore, to the induction of the DNA damage response. In both hepatoma cell 
lines and, of note, in primary human hepatocytes, the phosphorylation of ATR and 
CHK2 on the amino acid residues Ser428 and Thr68, respectively as well as 53BP1 
accumulation could be observed, indicating the activation of a DDR (c.f. figure 3.2 
and 3.3). The main role of the DDR is the protection of the genomic integrity against 
environmental or spontaneous DNA lesions, occurring during normal DNA 
metabolism. The activation of the DDR counteracts the induced DNA damage by the 
activation of specific and different DNA repair mechanisms (Ciccia and Elledge 
2010). The outcome of the DDR ranges from cell cycle arrest and DNA repair to the 
induction of cell death. In the case of severe DNA damage selective “killing“ helps to 
protect the genetic integrity, therefore, apoptosis is a frequently used pathway. The 
phosphorylation of p53 on serine 15, a typical phosphorylation site upon DNA 
damage (Wang 2001), demonstrates the important link between DNA damage and 
apoptosis in HBV-infected hepatocytes (c.f. figure 3.2). The important role of 
ATM/ATR-dependent p53 phosphorylation in the induction of apoptosis upon HBV 
infection was confirmed by the use caffeine, an ATR/ATM inhibitor. The decrease of 
apoptosis after treatment of HBV-infected hepatocytes with caffeine strengthened the 
hypothesis that DNA damage-induced p53 phosphorylation triggers the induction of 
apoptosis in HBV-infected hepatocytes (c.f. figure 3.5). Bearing in mind that 
apoptosis is the last choice; HBV infection must trigger severe DNA damage or 
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cellular stress to induce apoptosis rather than cell cycle arrest. The generation of 
cccDNA in the nucleus of infected hepatocytes could indeed trigger replication stress, 
induced by unscheduled replication of the cccDNA for virus propagation. 
Furthermore, HBV genome integration has been observed in patients suffering from 
chronic HBV infection (Shafritz, Shouval et al. 1981). Both, unscheduled replication 
as well as genomic integration causing genomic instability could generate DNA 
lesions leading to the activation of the DDR.  
In contrast to Zhao et al. (Zhao, Hou et al. 2008), who described that the ATR-
dependent p53 stabilization in hepatocytes inoculated with HBV-positive serum has 
no consequences for the virus, due to viral degradation of the proteins involved in the 
DNA damage response, the present study clearly describes the consequences of 
ATR-dependent p53 phosphorylation for the virus. In the HBV-infected hepatoma cell 
lines, HepG2 and Hep3B, p53 phosphorylation leads not only to the stabilization of 
p53 but also to the activation of several p53 target genes involved in the extrinsic and 
intrinsic apoptosis pathway and finally to the induction of apoptosis. Of note, 
ATM/ATR-dependent p53 phosphorylation and the following activation of p53 target 
genes was also detected in PHHs which demonstrates the clinically relevance of our 
findings. Figure 3.4 provides evidence that HBV-induced cellular stress, the 
subsequent activation of the DNA damage response and the activation of p53 target 
genes involved in the apoptosis machinery is sufficient enough to induce apoptosis.  
 
The fact that AdHBV L- infection did not lead to the induction of apoptosis in p53-/- 
Hep3B cells supports the suggestion that p53 is a crucial protein involved in the 
elimination of HBV-infected hepatocytes. However, the AdHBV wt construct was able 
to induce apoptosis in the absence of p53 (c.f. figure 3.4). Since HBV wt induces the 
highest activation of proteins involved in the DDR (c.f. figure 3.2) and, therefore, 
probably the most extended damage, it is possible that the role of p53 in Hep3B cells 
is taken over by another p53 family member, p73, a transcription factor also 
possessing pro-apoptotic functions, in the case of p53 damage or absence. 
Transfection of the p53 hot-spot mutant, p53R248W, decreases apoptosis induction 
in HBV-infected hepatocytes compared to HBV-infected hepatocytes transfected with 
a control plasmid (c.f. figure 3.12. c). Similar to the results obtained in Hep3B cells 
with HBV infection alone, the p53 hot-spot mutant p53R248W did not completely 
inhibit the apoptosis of HBV-infected hepatocytes. Therefore, the possibility that the 
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p53 family member p73 is able to substitute for mutant p53 might be an important 
implication for future therapeutic options for the treatment of chronic HBV 
infection.The role of p73 in the induction of apoptosis, tumourigenesis and tumour 
response to therapy was described in detail by Müller et al. (Müller, Schleithoff et al. 
2006).  
 
 
 
 
 
 
 
 
Figure 4.3 HBV infection triggers the phosphorylation of p53 through the DNA damage 
response Virus infection results in unscheduled replication and/or genomic integration of HBV into the 
host genome leading to cellular stress and, therefore, the onset of the DNA damage response. The 
phosphorylation of ATR on serine 428, the activation of CHK2 due to its phosphorylation on   
threonine 68 and the accumulation of 53BP1 are reliable indicators of DNA damage. Serine 15 
phosphorylation of p53 follows the phosphorylation of proteins involved in DNA damage and abolishes 
its association with its negative regulator Mdm2 (not shown here). Pathway was generated using the 
pathway builder from www.proteinlounge.com. 
 
 
4.2 HBV infection and the CD95 death receptor pathway 
An important pro-apoptotic gene transactivated by p53 is the death receptor CD95, 
which was found to play an important role in the elimination of HBV-infected 
hepatocytes and the induction of the immune response in an in vivo experiment 
performed in our group, recently. Briefly, CD95-deficient mice (B6.MRL-Faslpr/J) and 
C57BL/6 mice were infected with AdHBV wt and monitored for 28 days. While 
C57BL/6 mice were able to control HBV infection by inducing apoptosis in HBV-
infected hepatocytes and recovered within 28 days, B6.MRL-Faslpr/J mice could not 
eliminate the virus. C57BL/6 mice showed signs of seroconversion after day 14 
indicating the onset of an immune response against HBV, whereas there was no 
antiHBs detectable in B6.MRL-Faslpr/J mice. Hence, we postulated, that an intact 
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CD95 apoptosis signalling pathway is essential for the elimination of HBV-infected 
hepatocytes (unpublished data).  
In vitro analysis performed in hepatoma cell lines and, of note, also in PHHs infected 
with HBV allowed us to further analyse the important role of CD95 in the elimination 
of HBV-infected hepatocytes and to investigate the molecular mechanism involved in 
the CD95-mediated elimination of HBV-infected host cells. HBV infection led to the 
transactivation, transcription and expression of CD95 in hepatoma cell lines          
(c.f. figure 3.6). The time-dependent CD95 transactivation upon HBV infection has 
been shown by a former MD student, Andres Rademacher (unpublished data). Since 
p53 enhances not only the gene activation (Müller, Wilder et al. 1998) but also the 
expression of CD95, a direct interaction between the accumulation of p53 and the 
expression of CD95 on the surface of HBV-infected cells is suggested. In accordance 
with the in vivo results the importance of CD95-mediated apoptosis in viral clearance 
is demonstrated in this thesis. Since CD95-deficient mice (B6.MRL-Faslpr/J) were not 
able to eliminate the virus, we postulate that the predominant extrinsic apoptotic 
pathway involved in HBV clearance is the CD95 pathway. The important role of an 
intact p53 status for the activation of the CD95 pathway in HBV-infected hepatocytes 
was demonstrated by the use of the p53 hot-spot mutant p53R248W. This mutant did 
not only reduce the induction of apoptosis in hepatocytes infected with HBV, it also 
reduced CD95 transactivation and receptor expression on the cell surface of Hep3B 
cells (c.f. figure 3.12). Therefore, the data obtained with the p53 hot-spot mutant 
further contribute to the model, which suggests that inhibition of the CD95-mediated 
apoptosis of HBV-infected hepatocytes leads to viral persistence. This suggests a 
possible synergy of alterations of the p53 pathway and HBV-induced 
hepatocarcinogenesis.  
Stimulation and blocking experiments of the CD95 death receptor system revealed 
that HBV infection triggers CD95 receptor expression and consequently sensitizes 
HBV-infected hepatocytes towards CD95-mediated apoptosis (c.f. 3.7 and 3.8). 
While the agonistic antibody anti-APO-1 increased CD95-mediated apoptosis in 
HepG2 cells significantly, the necessary addition of exogenous p53 into Hep3B cells 
to actually obtain CD95 expression already resulted in up to 90% apoptosis in 
combination with AdHBV wt. Therefore, the addition of anti-APO-1 could not further 
enhance CD95-mediated apoptosis induction in Hep3B cells. However, the important 
role of CD95 could be demonstrated more clearly upon treatment of HBV-infected 
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cells with the CD95L containing supernatant of Jurkat 16 cells (SNJ16). In both cell 
lines SNJ16 treatment resulted in CD95-mediated apoptosis induction, which was 
confirmed by the use of the CD95L inhibitor APG101 (CD95Fc), a decoy receptor for 
CD95L.  
 
 
Figure 4.4 HBV infection leads to the 
transactivation, transcription and expression of 
functional CD95 Virus-induced p53 stabilization 
results in the transactivation of the p53 target gene 
CD95 and the following expression of functional 
CD95 on the surface of HBV-infected hepatocytes 
sensitizing the cells towards CD95-mediated 
apoptosis. Pathway was generated using the 
pathway builder from www.proteinlounge.com. 
 
 
 
 
 
Another death receptor, TRAILR2, has also been described to be associated with 
HBV infection (Liang, Liu et al. 2007). This is in accordance with our results showing 
an increased TRAILR2 transcription and expression upon HBV infection                
(c.f. figure 3.11), but according to our results obtained in the present study (in vivo 
and in vitro) TRAILR2 seems to play a rather subordinate role in the elimination of 
HBV-infected hepatocytes.  
 
 
4.3 Caspase-independent induction of apoptosis in HBV-infected hepatocytes 
The fact that treatment with APG101 did not completely protect HBV-infected 
hepatocytes from apoptosis, leads to the hypothesis that the CD95 pathway is indeed 
the predominant but not the only mechanism resulting in the apoptosis of HBV-
infected hepatocytes (c.f. figure 3.8). A small amount of HBV-infected hepatocytes 
must be eliminated through mechanisms independent of CD95. Regarding the fact 
that HBV infection did not only lead to the phosphorylation and stabilization of p53 
but also of JNK, the role of JNK in apoptosis induction of HBV-infected hepatocytes 
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should not be disregarded. As a member of the MAPK superfamily, JNK is able to 
phosphorylate several transcription factors including c-Jun and p53 as well as non-
transcription factors such as members of the Bcl-2 protein family (Liu and Lin 2005). 
The role of JNK in the induction of apoptosis is, so far, well-described, proposing that 
JNK activation can have pro-apoptotic or anti-apoptotic functions (Lin and Dibling 
2002; Yu, Minemoto et al. 2004; Liu and Lin 2005). HBV-induced phosphorylation of 
JNK favours the pro-apoptotic function of JNK, as HBV infection results in the 
induction of apoptosis. The Bax subfamily of Bcl-2-related proteins plays an essential 
role in JNK-mediated apoptosis. It has been shown that JNK promotes the 
translocation of the Bcl-2 protein family member Bax to the mitochondria triggering 
cytochrome c release (Tsuruta, Sunayama et al. 2004).  
In this study we demonstrate that HBV infection elicits the activation of Bax as well as 
the subsequent release of cytochrome c (c.f. figure 3.26). The up-regulation of the 
p53 target genes Noxa, Puma and Bax upon HBV infection and the boosted 
activation after exogenous Adp53 addition show a connection between p53 
stabilization and the activation of the intrinsic apoptosis signalling pathway upon HBV 
infection. Of note, accumulation of Bax could also been shown in primary human 
hepatocytes. The consequent alteration of the mitochondrial membrane potential and 
the release of cytochrome c, due to the binding of Bax and Bak to the voltage-
dependent anion channel (VDAC) (Tsuruta, Sunayama et al. 2004) are clear hints for 
the activation of the intrinsic apoptosis signalling pathway and the induction of 
apoptosis.  
Another mechanism leading to the alteration and the loss of mitochondrial membrane 
potential is the localization of the hepatitis B virus protein HBx, which is 
predominantly found in the cytoplasm close to the mitochondria. Laser confocal 
microscopy has shown that HBx directly interacts with the outer mitochondrial 
voltage-dependent anion channel VDAC3 leading to a decrease in the mitochondrial 
membrane potential. The HBx-induced loss of the mitochondrial outer membrane 
potential (MOMP) has been linked to cell death (Waris, Huh et al. 2001; Shirakata 
and Koike 2003; Lim, Kwon et al. 2010). The p53-independent alteration of the 
MOMP and the following cytochrome c release induced directly by HBx is another 
possible pathway explaining the significantly increased alteration of MOMP and the 
increased apoptosis induction in p53-/- Hep3B cells infected with HBV, independent of 
the extrinsic CD95-mediated apoptosis pathway.   
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Figure 4.5 Caspase-independent apoptosis induction in HBV-infected hepatocytes Stabilization 
of p53 leads to the activation of the p53 targets Puma, Noxa and Bax. Activation of Noxa and Puma 
inhibit the function of the anti-apoptotic Bcl-2 family members Bcl-2, Bcl-Xl and Mcl-1 leading to the 
activation of the pro-apoptotic protein Bax. Bax binding to the voltage-dependent anion channel 
(VDAC) results in a decrease of the mitochondrial membrane potential, the subsequent release of 
cytochrome c and finally the induction of apoptosis. JNK-mediated translocation of the Bcl-2 protein 
family member Bax to the mitochondria is also triggering cytochrome c release. The localization of 
HBx at the mitochondrial membrane and its direct interaction with the outer mitochondrial voltage-
dependent anion channel VDAC3 is additionally leading to a decrease in the mitochondrial membrane 
potential. Pathway was generated using the pathway builder from www.proteinlounge.com. 
 
The role of the tumour suppressor p53, the DNA damage response and the extrinsic 
and intrinsic apoptosis signalling pathway in the elimination of HBV-infected 
hepatocytes are described and discussed in detail in the present study. It is shown 
that the observed p53 stabilization and the subsequent activation of the apoptosis 
machinery in HBV-infected hepatocytes are dependent on the activation of the DNA 
damage response.  
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4.4 The role of the viral HBx protein in the elimination of HBV-infected cells 
The present data demonstrate the important role of HBx in the elimination of HBV-
infected hepatocytes; therefore, providing evidence for the pro-apoptotic function of 
HBx. In the present study we could describe the role of HBx in the induction of 
caspase-dependent and caspase-independent cell death. This is in accordance with 
Lim et al. (Lim, Kwon et al. 2010) who demonstrated the caspase-independent role of 
HBx in the induction of cell death. In contrast to the HBx knock-out HBV construct 
AdHBV X-, the HBx-containing constructs, AdHBV L- and AdHBV wt, were found to 
be able to induce CD95 receptor up-regulation and the activation of the pro-apoptotic 
Bcl-2 family members Bax, Puma and Noxa. Furthermore, only the infection with 
HBx-containing adenoviral constructs resulted in an adequate phosphorylation of 
prominent members of the DNA damage response. The marginal induction of a 
proper DNA damage response caused by HBx-negative constructs compared to 
infection with AdHBV wt and the consequent weaker p53 accumulation and 
stabilization are possible explanations for the reduced expression of CD95 and the 
pro-apoptotic Bcl-2 family members Bax, Puma and Noxa in hepatocytes infected 
with HBx-negative constructs. Playing an important role in viral replication, 
transcription and signal transduction HBx might be the viral protein responsible for 
the induction of cellular stress and DNA damage. Lacking central features essential 
for the viral life cycle, HBx-negative constructs induce only minor cellular stress and 
possibly DNA damage which is comparable with adenoviral GFP infection. 
Our observations suggest that not the missing HBx itself, but rather the lack of p53 
stabilization in hepatocytes infected with HBx-negative constructs is responsible for 
the reduced activation of CD95, Bax, Puma and Noxa. Hence, we hypothesise that 
HBx in not directly involved in the activation of death receptor-dependent cell death 
but that it is responsible for the induction of cellular stress and DNA damage upon 
HBV infection and the following activation of the DNA damage response and the 
extrinsic as well as intrinsic apoptosis signalling pathway which are finally leading to 
the elimination of HBV-infected hepatocytes. The direct role of HBx in the induction of 
cellular stress and DNA damage still needs to be investigated. Thus, further studies 
addressing the mechanism by which HBV induces the activation of the DDR are 
important aspects to be investigated in the future. 
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4.5 HBV infection, p53, CD95 and CD95L 
 
The expression of a functional CD95 receptor and, therefore, the possibility to 
activate the major apoptosis signalling pathway involved in the elimination of 
hepatocytes infected with HBV also indicates a link between infected cells and the 
immune system. Cytotoxic CD8+ T cells, able to secret the CD95 receptor ligand, 
CD95L, are said to be the main effector cells involved in the elimination of HBV-
infected hepatocytes. We have clearly demonstrated in the present study that the 
CD95 receptor, up-regulated upon HBV infection, is functional. It was shown that 
CD95-mediated elimination of HBV-infected hepatocytes is dependent on an intact 
p53 status and the further molecular mechanisms regulating the activation of the 
extrinsic and intrinsic apoptosis signalling pathway have been described in detail.  
In the present study we provide evidence that HBV-infected hepatocytes are indeed 
sensitive towards CD95-mediated apoptosis induced by CD95L secreted by 
lymphocytes. Beside the increased induction of apoptosis observed after CD95L 
addition (c.f. figure 3.8), experiments with multicellular tumour spheroids visualized 
the effect of CD95L on HBV-infected hepatocytes (c.f. figure 3.9 and 3.10). 
Multicellular tumour spheroids (MCTS) are a well-established 3-D in vitro system 
simulating the pathophysiological in vivo situation in tumour microregions. Spheroids 
are a commonly used system to study tumour-immune cell interactions. Spheroids 
generated with Hep3B cells were infected with HBV and/or treated with CD95L 
containing supernatant of J16 Jurkat cells. To boost the effect of HBV, cells were 
additionally co-infected with adenoviral p53. The importance of the CD95-CD95L 
system for the elimination of hepatocytes was already demonstrated in uninfected 
cells. Even though there were no infectious particles available in the medium which 
could trigger DNA damage and the following up-regulation of CD95, the addition of 
CD95L reduced the migration radius of the spheroids compared to untreated 
spheroids. This observation confirmed the conclusion discussed in several papers 
that CD95 is constitutively expressed in the liver leading to a high sensitivity towards 
CD95-mediated apoptosis of hepatocytes (Galle, Hofmann et al. 1995; Schilling, 
Schleithoff et al. 2009). While HBV infection alone merely led to a decreased 
migration of hepatocytes out of the spheroid, HBV infection combined with the 
CD95L-treatment resulted in marginal disaggregation of the spheroid and almost no 
cell migration. We, therefore, hypothesise that the addition of CD95L overcomes the 
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resistance of p53-deficient cells towards CD95-mediated apoptosis. As already 
mentioned above, upon severe DNA damage the p53 family member p73 seems to 
undertake the role of p53. Moreover, Müller et al. have been shown that TAp73 is 
indeed able to induce CD95 gene transactivation (Müller, Schilling et al. 2005). 
Based on the fact that p73 leads to the up-regulation of CD95 in p53-deficient 
hepatocytes, the disaggregation of the spheroid can be explained. The addition of 
exogenous Adp53 boosted the disaggregation effect and resulted in increased 
apoptosis of infected hepatocytes confirming the outstanding role of p53 in the CD95-
mediated apoptosis of HBV-infected hepatocytes (c.f. figure 3.9).  
The role of the other p53 family members, p63 and p73, in the elimination of HBV-
infected hepatocytes and their ability to combat p53 alterations in general has been 
studied by two MD students, Long-An Sun and Annabel Langhein, in our laboratory 
(unpublished data).  
 
 
4.6 AP-1-dependent CD95L transactivation, transcription and expression  
Another transcription factor which is phosphorylated upon HBV infection is the stress 
activated c-Jun N-terminal kinase (JNK). In the present study the role of JNK in the 
transactivation of the CD95L gene in HBV-infected hepatocytes could be clarified. 
CD95L expression is generally restricted to a few cell types, e.g. T cells and NK cells. 
However, it has been reported recently, that hepatocytes are not only sensitive 
towards CD95-mediated apoptosis but also able to express CD95L by themselves 
and are therefore able to eliminate other cells via CD95L-CD95-mediated 
cytotoxicity. Müller et al. previously identified a novel AP-1 element in the CD95L 
promoter to be responsible for the induction of apoptosis upon treatment with 
chemotherapy in hepatoma cells (Eichhorst, Müller et al. 2000). c-Jun, a component 
of the transcription factor AP-1, was identified as an important protein involved in 
CD95L transactivation, which could be confirmed in the present study by the use of a 
JNK inhibitor and the following reduction in CD95L transactivation in bleomycin-
treated hepatocytes (c.f. figure 3.14).  
HBV infection resulted not only in the phosphorylation of JNK, the upstream regulator 
of c-Jun, and, therefore, the transcription factor AP-1; it also triggered the 
transactivation, transcription and expression of CD95L.  
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Due to the use of (i) four distinct CD95L reporter constructs, differing in the length of 
the upstream part of the promoter and thus possessing or lacking specific binding 
sites, inhibitors or enhancers, (ii) the use of a JNK inhibitor as well as (iii) 5’ UTR   
AP-1 binding site deletion constructs, JNK could be identified as the prevalent protein 
involved in CD95L transactivation in HBV-infected hepatocytes.  
Since the use of the four different reporter constructs did not favour a binding site 
upstream the promoter, a potential binding site in the 5’ UTR of the CD95L gene was 
tested for its role in CD95L transactivation. While there were only minor differences in 
the transactivation fold increase of the different promoter constructs, the use of a 
JNK inhibitor (JNK inhibitor II) led to a significant decrease in the transactivation of 
CD95L pointing to the involvement of an AP-1 binding site in transactivation of the 
CD95L gene (c.f. figure 3.17 and 3.18). Taking the fact into account that the use of a 
JNK II inhibitor resulted in the inhibition of CD95L transactivation and that HBV 
infection led to the phosphorylation of JNK, we postulate that CD95L transactivation 
in HBV-infected hepatocytes is triggered by Thr183/ Tyr185 phosphorylation of JNK and 
the subsequent activation of AP-1. Deletion of the 5’ UTR AP-1 binding site located 
between +84 and +91 in the CD95L reporter gene constructs resulted in a decreased 
CD95L transactivation similar to the treatment with the JNK inhibitor. Thus, the 
results obtained here suggest that the AP-1 binding site in the 5’ UTR of the CD95L 
gene is the major binding site responsible for the transactivation of the CD95L gene 
in HBV-infected hepatocytes (c.f. figure 3.20).  
HBV infection did not only lead to the transactivation of the CD95L gene, it also 
resulted in the transcription and expression of CD95L. The human CD95L exists in a 
soluble (sCD95L) and a membrane-bound form (mCD95L), whereby the soluble form 
is generated from the membrane-bound form through cleavage by metalloproteinase 
on the cell surface (Strauss, Osen et al. 2007). In contrast to mCD95L which is 
triggering CD95-mediated apoptosis by the formation of trimers or even higher 
molecular structures very efficiently, the role of sCD95L in apoptosis induction is still 
controversial (Strauss, Osen et al. 2007). Nevertheless, the results obtained in the 
present study show that sCD95L undoubtedly induces apoptosis (c.f. figure 3.8, 
treatment of HBV-infected hepatocytes with SNJ16). While the amount of sCD95L 
already increased slightly upon infection with AdHBV X-, and even more upon 
infection with HBx containing constructs, the expression of mCD95L showed the 
opposite pattern with AdHBV wt-harbouring cells having the least amount of mCD95L 
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as detected by ELISA. Similar pattern in CD95L expression was seen in cells treated 
with bleomycin. Upon bleomycin stimulation sCD95L expression increased and 
mCD95L expression dropped (c.f. figure 3.15). On the contrary, CD95L FACS which 
only detects membrane-bound CD95L first showed an increase (48 h p.i.) in mCD95L 
in cells infected with the HBx-containing constructs, before the amount of mCD95L 
fell back to the AdGFP level at 72 h p.i. Therefore, it is postulated that the majority of 
mCD95L is cleaved off from the cell membrane by metalloproteinases at 48 h to 72 h 
after HBV infection. The cleavage of mCD95L by metalloproteinases is a well 
feasible mechanism resulting in an increased amount of sCD95L which is able to 
trigger the activation of the CD95L-CD95-mediated apoptosis signalling pathway in 
neighbouring hepatocytes. The secretion of sCD95L enables the infected cells to kill 
and to be killed, nevertheless, there are indications in the literature that mCD95L is 
also playing an important role in the induction of apoptosis (Barnhart, Pietras et al. 
2005). Therefore, further investigations on the expression of sCD95L and mCD95L 
upon HBV infection could provide valuable insights into the so far uncovered details 
of apoptosis signalling and they definitely deserve further attention. 
 
Knowing that HBV infection triggers CD95L expression via the activation of JNK and 
the subsequent AP-1-dependent activation of CD95L transcription the question 
regarding the upstream mechanism of JNK phosphorylation emerged. The tumour 
necrosis factor -alpha (TNF-α) was described as a possible inducer of JNK activation 
(Lin and Dibling 2002; Liu and Lin 2005). Indeed, additional treatment of HBV-
infected hepatocytes with recombinant TNF-α led to a significant increase in CD95L 
transactivation suggesting a potential role of TNF-α in the induction of CD95L and 
maybe JNK phosphorylation. Inhibition of TNF-α with Enbrel, a TNF-α inhibitor, 
however, did not result in a decreased CD95L transactivation (c.f. figure 3.21). 
Regarding these results we postulate that JNK phosphorylation and the subsequent 
transactivation of CD95L in HBV-infected hepatocytes are independent of TNF-α.   
Beside TNF-α, reactive oxygen species (ROS) have been shown to be crucial for 
activation-induced CD95L expression in T cells. The ROS-inducible transcription 
factors AP-1 and NF-ĸB were found to be responsible for final CD95L expression and 
CD95-dependent apoptosis in T cells (Kaminski, Kiessling et al. 2007; Kiessling, 
Linke et al. 2010). The role of ROS in the HBV-induced inflammation-cirrhosis-cancer 
axis is well defined. Oxidative stress induced either by the virus itself or by the 
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immune response of the host, is suggested to be an important pathological 
mechanism in chronic liver diseases (Lee, Hwang et al. 2004). The role of HBx-
induced ROS in hepatocellular carcinogenesis was described previously by Ha et al. 
indicating a ROS-mediated dysregulation of PTEN/Akt pathway (Ha and Yu 2010). 
The HBx-mediated loss of MOMP is not only linked to cell death, but also to oxidative 
liver injury which is induced by the release of ROS. Alteration of the mitochondrial 
membrane potential results in the activation of several response stimuli amongst 
others the production of ROS. Furthermore, HBx was identified to be the crucial 
protein needed for ROS production and the subsequent activation of the transcription 
factors NF-ĸB and STAT-3 (Waris, Huh et al. 2001; Lim, Kwon et al. 2010). The 
correlation between ROS, JNK and AP-1 in the cell death of hepatocytes has been 
illustrated recently (Czaja 2003). In contrast to Melino et al. (Melino, Bernassola et al. 
2000), who showed that the reactive oxygen species-nitric oxide (NO) inhibits the 
AP-1 dependent CD95L transactivation in Jurkat T cells, our data provides evidence 
for the ROS-dependent CD95L transactivation in hepatocytes. Blocking of ROS with 
the reactive oxygen species inhibitor N-acetyl L-cysteine (NAC) significantly 
decreased the CD95L transactivation in HepG2 cells upon bleomycin treatment or 
HBV infection. This is in accordance with Kaminski et al. (Kaminski, Kiessling et al. 
2007), who demonstrated that ROS enhance NF-ĸB and AP-1 activation and 
therefore, the subsequent NF-ĸB and AP-1-dependent up-regulation of CD95L 
transactivation in T cells. Since ROS-mediated cell death of hepatocytes is 
associated with an overexpression of JNK/AP-1 (Czaja 2003) and since we observed 
that ROS inhibition results in the decrease of CD95L transactivation in HBV-infected 
hepatocytes, we hypothesise that HBV-induced phosphorylation of JNK and the 
subsequent CD95L transactivation are dependent on ROS. 
Similar to the results obtained for CD95 regulation, infection with the HBx knock-out 
adenoviral HBV construct, AdHBV X-, resulted in a minor transactivation, 
transcription and expression of CD95L. As HBx was identified as the crucial protein 
needed for ROS production (Lim, Kwon et al. 2010) and as we identified ROS to be 
essential for CD95L transactivation in HBV-infected hepatocytes, we are able to 
explain the decreased CD95L transactivation and expression in AdHBV X-infected 
hepatocytes. This is in accordance with Kasibhatla, Shin, Lee and Yoo who found 
that HBx induces CD95L activity through an Egr (early growth response protein) 
binding site by interacting and increasing the transcriptional activity of Egr 2 and    
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Egr 3 and, therefore, inducing its transactivational function (Kasibhatla, Genestier et 
al. 1999; Shin, Shin et al. 1999; Lee, Kang et al. 2001; Yoo and Lee 2004). While the 
authors’ results regarding the stimulatory role of HBx could be confirmed in the 
present study, the identity of the transcription factor responsible for CD95L 
transactivation was contradictory. Instead of Egr, AP-1 binding to its 5’ UTR binding 
site was identified as the major event responsible for CD95L transactivation.  
 
The results obtained here indicate that HBV infection leads to the transactivation, 
transcription and expression of sCD95L, proposing a new mechanism for the 
elimination of HBV-infected hepatocytes independently of cytotoxic T cells. However, 
sCD95L secretion of HBV-infected hepatocytes and, therefore, the self-killing of 
hepatocytes do not lessen the important role of cytotoxic T cells in the elimination of 
virus-infected cells. So far, it is indisputable that cytotoxic T cells are the main 
effector cells involved in virus elimination by a polyclonal, vigorous and multi-specific 
response. This has been clearly shown in transgenic mice, chimpanzees and last but 
not least in patients infected acute or chronically with HBV (Chisari 1997; Thimme, 
Wieland et al. 2003). In conclusion and of clinical importance our findings propose an 
additional new pathway for the elimination of HBV-infected hepatocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 107 Discussion 
In summary, upon the activation of the DNA damage pathway, p53 promotes cell 
death via the extrinsic and intrinsic apoptosis signalling pathway in HBV-infected 
hepatocytes. Stabilization of p53 is achieved by ATM/ATR-dependent serine 15 
phosphorylation and JNK-mediated abolishment of p53-Mdm2 interaction. We could 
show that the p53 target genes CD95 and Bax are transactivated by p53 resulting in 
an up-regulation of the CD95 receptor, which is crucial for the elimination of HBV-
infected hepatocytes as well as the activation of Bax-mediated cytochrome c release. 
The tumour suppressor p53 and its target CD95 were identified as essential proteins 
for the elimination of HBV-infected hepatocytes. The particular role of CD95 was 
confirmed in a previously performed in vivo experiment in our laboratory. The results 
of the in vitro and in vivo experiments highlight the important roles of p53 and CD95, 
without both, neither the induction of apoptosis nor the onset of a proper immune 
response was possible. Several in vitro experiments verified the responsiveness of 
HBV-infected cells towards CD95-mediated apoptosis and provided further evidence 
for the molecular mechanisms involved in the elimination of HBV-infected 
hepatocytes. The present study furthermore suggests a new mechanism for the 
elimination of HBV-infected hepatocytes through the secretion of sCD95L by infected 
hepatocytes themselves. The 5’ UTR AP-1 element was identified as the crucial 
binding site for CD95L transactivation in HBV-infected hepatocytes.  
In conclusion, the important role of an intact p53 status for the elimination of HBV-
infected hepatocytes, the subsequent activation of the apoptosis signalling pathways 
and the ability of hepatocytes to secret CD95L may be an underlying mechanism for 
the diverse outcomes of an HBV infection (HBV clearance vs. chronicity). However, it 
should be kept in mind and this has also be shown in detail in the present work that 
even though p53 and CD95 could be identified as crucial proteins involved in the 
elimination of HBV-infected hepatocytes, the elimination of HBV-infected cells is 
regulated by a large and connected network of proteins and pathways working 
together to obtain a sufficient virus eradication.  
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6. Appendix 
 
6.1 Abbreviations 
 
aa amino acid MLH1 MutL protein homologue 1 
ADCC antibody-dependent cell-
mediated cytotoxicity 
MOI multiplicity of infection 
ALT alanine amino transferase MOMP mitochondrial outer membrane 
potential 
APC antigen-presenting cell MRN 
complex 
MRE11-Rad50-NBS1 
AST aspartate transaminase mRNA messenger RNA 
ATM ataxia-teleangiectasia mutated NK cells natural killer cells 
ATR ataxia-teleangiectasia and Rad3 
related 
Na sodium 
Bax Bcl-2-associated X NAC N-acetyl L-cysteine 
BH3 Bcl-2-homology domain-3 O2 oxygen 
BS binding site O/N over night 
cccDNA covalently closed circular DNA ORF  open reading frame 
°C degree Celsius PAR poly(ADP-ribose)-polymers 
CHK1/2 checkpoint kinase PARP-1 poly(ADP-ribose)-polymerase 1  
c.f. confer, compare PBS phosphate buffered saline 
CMV cytomegalovirus immediate/ 
early gene promoter 
PCR polymerase chain reaction 
∆ delta p.i. post infection 
DDR DNA damage response P/I PMA/Ionomycin 
DISC death-inducing signalling 
complex 
PHH primary human hepatocytes 
DNA deoxyribonucleic acid pgRNA pregenomic RNA 
dsDNA double-stranded DNA PMSF phenylmethylsulfonylfluorid  
DTT dithiothreitol PRMT5 protein arginine methyltransferase 
5 
ELISA enzyme-linked immunosorbent 
assay 
REs response elements 
FACS fluorescent-activated cell sorting rcDNA relaxed circular viral DNA 
FCS fetal calf serum rpm revolutions per minute 
FADD Fas-associated death domain ROS reactive oxygen species 
HBV hepatitis B virus RT room temperature 
HEPES 4-(2-hydroxyethyl)-
1piperazineethanesulfonic acid 
sCD95L soluble CD95L 
HCC hepatocellular carcinoma SDS sodium dodecyl sulphate 
HSCs hepatic stellate cells sgRNA subgenomic RNA 
H2O water SMYD2 SET and MYND domain-containing 
2 
IU infectious units SVPs subviral enveloped particles 
IFN interferon TLR toll-like receptor 
JNK Jun N-terminal kinase TNF tumour necrosis factor  
Kat5 K (lysine) acetyltransferase 5 TNFR tumour necrosis factor receptor  
LSECs liver sinusoidal endothelial cells U units 
miRNA microRNA UTR untranslated region 
MCTS multicellular tumour spheroid UV ultraviolet light 
mCD95L  Membrane-bound CD95L wt wild-type 
MEKK1 mitogen-activated protein kinase 
kinase kinase 1 
53BP1 53 binding protein 1 
MKK4 mitogen-activated protein kinase 
kinase 4 
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6.2 Size units and physical scales 
 
 
A ampere min minutes 
°C degree Celsius rpm revolutions per minute 
g gram s seconds 
h hours U units 
l litre V volt 
M molar (mol/l) W watt 
    
    
 
6.3 Prefix of scale units 
 
M mega   106 µ micro 10-6 
k kilo 103 n nano 10-9 
c centi 102 p pico 10-12 
m milli 10-3 f femto 10-15 
 
 
 
6.4 Three letter code of amino acids 
 
Ala alanine Met methionine 
Cys cysteine Asn asparagine 
Asp aspartic acid Gln glutamine 
Glu glutamic acid Arg arginine 
Phe phenylalanine Ser serine 
Gly glycine Thr threonine 
His histidine Val valine 
Ile isoleucine Trp trypthophane 
Lys lysine Tyr tyrosine 
Leu leucine   
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6.5 Plasmid gene cards 
 
(a)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
Figure 6.1 Overview of the 
CD95L reporter plasmids. 
(a) Map of the -36/+100 
CD95L-luc plasmid used for 
CD95L reporter assays. 
Shown are the main 
restriction sites, the antibiotic 
resistance and the insert. The 
plasmid was constructed by 
Min Li-Weber (DKFZ) who 
generously provided the 
different plasmids. (b) 
Sequences of the different 
reporter constructs. The 
flanking plasmid sequence is 
shown in blue (only shown for 
the -36/+100 construct). The 
used restriction sites (HindIII 
and XhoI) are shown in 
turquoise, the AP-1 binding 
site in purple and the TATA 
Box in red. 
 
 
 
 
 
 
AmpR
-36/+100 CD95L-luc
SV40-polyA
huCD95LP
luci
beta-globin 3‘
BamHI
PstISphI
HindIII
BamHI
XbaI
XhoI
BgllI
XbaI
EcoRI
-36
+100
Plasmid name: CD95L -36/+100 Luc
Plasmid size: Vector 5.5kb, insert -36/+100bp
Constructed by: Min Li-Weber
References: Mol. Cell. Bio., 2000, 20:7826-7837
CD95 Ligand Luc Plasmids
The plasmids containing -220/+100, -537+100 and   
-1204/+100 were generated in the same way. 
Plasmid cards not shown here.
-220
AAGCTTCAGCAACTGAGGCCTTGAAGGCTGTTATCAGAAAATTGTGGGCGGAAACTTC
CAGGGGTTTGCTCTGAGCTTCTTGAGGCTTCTCAGCTTCAGCTGCAAAGTGAGTGGGT
GTTTCTTTGAGAAGCAGAATCAGAGAGAGAGAGATAGAGAAAGAGAAAGACAGAGGT
GTTTCCCTTAGCTATGGAAACTCTATAAGAGAGATCCAGCTTGCCTCCTCTTGAGCAGT
CAGCAACAGGGTCCCGTCCTTGACACCTCAGCCTCTACAGGACTGAGAAGAAGTAAA
ACCGTTTGCTGGGGCTGGCCTGACTCACCAGCTGCCTCTAGAGGATCCAGATCTCGAG
-537
AAGCTCATGGTCTCTCCCCTCAGAGCCAT
TTTCAGTAAAATTTTTATAGTTTAAAAAATACGGTTCTGAACAATTTTTGTTAGAGTTAT
TTTGGGATTTTTAAATAGTTTTTTGGTTGTGTATATGGTAGAATTCTTAAAATTATACAA
TTATAATGTATAAAAAAGCATGCAATTATAATTCATAAAATTATAGCCCCACTGACCATT
CTCCTGTAGCTGGGAGCAGTTCACACTAACAGGGCTATACCCCCATGCTGACCTGCTC
TGCAGGATCCCAGGAAGGTGAGCATAGCCTACTAACCTGTTTGGGTAGCACAGCGACA
GCAACTGAGGCCTTGAAGGCTGTTATCAGAAAATTGTGGGCGGAAACTTCCAGGGGTT
TGCTCTGAGCTTCTTGAGGCTTCTCAGCTTCAGCTGCAAAGTGAGTGGGTGTTTCTTTG
AGAAGCAGAATCAGAGAGAGAGAGATAGAGAAAGAGAAAGACAGAGGTGTTTCCCTT
AGCTATGGAAACTCTATAAGAGAGATCCAGCTTGCCTCCTCTTGAGCAGTCAGCAACA
GGGTCCCGTCCTTGACACCTCAGCCTCTACAGGACTGAGAAGAAGTAAAACCGTTTGC
TGGGGCTGGCCTGACTCACCAGCTGCCTCTAGAGGATCTCGAG
-1204
AAGCTTCGAGGGTGTCTGATATTCTGATATTTCAAAACAGAATAGAAATATGTATTTTAA
TGTGTATTTAATATATATATTTTAAAATATTTTTAATGTTGATACTAAAAGTGGTCAGTTG
GGCTCAGTGCAGTGGCTCATGCCTGTAATTCCAGCACTTTGGGAAACTGAGGCAGGAG
GATGTCTTGAAGCTAGGAGTTTGAGACAAGCCTGGGCAAC{...} 
AGGTGTTTCCCTTAGCTATGGAAACTCTATAAGAGAGATCCAGCTTGCCTCCTCTTGAG
CAGTCAGCAACAGGGTCCCGTCCTTGACACCTCAGCCTCTACAGGACTGAGAAGAAGT
AAAACCGTTTGCTGGGGCTGGCCTGACTCACCAGCTGCCTCTAGAGGATCTCGAG
CATCAATGTATCTTATCATGTCTGGATCTCGAAGCTTAACTC
-36
TATAAGAGAGATCCAGCT
TGCCTCCTCTTGAGCAGTCAGCAACAGGGTCCCGTCCTTGACACCTCAGCCTCTACA
GGACTGAGAAGAAGTAAAACCGTTTGCTGGGGCTGGCCTGACTCACCAGCTGCCTC
TAGAGGATCTCGAGATCCATTCCGGTACTGTTGGTAAAATGGAAGACGCCAAAAACAT
AAAGAAAGGCCCGGCGCCATTCTATCCTCTAGAGGATGGAA CCGCTGGAGA
HindIII/ XhoI
Flanking Plasmid Sequence
TATA Box
AP-1 Binding Site
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
Figure 6.2 Overview of the 
CD95L reporter plasmids 
(AP-1 Deletion). (a) Map of 
the -36/+81 CD95L-luc 
plasmid used for CD95L 
reporter assays. Shown are 
the main restriction sites, the 
antibiotic resistance and the 
insert. (b) Sequences of the 
different reporter constructs. 
The used restriction sites 
(HindIII and XhoI) are shown 
in turquoise, the AP-1 binding 
site in purple and the TATA 
Box in red. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AmpR
-36/+81 CD95L-luc
SV40-polyA
huCD95LP
luci
beta-globin 3‘
BamHI
PstISphI
HindIII
BamHI
XbaI
XhoI
BgllI
XbaI
EcoRI
-36
+81
Plasmid name: CD95L -36/+81 Luc
Plasmid size: Vector 5.5kb, insert -36/+81bp
Constructed by: Natalie Joschko (original 
plasmid provided by Min Li-Weber (DKFZ)
References: Mol. Cell. Bio., 2000, 20:7826-7837
CD95 Ligand Luc Plasmids (AP-1 Deletion)
The plasmids containing -220/+100, -537+100 and   
-1204/+100 were generated in the same way. 
Plasmid cards not shown here.
-36
AAGCTTAACTC
TATAAGAGAGATCCAGCTTGCCTCCTCTTGAGCAGTCAGCAACAGGGTCCCGTCCTT
GACACCTCAGCCTCTACAGGACTGAGAAGAAGTAAAACCGTTTGCTGGGGCTGGCC
CTCGAG
HindIII/ XhoI
Flanking Plasmid Sequence
TATA Box
-220
AAGCTTCAGCAACTGAGGCCTTGAAGGCTGTTATCAGAAAATTGTGGGCGGAAACTTC
CAGGGGTTTGCTCTGAGCTTCTTGAGGCTTCTCAGCTTCAGCTGCAAAGTGAGTGGGT
GTTTCTTTGAGAAGCAGAATCAGAGAGAGAGAGATAGAGAAAGAGAAAGACAGAGGT
GTTTCCCTTAGCTATGGAAACTCTATAAGAGAGATCCAGCTTGCCTCCTCTTGAGCAGT
CAGCAACAGGGTCCCGTCCTTGACACCTCAGCCTCTACAGGACTGAGAAGAAGTAAA
ACCGTTTGCTGGGGCTGGCCCTCGAG
-537
AAGCTCATGGTCTCTCCCCTCAGAGCCAT
TTTCAGTAAAATTTTTATAGTTTAAAAAATACGGTTCTGAACAATTTTTGTTAGAGTTAT
TTTGGGATTTTTAAATAGTTTTTTGGTTGTGTATATGGTAGAATTCTTAAAATTATACAA
TTATAATGTATAAAAAAGCATGCAATTATAATTCATAAAATTATAGCCCCACTGACCATT
CTCCTGTAGCTGGGAGCAGTTCACACTAACAGGGCTATACCCCCATGCTGACCTGCTC
TGCAGGATCCCAGGAAGGTGAGCATAGCCTACTAACCTGTTTGGGTAGCACAGCGACA
GCAACTGAGGCCTTGAAGGCTGTTATCAGAAAATTGTGGGCGGAAACTTCCAGGGGTT
TGCTCTGAGCTTCTTGAGGCTTCTCAGCTTCAGCTGCAAAGTGAGTGGGTGTTTCTTTG
AGAAGCAGAATCAGAGAGAGAGAGATAGAGAAAGAGAAAGACAGAGGTGTTTCCCTT
AGCTATGGAAACTCTATAAGAGAGATCCAGCTTGCCTCCTCTTGAGCAGTCAGCAACA
GGGTCCCGTCCTTGACACCTCAGCCTCTACAGGACTGAGAAGAAGTAAAACCGTTTGC
TGGGGCTGGCCCTCGAG
-1204
AAGCTTCGAGGGTGTCTGATATTCTGATATTTCAAAACAGAATAGAAATATGTATTTTAA
TGTGTATTTAATATATATATTTTAAAATATTTTTAATGTTGATACTAAAAGTGGTCAGTTG
GGCTCAGTGCAGTGGCTCATGCCTGTAATTCCAGCACTTTGGGAAACTGAGGCAGGAG
GATGTCTTGAAGCTAGGAGTTTGAGACAAGCCTGGGCAAC{...} 
AGGTGTTTCCCTTAGCTATGGAAACTCTATAAGAGAGATCCAGCTTGCCTCCTCTTGAG
CAGTCAGCAACAGGGTCCCGTCCTTGACACCTCAGCCTCTACAGGACTGAGAAGAAGT
AAAACCGTTTGCTGGGGCTGGCCCTCGAG
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